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ABSTRACT 
 
Brittany Virginia Worley: Structure-Activity Characterization of Nitric Oxide-Releasing 
Dendrimers as Dual-Action Antibacterial Agents 
(Under the direction of Mark Schoenfisch) 
 
The increasing prevalence of antibiotic-resistant bacteria coupled with the inherent 
resistance of biofilm-based infections have necessitated the development of new antibacterial 
agents capable of eradicating biofilms without fostering resistance.  Nitric oxide (NO), an 
endogenously produced free radical, holds great promise as an antibacterial agent due to its broad-
spectrum antimicrobial action.  Combining NO with contact-based biocides on a macromolecular 
scaffold should further enhance bactericidal action.  Herein, the synthesis of NO-releasing 
antibacterial dendrimers and their anti-biofilm capabilities as a function of exterior modification 
are described. 
Dual-action antibacterial agents were synthesized through the functionalization of 
poly(amidoamine) dendrimer scaffolds with contact-based biocides and subsequent modification 
with N-diazeniumdiolate NO donors.  Quaternary ammonium- and alkyl chain-modified 
dendrimers were designed with a range of generations and alkyl chain lengths.  Nitric oxide storage 
was turned so that each set of modified dendrimers exhibited similar NO totals, allowing for the 
evaluation of antibacterial action independent of NO-release payloads. 
The antibacterial action of dual-action dendrimer biocides proved dependent on dendrimer 
generation, alkyl chain length, and bacterial Gram class.  Longer alkyl chain modifications were 
significantly more bactericidal than both unmodified scaffolds and shorter alkyl chains.  Efficacy 
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of the shorter chains was improved with higher dendrimer generations and the addition of NO 
release.  Long alkyl chain dendrimers did not benefit from NO release due to the significant 
membrane damage they induced precluding intracellular NO buildup.  The anti-biofilm action of 
alkyl chain-modified dendrimers was dependent on the biocide’s ability to penetrate into the 
biofilm and compromise cell membranes, with longer alkyl chains improving biofilm eradication 
due to greater membrane intercalation.  The addition of NO release enhanced the efficacy of 
dendrimer biocides incapable of good biofilm penetration, indicating the utility of dual-action 
dendrimers as broad-spectrum anti-biofilm agents. 
Electrospun polyurethane fibers capable of delivering NO-releasing dendrimers were 
fabricated by doping dendrimers into polyurethane solutions prior to electrospinning.  The 
electrospun fiber mats were semi-porous and exhibited sufficient water uptake, demonstrating 
promise as potential wound dressing materials.  Dendrimer- and NO-release rates were tunable by 
altering the dendrimer modification and polyurethane composition.  Nitric oxide-releasing fibers 
exhibited moderate to high antibacterial activity against planktonic bacteria with minimal 
cytotoxic effects. 
 
 
 
 
 
 
  
v 
 
 
 
 
 
To my family –  
for your love, support, and encouragement to dream big and succeed 
 
 
 
  
vi 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
This dissertation was only made possible with the help of many people.  First, I would like 
to thank my advisor, Dr. Mark Schoenfisch, for giving me the opportunity to work with him and 
always pushing me to grow and better myself as a scientist.  I’d also like to thank him for providing 
both personal and professional support, especially over these last few months as I figured out my 
next step after grad school.  Additionally, I would like to thank my undergraduate advisor, Dr. 
Mark Meyerhoff, for taking me into his lab and sparking my interest in analytical chemistry, as 
well as his continued support through both my undergraduate and graduate studies. 
I have to acknowledge the entire Schoenfisch lab, both past and present, for providing a 
positive work environment, including their assistance with experiments, critical evaluations of my 
research, and general support throughout my time here.  Specifically, I would like to thank Dr. 
Alexis Carpenter, Dr. Yuan Lu, and Dr. Danielle Slomberg, who trained me when I joined the lab 
and helped me develop my first research projects.  I would also like to thank Dr. Wesley Storm 
and Dr. Chris Backlund, who were not only great friends and colleagues, but were also great 
mentors who continued to support my science well after their defense dates.  I also need to send a 
huge thanks to Robert Soto, whose knowledge and expertise were critical in helping me complete 
some of this work.  Robert is an amazing scientist and friend, and I’d like to thank him specifically 
for his SEM imaging, electrospinning, polymer knowledge, and general advice on life and science.  
Finally, I would like to thank my undergraduate researchers, Kelci Schilly and Blake Schofield, 
whose hard work is evidenced in several chapters of this dissertation.  In particular, I’d like to 
acknowledge Kelci’s dedication to her research project, working long hours that included 
vii 
 
weekends and snow days.  She was a fantastic undergraduate researcher, and I wish her the best 
of luck in the future! 
I would next like to acknowledge some of the amazing facilities we have at UNC.  First, 
all of the individuals from Chapel Hill Analytical and Nanofabrication Lab (CHANL), including 
Dr. Carrie Donley (XPS), Dr. Amar Kumbhar (TEM), and Dr. Wallace Ambrose (microscopy).  I 
would also like to thank Dr. Michael Chua and Dr. Neal Kramacy at the (now defunct) Michael 
Hooker Microscopy Facility for their assistance with confocal microscopy.   
Finally, I need to thank my family and friends, without whom I never would have made it 
this far.  My amazing friends Elise Brown, Kelsey Clancy Dzwilewski, and Jeannie Lieder, whose 
love and support know no distance.  To the friends I made along the way – Matt Jackson, Allan 
Bunch, Stephanie Moore, Emilie Mainz, and Erin Redman.  No one else can quite understand the 
crazy life that is grad school, and I’m thankful I had all of you with me as we moved through it.  I 
would like to thank my entire extended family, who have supported me with kind words, care 
packages, and free dinners throughout my entire undergraduate and graduate careers.  I especially 
need to thank my parents, Keith and Sara, and my brother, Eric, for their continued love and 
encouragement.  You have been wonderful and supportive parents, and I am eternally grateful for 
you believing in me even when I didn’t believe in myself.  Thank you for helping me become who 
I am today.  Finally, I need to thank my amazing partner Josh for standing by me through my 
craziest moments and always making me smile.  Your patience, love, and support pulled me 
through each pitfall and made each success brighter, and I’m thankful every day I didn’t have to 
do this without you.  To my entire family, thank you and I love you. 
 
 
  
viii 
 
 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES ....................................................................................................................... xiv 
LIST OF SCHEMES.................................................................................................................... xvi 
LIST OF FIGURES .................................................................................................................... xvii 
LIST OF ABBREVIATIONS AND SYMBOLS ....................................................................... xxii 
CHAPTER 1: Design of Novel Antibacterial Agents for Enhanced  
Biofilm Eradication ..................................................................................................1 
1.1 Biofilm-based infections ................................................................................................1 
1.1.1 Biofilm formation ...........................................................................................2 
1.1.2 Protective mechanisms of biofilms .................................................................5 
1.2 Current research into anti-biofilm therapeutics .............................................................8 
1.2.1 Prevention of initial biofilm attachment .........................................................8 
1.2.2 Exopolysaccharide matrix disruption ...........................................................10 
1.2.3 Quorum sensing inhibition ............................................................................11 
1.2.4 Development of novel anti-biofilm agents ...................................................12 
1.3 Nitric oxide ..................................................................................................................14 
1.3.1 Physiological roles of nitric oxide ................................................................15 
1.3.2 Antimicrobial properties of nitric oxide .......................................................16 
1.4 Nitric oxide-releasing materials ...................................................................................19 
1.4.1 Nitric oxide donors .......................................................................................19 
1.4.2 Macromolecular nitric oxide-release scaffolds .............................................20 
ix 
 
1.4.3. Effect of nitric oxide-releasing scaffold  
properties on biofilm eradication ................................................................23 
1.5 Designing dual-action therapeutics ..............................................................................25 
1.6 Dendrimers as scaffolds for dual-action antibacterial agents ......................................30 
1.6.1 Antibacterial dendrimer scaffolds .................................................................30 
1.6.2 Nitric oxide-releasing dendrimers.................................................................33 
1.7 Summary of Dissertation Research ..............................................................................35 
1.8 References ....................................................................................................................38 
CHAPTER 2: Dual-Action Nitric Oxide-Releasing Poly(amidoamine)  
Dendrimers .............................................................................................................56 
2.1 Introduction ..................................................................................................................56 
2.2 Materials and Methods .................................................................................................58 
2.2.1 Synthesis of quaternary ammonium-modified  
PAMAM dendrimers ....................................................................................59 
2.2.2 Synthesis of alkyl chain-modified PAMAM  
dendrimers.....................................................................................................60 
2.2.3 N-Diazeniumdiolation of QA- and alkyl  
chain-modified PAMAM dendrimers ...........................................................61 
2.2.4 Characterization of single- and dual-action  
PAMAM dendrimers ....................................................................................62 
2.2.5 Characterization of NO storage and release ..................................................63 
2.3 Results and Discussion ................................................................................................65 
2.3.1 Synthesis and characterization of quaternary  
ammonium-modified dendrimers ..................................................................65 
2.3.2 Synthesis and characterization of alkyl  
chain-modified dendrimers ...........................................................................71 
2.4 Conclusions ..................................................................................................................80 
x 
 
2.5 References ....................................................................................................................82 
CHAPTER 3: Antibacterial Action of Dual-Action Dendrimers  
against Planktonic Bacteria ....................................................................................85 
3.1 Introduction ..................................................................................................................85 
3.2 Materials and Methods .................................................................................................88 
3.2.1 Planktonic bactericidal assays.......................................................................89 
3.2.2 Confocal microscopy to assess dendrimer-bacteria  
association .....................................................................................................90 
3.2.3 Confocal microscopy for detection of intracellular  
NO and cell death..........................................................................................91 
3.2.4 In vitro cytotoxicity.......................................................................................92 
3.3 Results and Discussion ................................................................................................92 
3.3.1 Antibacterial action of QA-modified PAMAM  
dendrimers.....................................................................................................92 
3.3.2 Antibacterial action of alkyl chain-modified  
PAMAM dendrimers ..................................................................................103 
3.3.3 In vitro cytotoxicity.....................................................................................107 
3.4 Conclusions ................................................................................................................112 
3.5 References ..................................................................................................................114 
CHAPTER 4: Anti-Biofilm Efficacy of Dual-Action Dendrimers ..............................................117 
4.1 Introduction ................................................................................................................117 
4.2 Materials and Methods ...............................................................................................119 
4.2.1 Biofilm eradication assays ..........................................................................120 
4.2.2 Confocal microscopy to assess penetration into 
S. aureus biofilms .......................................................................................122 
4.2.3 Confocal microscopy for detection of intracellular  
xi 
 
NO and cell death........................................................................................123 
4.2.4 In vitro cytotoxicity.....................................................................................124 
4.3 Results and Discussion ..............................................................................................125 
4.3.1 Anti-biofilm efficacy of alkyl chain-modified  
PAMAM dendrimers ..................................................................................125 
4.3.2 In vitro cytotoxicity.....................................................................................138 
4.3.3 Synergy of dual-action dendrimers with vancomycin ................................142 
4.4 Conclusions ................................................................................................................146 
4.5 References ..................................................................................................................148 
CHAPTER 5: Nitric Oxide-Releasing Single-Component Electrospun 
Polyurethane Fibers .............................................................................................153 
5.1 Introduction ................................................................................................................153 
5.2 Materials and Methods ...............................................................................................155 
5.2.1 Synthesis of QA- and alkyl chain-modified  
PAMAM dendrimers ..................................................................................156 
5.2.2 N-Diazeniumdiolation of QA- and alkyl  
chain-modified PAMAM dendrimers .........................................................158 
5.2.3 Fabrication of single-component electrospun  
polyurethane fibers......................................................................................159 
5.2.4 Characterization of NO storage and release ................................................159 
5.2.5 Characterization of electrospun polyurethane fibers ..................................160 
5.2.6 In vitro cytotoxicity.....................................................................................162 
5.2.7 In vitro cell proliferation .............................................................................162 
5.2.8 Bacterial adhesion assays of single-component fibers ................................163 
5.3 Results and Discussion ..............................................................................................164 
xii 
 
5.3.1 Synthesis and characterization of NO-releasing  
G4 dendrimers .............................................................................................164 
5.3.2 Fabrication and characterization of single- 
component electrospun polyurethane fibers ...............................................165 
5.3.3 Fabrication and characterization of electrospun  
Tecoflex fibers with various dendrimer dopants ........................................174 
5.3.4 In vitro cytotoxicity and cell proliferation ..................................................183 
5.3.5 Antibacterial action of NO-releasing single-  
component electrospun fibers .....................................................................187 
5.4 Conclusions ................................................................................................................190 
5.5 References ..................................................................................................................191 
CHAPTER 6: Active Release of Dual-Action Dendrimers from Co-Axial 
Electrospun Polyurethane Fibers .........................................................................195 
6.1 Introduction ................................................................................................................195 
6.2 Materials and Methods ...............................................................................................197 
6.2.1 Synthesis of QA- and alkyl chain-modified  
PAMAM dendrimers ..................................................................................198 
6.2.2 N-Diazeniumdiolation of QA- and alkyl  
chain-modified PAMAM dendrimers .........................................................200 
6.2.3 Fabrication of electrospun polyurethane fibers...........................................200 
6.2.4 Characterization of NO storage and release ................................................201 
6.2.5 Characterization of electrospun polyurethane fibers ..................................202 
6.2.6 Zone of inhibition assays ............................................................................203 
6.2.7 Bacterial log reduction assays .....................................................................204 
6.2.8 Fluorescence microscopy for detection of  
intracellular NO and cell death ...................................................................205 
6.2.9 In vitro cytotoxicity.....................................................................................205 
xiii 
 
6.3 Results and Discussion ..............................................................................................207 
6.3.1 Synthesis and characterization of NO-releasing  
G4 dendrimers .............................................................................................207 
6.3.2 Fabrication and characterization of electrospun  
polyurethane fibers......................................................................................207 
6.3.3 Zone of inhibition .......................................................................................219 
6.3.4 Bacterial log reduction ................................................................................222 
6.3.5 In vitro cytotoxicity.....................................................................................228 
6.4 Conclusions ................................................................................................................230 
6.5 References ..................................................................................................................231 
CHAPTER 7: Summary and Future Directions ...........................................................................237 
7.1 Summary ....................................................................................................................237 
7.2 Future Directions .......................................................................................................241 
7.2.1 Studies to increase the antibacterial action of  
dual-action scaffolds ...................................................................................242 
7.2.2 Methods to extend nitric oxide release from  
electrospun fibers ........................................................................................243 
7.2.3 Antibacterial action against polymicrobial biofilms ...................................245 
7.3 Conclusions ................................................................................................................247 
7.4 References ..................................................................................................................248 
APPENDIX: Supplemental Information for Chapter 6 ...............................................................252 
 
 
 
 
xiv 
 
LIST OF TABLES 
 
Table 2.1 Percent functionalization and corresponding molecular weight for 
QA-modified G1 and G4 PAMAM dendrimers ....................................................66 
 
Table 2.2  Nitric oxide-release properties for G1 and G4 QA-modified 
dendrimers in PBS (pH 7.4, 37 °C) as measured by a 
chemiluminescence NO analyzer ...........................................................................68 
 
Table 2.3 Percent functionalization, corresponding molecular weight, and 
critical vesicle concentrations for alkyl chain-modified PAMAM 
dendrimers..............................................................................................................75 
 
Table 2.4 Nitric oxide-release properties of alkyl chain-modified dendrimers 
in phosphate buffered saline (pH 7.4, 37 °C) as measured by a 
chemiluminescence NO analyzer ...........................................................................78 
 
Table 3.1 Minimum bactericidal concentrations (MBC4h) and bactericidal 
NO doses for single- and dual-action QA-modified dendrimers 
against S. aureus and P. aeruginosa ......................................................................94 
 
Table 3.2  Minimum bactericidal concentration (MBC24h) for single- and 
dual-action alkyl chain-modified dendrimers against planktonic P. 
aeruginosa, S. aureus, and MRSA.......................................................................104 
 
Table 4.1 Minimum biofilm eradication concentrations (MBEC24h) for 
single- and dual-action alkyl chain-modified dendrimers against P. 
aeruginosa, S. aureus, and MRSA biofilms ........................................................128 
 
Table 4.2 Inhibitory concentrations at 50% cell viability (IC50) for single- 
and dual-action alkyl chain-modified dendrimers against L929 
mouse fibroblast cells ..........................................................................................140 
 
Table 4.3 Calculated therapeutic index (TI) for each dendrimer biocide 
against P. aeruginosa, S. aureus, and MRSA biofilms .......................................141 
 
Table 4.4 Combined biofilm eradication concentrations and calculated 
fractional bactericidal concentration index (FBC24h) against S. 
aureus and MRSA biofilms .................................................................................144 
 
Table 5.1 Characterization and NO-release properties of G4 dendrimers in 
PBS (pH 7.4, 37 °C) as measured by a chemiluminescence NO 
analyzer ................................................................................................................166 
xv 
 
 
Table 5.2 Characterization of single-component electrospun polyurethane 
fibers ....................................................................................................................170 
 
Table 5.3 Nitric oxide-release properties for G4 octyl/NO-doped electrospun 
polyurethane fibers in PBS (pH 7.4, 37 °C) ........................................................172 
 
Table 5.4 Characterization of electrospun Tecoflex fibers ..................................................179 
 
Table 5.5 Nitric oxide-release properties for NO-releasing electrospun 
Tecoflex fibers in PBS (pH 7.4, 37 °C) ...............................................................181 
 
Table 5.6 Average log reduction of adhered bacterial viability ...........................................189 
 
Table 6.1  Characterization of electrospun polyurethane fibers ...........................................215 
 
Table 6.2  Total nitric oxide storage and dendrimer encapsulation by fiber 
mass......................................................................................................................216 
 
Table 6.3  Nitric oxide-release properties for NO-releasing electrospun fibers 
in PBS (pH 7.4, 37 °C)  .......................................................................................221 
 
Table 6.4  Average zone of inhibition against planktonic bacteria .......................................223 
 
Table 6.5  Average log reduction against planktonic bacteria ..............................................226 
 
Table A.1  Characterization and NO-release properties of G4 dendrimers ...........................253 
 
Table A.2  Inhibitory concentrations at 50% viability (IC50) against L929 
mouse fibroblast cells ..........................................................................................254 
 
 
 
  
xvi 
 
LIST OF SCHEMES 
 
Scheme 2.1 Reaction of PAMAM scaffold with either (A) QA or (B) alkyl 
chain epoxides to yield single-action dendrimers, followed by 
reaction with high pressures of NO to yield dual-action, NO-
releasing dendrimers ..............................................................................................64 
 
Scheme 6.1  Reaction of G4 PAMAM scaffold with either (A) octyl alkyl chain 
or (B) octylQA epoxides to yield G4 octyl and G4 octylQA 
dendrimers, respectively, followed by reaction with high pressures 
of NO to generate NO-releasing dendrimers .......................................................208 
 
  
xvii 
 
LIST OF FIGURES 
 
Figure 1.1 Stages of pathogenic biofilm formation ...................................................................3 
 
Figure 1.2  Schematic representation of biofilm protection mechanisms ..................................4 
 
Figure 1.3 Schematic representation of the multi-mechanistic killing pathways 
of NO and its byproducts .......................................................................................17 
 
Figure 1.4 (A) Possible decomposition mechanisms for S-nitrosothiol (RSNO) 
NO donors, including heat, light, and copper-mediated 
decomposition. (B) Formation of N-diazeniumdiolate NO donors 
on secondary amines followed by proton-initiated decomposition 
to yield two moles of NO for every mole of NO donor .........................................21 
 
Figure 1.5 Modes of combination therapies ............................................................................26 
 
Figure 1.6 Mechanisms of action for quaternary ammonium (QA) compounds ....................29 
 
Figure 1.7 Structure of poly(amidoamine) (PAMAM) dendrimer scaffold ............................32 
 
Figure 2.1 Representative (A) Fourier transform infrared spectra of G1 QA-
modified dendrimers. Representative (B) N 1s and Cl 2p XPS 
spectra for G1 QA-modified dendrimers ...............................................................67 
 
Figure 2.2 Representative UV-vis spectra for NO-releasing QA-modified 
dendrimers..............................................................................................................69 
 
Figure 2.3 Formation of dendrimer vesicles at pH 7.4 ............................................................72 
 
Figure 2.4 Surface tension plots of (A) G4 dodecylQA and (B) G4 butylQA. 
Transmission electron microscopy images of (C) G4 dodecylQA 
dendrimer vesicles .................................................................................................73 
 
Figure 2.5 Fourier transform infrared spectra of G1 alkyl chain-modified 
dendrimers..............................................................................................................76 
 
Figure 2.6 Representative UV-vis spectra for NO-releasing alkyl chain-
modified dendrimers ..............................................................................................79 
 
Figure 3.1 Confocal microscopy images of P. aeruginosa exposed to 50 
µg/mL RITC-tagged G4 methylQA and dodecylQA dendrimers at 
(A) 0, (B) 4, (C) 6, (D) 8, and (E) 10 min after dendrimer addition ......................96 
xviii 
 
 
Figure 3.2  Confocal microcopy images of S. aureus exposed to 50 µg/mL 
RITC-tagged G4 methylQA and dodecylQA dendrimers at (A) 0, 
(B) 20, (C) 24, (D) 28, and (E) 32 min after dendrimer addition ..........................97 
 
Figure 3.3  Confocal microcopy images of P. aeruginosa exposed 50 µg/mL 
RITC-tagged (A) G4 methylQA and (B) G4 butylQA dendrimers 
after 20 min exposure...........................................................................................100 
 
Figure 3.4 Confocal microscopy images of P. aeruginosa and S. aureus 
exposed to 20 µg/mL G4 dodecylQA/NO dendrimers at (A) 0, (B) 
25, (C) 35, (D) 45, and (E) 60 min after dendrimer addition ...............................101 
 
Figure 3.5 Viability (%) of L929 mouse fibroblast cells following 4 h 
exposure to single- (blue) and dual-action (green) QA-modified 
dendrimers, as well as unmodified PAMAM dendrimer (red), at 
the MBC4h against (A) S. aureus and (B) P. aeruginosa compared 
to untreated control cells ......................................................................................109 
 
Figure 3.6 Viability (%) of L929 mouse fibroblast cells following 24 h 
exposure to single- (blue) and dual-action (green) alkyl chain-
modified dendrimers compared to untreated control cells ...................................110 
 
Figure 4.1 Confocal microscopy images of (A) P. aeruginosa and (B) S. 
aureus biofilms exposed to 100 µg/mL G1 hexyl/NO dendrimers 
for 2 h ...................................................................................................................129 
 
Figure 4.2 Confocal microscopy images of P. aeruginosa biofilms exposed to 
100 µg/mL G1 butyl/NO and G1 hexyl/NO dendrimers for (A) 1 h 
and (B) 2 h ...........................................................................................................131 
 
Figure 4.3 Confocal microscopy images of S. aureus biofilms exposed to 50 
µg/mL RITC-tagged (A) G1 butyl, (B) G2 butyl, (C) G4 butyl, (D) 
G1 hexyl, (E) G2 hexyl, and (F) G4 hexyl dendrimers for 1 h ............................132 
 
Figure 4.4 Confocal microscopy images of S. aureus biofilms exposed to 250 
µg/mL (A) G1 hexyl/NO and (B) G2 hexyl/NO dendrimers for 3 h ...................136 
 
Figure 4.5 Viability (%) of L929 mouse fibroblast cells following 24 h 
exposure to individual (solid) and combined (hashed) dendrimer 
and vancomycin biofilm eradication concentrations against (A) S. 
aureus and (B) MRSA biofilms ...........................................................................145 
 
xix 
 
Figure 5.1 Scanning electron micrographs of blank, control, and NO-releasing 
G4 octyl-doped electrospun Tecoplast, Tecoflex, and Hydrothane 
fibers ....................................................................................................................169 
 
Figure 5.2 Representative total NO-release curves for (A) G4 octyl/NO-doped 
electrospun Tecoplast, Tecoflex, and Hydrothane fibers and (B) 
NO-releasing dendrimer-doped electrospun Tecoflex fibers. 
Representative NO-release curves for (C) G4 hexyl/NO, (D) G4 
octyl/NO, (E) G4 dodecyl/NO, and (F) G4 octylQA/NO-doped 
electrospun Tecoflex fibers ..................................................................................173 
 
Figure 5.3 Electron micrographs of G4 RITC octyl-doped (A) Tecoplast, (B) 
Tecoflex, and (C) Hydrothane fibers.  (D) Fluorescence image of 
Tecoplast-G4 RITC octyl fibers...........................................................................175 
 
Figure 5.4 Dendrimer delivery (%) for control (solid line) and NO-releasing 
(dashed line) G4 octyl-doped electrospun Tecoplast (red), Tecoflex 
(blue), and Hydrothane (green) fibers after 2 h, 1 d, or 7 d soaking 
in PBS (pH 7.4, 37 °C) ........................................................................................176 
 
Figure 5.5 Scanning electron micrographs of control and NO-releasing G4 
hexyl-, G4 dodecyl-, and G4 octylQA-doped electrospun Tecoflex 
fibers ....................................................................................................................178 
 
Figure 5.6 Dendrimer delivery (%) for control (solid line) and NO-releasing 
(dashed line) G4 hexyl- (red), G4 octyl- (blue), G4 dodecyl- 
(green), and G4 octylQA- (purple) doped electrospun Tecoflex 
fibers after 2 h, 1 d, or 7 d soaking in PBS (pH 7.4, 37 °C) ................................182 
 
Figure 5.7 Viability (%) of L929 mouse fibroblast cells following (A,C) 2 h 
or (B,D) 24 h exposure to blank (solid), control (diagonal lines), 
and NO-releasing (horizontal lines) (A,B) G4 octyl-doped 
electrospun fibers or (C,D) dendrimer-doped electrospun Tecoflex 
fibers ....................................................................................................................184 
 
Figure 5.8 (A) Viability (%) of L929 mouse fibroblast cells adhered to control 
(diagonal lines) and NO-releasing (horizontal lines) dendrimer-
doped Tecoflex electrospun fibers following 24 h exposure. (B) 
Scanning electron micrographs of L929 mouse fibroblast cells 
adhered to blank, control, and NO-releasing G4 octyl-doped 
Tecoflex electrospun fibers following 24 h exposure ..........................................185 
 
xx 
 
Figure 5.9 Viability of (A,B) P. aeruginosa or (C,D) S. aureus adhered to 
blank (solid), control (diagonal lines), and NO-releasing 
(horizontal lines) dendrimer-doped Tecoflex electrospun fibers 
following 2 or 6 h exposure .................................................................................188 
 
Figure 6.1  Scanning electron micrographs of blank, control, and NO-releasing 
G4 octyl-doped electrospun SG 80A/HP 93A, TP 470/SG 80A, 
and TP 470/HP 93A fibers ...................................................................................210 
 
Figure 6.2  Image of electrospun fiber substrates (1.267 cm2).  From left to 
right: SG 80A/HP 93A, TP 470/SG 80A, and TP 470/HP 93A ..........................211 
 
Figure 6.3  Histograms depicting fiber diameter distribution in nm for blank, 
control, and NO-releasing G4 octyl-doped electrospun SG 80A/HP 
93A, TP 470/SG 80A, and TP 470/HP 93A fibers ..............................................214 
 
Figure 6.4  (A) Delivery of control (solid line) and NO-releasing (dashed line) 
G4 octyl dendrimers from electrospun SG 80A/HP 93A fibers at 
15 (blue) and 25 (purple) mg/mL initial dendrimer concentration. 
(B) Delivery of control (solid line) and NO-releasing (dashed line) 
G4 octyl dendrimers from electrospun SG 80A/HP 93A (blue), TP 
470/SG 80A (red), TP 470/HP 93A (black) fibers.  (C) Delivery of 
control (solid line) and NO-releasing (dashed line) G4 octyl 
(square) and G4 octylQA (triangle) dendrimers from electrospun 
TP 470/HP 93A fibers ..........................................................................................220 
 
Figure 6.5  Fluorescence microscopy images of P. aeruginosa exposed to TP 
470/HP 93A-G4 octyl/NO fibers for 5 and 15 minutes .......................................227 
 
Figure 6.6  Viability (%) of L929 mouse fibroblast cells following (A) 2 h or 
(B) 24 h exposure to blank, control, and NO-releasing electrospun 
SG 80A/HP 93A (blue), TP 470/SG 80A (red), TP 470/HP 93A 
(gray) fibers ..........................................................................................................229 
 
Figure A.1  Custom electrospinning apparatus in co-axial configuration ...............................255 
 
Figure A.2  Scanning electron micrographs and fiber diameter histograms of 
TP 470/HP 93A-G4 octylQA electrospun fibers .................................................256 
 
Figure A.3  Scanning electron micrographs of RITC-tagged TP 470/HP 93A 
electrospun fibers .................................................................................................257 
 
Figure A.4  Representative nitric oxide-release profiles of electrospun fibers .......................258 
xxi 
 
 
Figure A.5  Representative zone of inhibition images against planktonic 
bacteria .................................................................................................................259 
 
Figure A.6  Viability of planktonic bacteria after 2 h exposure to TP 470/HP 
93A electrospun fibers .........................................................................................260 
  
Figure A.7  Viability of planktonic bacteria after 24 h exposure to TP 470/HP 
93A electrospun fibers .........................................................................................261 
 
Figure A.8  Viability (%) of L929 mouse fibroblast cells following 2 h (solid) 
or 24 h (diagonal lines) exposure to blank, control, and NO-
releasing electrospun TP 470/HP 93A-G4 octylQA fibers ..................................262 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
xxii 
 
LIST OF ABBREVIATIONS AND SYMBOLS 
 
~  approximately 
°C  degree(s) Celsius 
>  greater than 
≥  greater than or equal to 
<  less than 
≤  less than or equal to 
[NO]max  maximum NO flux 
%  percent 
±  standard deviation of the mean 
×g  times the force of gravity 
µg  microgram(s) 
µL  microliter(s) 
µm2   micrometers squared 
µM  micromolar 
µmol  micromole(s) 
Abs  absorbance 
Ag  silver 
Ag+   silver ion(s) 
AHAP3 N-(6-aminohexyl)amino-propyltrimethoxysilane 
AMP  antimicrobial peptide 
Ar  argon 
BP  band-pass 
xxiii 
 
Ca2+  calcium ion(s) 
cfu  colony forming units 
cGMP  cyclic guanosine monophosphate 
Cl  chlorine atom(s) 
Cl+   oxidative chlorine 
CO2   carbon dioxide 
cm  centimeter(s) 
cm-1  wavenumber(s) 
cm2  centimeters squared 
cNOS  constitutive nitric oxide synthase 
CVC  critical vesicle concentration 
d  day(s) 
Da  Daltons 
DAF-2  4,5-diaminofluorescein 
DAF-2 DA 4,5-diaminofluorescein diacetate 
DETA/NO N-diazeniumdiolate-modified diethylenetriamine  
DMEM Dulbecco’s modified Eagle’s medium 
DMF  N,N-dimethylformamide 
DNA  deoxyribonucleic acid 
E. coli   Eschericia coli 
E. faecalis  Enterococcus faecalis 
EDA  ethylene diamine 
e.g.  exempli gratia (for example) 
xxiv 
 
et al.   et alia (and others) 
eNOS  endothelial nitric oxide synthase 
EPS  exopolysaccharide  
eV  electron volts 
FBC24h  24 h fractional bactericidal concentration index 
FBS  fetal bovine serum 
Fe3+   iron ion(s) 
FISH  fluorescent in situ hybridization 
FTIR  Fourier transform infrared spectroscopy 
Ga  gallium  
G1  generation 1 
G2  generation 2 
G3   generation 3 
G4   generation 4 
GSNO  S-nitroso-L-glutathione 
h  hour(s) 
1H NMR proton nuclear magnetic resonance 
HCl  hydrochloric acid 
HP 93A Tecophilic 
IC50  inhibitory concentration at 50% viability 
i.e.   id est (that is) 
iNOS  inducible nitric oxide synthase 
K. pneumonia Klebsiella pneumoniae 
xxv 
 
KOH  potassium hydroxide 
kV  kilovolt(s) 
LB  Luria-Bertani 
MAP3  N-methylaminopropyltrimethoxysilane 
MBC4h  4 h minimum bactericidal concentration 
MBC24h 24 h minimum bactericidal concentration 
MBEC24h 24 h minimum biofilm eradication concentration 
MeOH  methanol 
min  minute(s) 
mg  milligram(s) 
mL  milliliter(s) 
mS  millisiemen(s) 
mm  millimeter(s) 
mM  millimolar 
mmol  millimole(s) 
MRSA  methicillin-resistant Staphylococcus aureus  
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt 
mW  milliwatt(s) 
MWCO molecular weight cutoff 
n  number of dendrimer terminal end groups 
N2   nitrogen gas 
N2O3   dinitrogen trioxide 
N.A.  numerical aperature 
xxvi 
 
NaOMe sodium methoxide 
nm  nanometer(s) 
nM  nanomolar 
NO  nitric oxide 
NOA  nitric oxide analyzer 
NOS  nitric oxide synthase 
nNOS  neuronal nitric oxide synthase 
O2  oxygen 
O2
-   superoxide 
ONOO- peroxynitrite 
P. aeruginosa Pseudomonas aeruginosa 
PAMAM poly(amidoamine) 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PEG  poly(ethylene glycol) 
pH  -log of proton concentration 
PI  propidium iodide 
PIA  polysaccharide intercellular adhesion 
PLGA  poly(lactic-co-glycolic acid)  
PLGH  poly(lactic-co-glycolic-co-hydroxymethyl propionic acid) 
pM  picomolar 
pmol  picomole(s) 
PMS  phenazine methosulfate 
xxvii 
 
ppb  parts per billion 
PPI  polypropylenimine 
ppm  parts per million 
PROLI/NO N-diazeniumdiolate-modified L-proline 
PS  penicillin streptomycin 
QA  quaternary ammonium 
QS  quorum sensing  
RIP  RNA III inhibiting peptide  
RITC  rhodamine b isothiocyanate 
RNA  ribonucleic acid 
RSNO  S-nitrosothiol 
s  second(s) 
S. aureus  Staphylococcus aureus 
S. epidermidis  Staphylococcus epidermidis 
SEM  scanning electron microscope 
SG 80A Tecoflex 
SNAP  S-nitroso-N-acetylpenicillamine 
STAMP selectively targeted antimicrobial peptide 
t1/2  half-life 
t[NO]  total NO release 
t[NO]2h 2 h total NO release 
t[NO]4h  4 h total NO release 
t[NO]HCl total NO release in 50 mM HCl 
xxviii 
 
td  duration of NO release 
tmax  time required to reach maximum NO flux 
TEA  triethylamine 
TEM  transmission electron microscopy 
THF  tetrahydrofuran 
TI  therapeutic index 
TP 470 Tecoplast 
TSA  tryptic soy agar 
TSB  tryptic soy broth 
UV  ultraviolet 
v/v  volume to volume ratio 
v/v/v  volume to volume to volume ratio 
vis  visible  
vol%  percent by volume 
WD   weight of dry fiber mat 
WH   weight of hydrated fiber mat 
wt%  percent by weight 
XPS  x-ray photoelectron spectroscopy 
Zn2+   zinc ion(s) 
ZOI  zone of inhibition 
1 
 
 
 
CHAPTER 1: 
Designing Novel Antibacterial Agents for Enhanced Biofilm Eradication 
Biofilm-based infections, especially those caused by the opportunistic pathogens 
Pseudomonas aeruginosa and Staphylococcus aureus, continue to pose a tremendous challenge to 
the medical field.1-3  Biofilms are bacterial communities encased in a protective exopolysaccharide 
matrix that demonstrate a variety of protective mechanisms, allowing for their persistence despite 
treatment with antibiotics or antiseptics.4-6  The inability of current therapeutics to effectively 
eradicate biofilms promotes bacterial resistance.  Nitric oxide is an endogenously produced free 
radical that plays a central role in the host immune response to infection, exhibits broad-spectrum 
antibacterial action, and is unlikely to foster resistance, making it an ideal candidate for the 
development of novel biocidal agents.7-10  This chapter will describe the formation and protective 
mechanisms of biofilm-based infections, current research into more effective anti-biofilm 
therapeutics, the existing state of macromolecular scaffolds for controlled nitric oxide release, and 
the emergence of dual-action nitric oxide-releasing dendrimers as novel antibacterial agents. 
1.1 Biofilm-based infections 
Traditionally, planktonic (i.e., free-floating) bacteria have been used to evaluate antibiotic 
susceptibility; however, the majority of bacterial infections are believed to be caused by 
communities of bacteria called biofilms.4, 11-13  As opposed to their free-floating counterparts, 
biofilm-based bacteria are encased in a complex exopolymeric matrix that tethers the biofilm to a 
surface, protecting it from invasion by antimicrobial agents (e.g., antibiotics, antiseptics).4, 12, 14  
Biofilms are significantly more difficult to treat, often requiring therapeutic doses 3–4 orders of 
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magnitude greater than those required to eradicate planktonic bacteria.6, 15  It is thus important to 
examine the formation of these biofilm communities and the protective mechanisms that allow 
them to persist when designing new antibacterial agents. 
1.1.1  Biofilm formation 
Biofilm-based bacterial infections have been observed on most, if not all, implanted 
medical devices.2, 11, 14  The formation of a biofilm is initiated by the irreversible attachment of 
planktonic bacteria to both living and inanimate surfaces, including human tissue and medical 
implants (Figure 1.1).4-6, 11, 13, 14, 16, 17  Both the chemical properties of the underlying surface and 
the identity of colonizing bacterial cells impact the rate and extent of biofilm formation.6  While 
biofilms have been observed on both rough and smooth surfaces ranging from very hydrophobic 
(e.g., Teflon, silicone) to charged and hydrophilic (e.g., glass, metal) materials, rougher and more 
hydrophobic materials develop biofilms more rapidly.4  Bacterial appendages such as flagella or 
pili increase the rate of microbial attachment to surfaces, allowing bacteria to overcome repulsive 
or removal forces and remain attached.4 
After irreversible attachment, bacteria begin to form microcolonies and secrete an 
exopolysaccharide (EPS) matrix that both surrounds and protects the biofilm.4, 6, 11, 13  Although 
the specific composition of the EPS is dictated by the bacterial species it encloses, the matrix is 
generally composed of a combination of polysaccharides, proteins, glycoproteins, and DNA.2, 4, 17  
The EPS matrix provides the structural integrity critical for biofilm formation and survival.4  
During biofilm maturation, EPS synthesis is up-regulated and develops the complex biofilm  
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Figure 1.1 Stages of pathogenic biofilm formation: 1) initial and irreversible attachment of 
planktonic bacteria; 2) biofilm maturation and exopolysaccharide matrix production; 3) dispersion 
of planktonic cells to further infection.  The biofilm community is protected from antimicrobial 
agents and the host immune response.  Figure adapted from Monroe et al.14 (Copyright 2007) 
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Figure 1.2 Schematic representation of biofilm protection mechanisms, including the inability of 
antimicrobial agents to penetrate into the biofilm (yellow), the extreme chemical 
microenvironment at the biofilm depths (pink), and the presence of surviving “persister” cells 
(purple).  Reprinted with permission from the Center for Biofilm Engineering (Montana State 
University, Copyright 2001, www.biofilm.montana.edu).  
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architecture that protects the bacterial community from the immune response and antimicrobial 
agents.17  The protective mechanisms of the EPS matrix will be described in detail in Section 1.1.2.  
The resulting EPS-confined biofilms are highly hydrated (98% water), persistently bound to the 
underlying surface, and heterogeneous in space, time, and bacterial composition.4  Although P. 
aeruginosa and S. aureus are two of the most commonly isolated species in clinical infections, a 
more complex bacterial microflora has been observed with improvements in bacterial isolation 
techniques.2, 18, 19  Consequently, the accumulation of a complex biofilm composed of a diverse 
bacterial community is considered to be responsible for promoting systemic infection via the 
detachment of cells and aggregates from the parent biofilm.4 
1.1.2  Protective mechanisms of biofilms 
In addition to the increasing prevalence of antibiotic resistant bacteria,20-22 biofilm-based 
bacterial infections are notoriously resistant to standard antimicrobial treatment.4-6, 23, 24  Antibiotic 
treatments that are effective at killing planktonic bacteria are often ineffective against biofilms, 
with biofilm eradication often requiring a 1,000–10,000-fold increase in therapeutic dose.6, 15  Of 
importance, the common mechanisms of antibiotic resistance, including expression of efflux 
pumps, modified enzymes and target sites, and production of alternative metabolic pathways, are 
not necessarily responsible for the protection of these bacterial communities.22, 24  Biofilms instead 
exhibit several unique protective mechanisms that contribute to their overall robustness (Figure 
1.2).4, 5, 24 
The first of these protective mechanisms is the inability of antimicrobial agents to penetrate 
beyond the surface layers of the biofilm.5, 24  Diffusion through a biofilm may be slowed or 
completely prevented by charge interactions between antimicrobial agents and the EPS matrix, 
size exclusion by the matrix architecture, and/or reduced motility due to EPS viscosity.5, 13  In vitro 
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measurements of antibiotic penetration in biofilms have exhibited a wide variation in permeation 
rates through such matrices, dependent on both the antibiotic structure and biofilm architecture.23, 
24  Significant limitations in biofilm penetration have been reported for beta-lactams and 
aminoglycosides.23  In particular, positively-charged aminoglycosides are believed to bind to the 
negatively charged polymers within the biofilm, leading to antibiotic adsorption to the biofilm 
matrix and inhibited biofilm penetration.24  In addition to restricted penetration, antimicrobial 
agents may be deactivated through reaction with or binding to the biofilm EPS matrix.23, 25  For 
example, Nichols et al. demonstrated that the addition of alginate during biofilm formation reduced 
inhibition zones for tobramycin against Escherichia coli and S. aureus, suggesting the EPS matrix 
either interferes with antimicrobial action of tobramycin or inhibits its diffusion through the 
biofilm.26  In a similar study, Coquet et al. observed a decrease in antimicrobial action for both 
tobramycin and imipenem against alginate-embedded P. aeruginosa biofilms compared to 
planktonic bacteria.27  While the combination of tobramycin and imipenem was synergistic against 
planktonic cultures of P. aeruginosa, no synergy was displayed for the biofilm cultures. 
The extreme chemical microenvironment within the biofilm further contributes to the 
decreased activity of antimicrobial agents.5  Available oxygen is often consumed at the biofilm 
surface layers, leading to anaerobic pockets in the biofilm depths.24  Additionally, the 
accumulation of acidic waste products may lead to pH gradients (>1 pH unit) between the EPS 
matrix and the biofilm interior.23, 24  The pH, oxygen, and carbon dioxide gradients contribute to 
undesirable antibiotic effects within the deepest layers of the biofilm, where the acidic and 
anaerobic conditions are most dramatic.6  In particular, aminoglycosides have demonstrated 
decreased efficacy against the same bacteria strains in anaerobic as opposed to aerobic 
conditions,23, 24 and both aminoglycosides and tetracyclines are less effective under acidic 
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conditions.6  These chemical gradients also lead to heterogeneity within the bacterial community 
with respect to growth states, with populations ranging from the continuously proliferating to the 
metabolically inactive.5, 23, 24  The depletion of nutrients may cause bacteria to enter a slow- or 
non-growing state where they are protected from killing.  The varied rates of bacterial growth 
dramatically dictate the effectiveness of antibiotics, many of which only target rapidly growing 
bacteria.6, 23, 24 
Quorum sensing (QS) is a method of cell-to-cell communication between bacterial cells 
that allows for cell density and/or population-based gene regulation.28, 29  Individual bacterial cells 
produce and release small QS signaling molecules to detect and relay information on the 
characteristics of the surrounding environment.  The development of antibiotic and biocide 
tolerance or resistance phenotypes in biofilms is thought to be partially regulated by QS, although 
the exact mechanism is unknown.28, 30  The dense, confined biofilm environment enables the 
accumulation of QS signaling molecules, triggering QS-regulated gene expression and affecting 
the host immune response.28  For example, the release of various virulence factors by pathogenic 
bacteria is regulated by QS processes.2, 31  In the case of P. aeruginosa, production of the leukocidal 
toxin rhamnolipid B shields against invading neutrophils and other cellular components of the host 
response, contributing to the persistence of P. aeruginosa biofilms.2, 30 
The final proposed mechanism for increased biofilm survival is the presence of a 
subpopulation of “persister” bacteria that form a unique and highly protected phenotypic state.5, 23, 
24  Cells in this persister phenotype are considered to be specialized survivor cells and are neither 
defective nor antibiotic-stimulated.13  The hypothesized presence of persister bacteria is based on 
the survival of a small population (<1% of the original bacterial community) despite prolonged, 
continued exposure to antibiotics32, 33 and is further supported by the ability of bacterial biofilms 
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to resist killing by chemical disinfectants (e.g., chlorine bleach, glutaraldehyde, hydrogen 
peroxide) and antibiotics.23, 34  Further, this subpopulation of highly persistent bacteria is observed 
in newly formed biofilms that are too thin to provide an adequate barrier to antibiotic diffusion or 
metabolic gradients.34, 35  The presence of a persister subpopulation within a bacterial biofilm may 
promote the longevity and wide-spread resistance of bacteria to antimicrobial agents and 
disinfectants comprised of varying chemistries. 
1.2 Current research into anti-biofilm therapeutics 
The protective mechanisms exhibited by biofilms contributes to their ability to withstand 
treatment with antibiotics or antiseptics.  Further, the increased occurrence of antibiotic-resistant 
bacteria coupled with a decline in new antibiotic research has necessitated the development of 
novel therapies capable of lessening or completely eliminating biofilm-based infections.  This 
section describes the ongoing research aimed at either disrupting biofilm formation or killing 
established biofilms to reduce the bacterial burden in clinical infections. 
1.2.1  Prevention of initial biofilm attachment 
The majority of research on minimizing biofilm attachment focuses on developing or 
modifying surfaces to either prevent the initial bacterial adhesion (i.e., antifouling) or kill adhered 
bacterial cells (i.e., antimicrobial) through both passive or active strategies.4, 13, 36  Passive 
strategies rely on mechanisms intrinsic to the material itself to prevent fouling as opposed to 
actively releasing a biocidal agent.37  Active-release antimicrobial materials can be engineered 
through covalently binding, non-covalently immobilizing, or doping antimicrobial agents on or 
within a material to facilitate release.36  For example, antibiotics38-42 and silver43-47 have been 
incorporated into materials to allow for localized release, which advantageously avoids large, 
systemic doses and maintains antimicrobial action close to the potential infection site. 
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As microbial cell membranes tend to be hydrophobic and negatively-charged, antifouling 
properties are often imparted to surfaces through chemical modification with hydrophilic or 
negatively charged functional groups.48  Poly(ethylene glycol) (PEG) is one of the most highly 
investigated hydrophilic polymers for antifouling biomedical applications.  The utility of PEG 
stems from reducing protein adsorption and bacterial attachment through hydration and steric 
effects.49, 50  Unfortunately, resisting protein adhesion alone does not necessarily correlate with 
reduced bacterial adhesion due to adhesion mechanisms that do not rely on proteins and the 
instability of PEG coatings in physiological solutions.51, 52  The use of negatively charged polymer 
coatings (e.g., heparin, albumin) has resulted in significant reductions in catheter-related 
infections.53, 54  For example, a recent study demonstrated reduced adhesion of Staphylococcus 
epidermidis with a heparin-like polyurethane containing negatively charged sulfate groups.55  
Similarly, polycationic antimicrobial surfaces have been developed by tethering quaternary 
ammonium moieties to polymer coatings.56-58  While the QA-modified surfaces effectively killed 
adhered bacteria, these immobilized antimicrobial or anti-infective agents are often only toxic to 
the first wave of incoming bacteria, providing little antimicrobial action once layers of dead 
bacterial cells accumulate.11, 56   
Other research has focused on preventing bacterial attachment through an induced antibody 
response.  The initial bacterial attachment is normally facilitated by adhesion proteins (adhesins), 
with interactions between bacterial adhesins and host tissue being critical for biofilm formation.29  
Thus, the development of antibodies for specific adhesins to inhibit bacterial adhesion and 
colonization was hypothesized to reduce infection.59  Adhesins tend to be highly conserved 
proteins and lack major variation (~2% divergence) between similar bacterial strains, likely due to 
the required recognition of limited host receptors by all pathogenic strains.59, 60  The lack in 
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variation between adhesins allows for the development of antibodies that should be effective 
against a wide range of bacterial strains.  Langermann et al. reported antibodies against a single 
FimH adhesin protein with specificity for >90% of E. coli strains expressing the FimH adhesin.61  
This approach blocked the binding of E. coli to bladder cells in vitro.  Vaccination of mice with 
the FimH adhesin vaccine reduced the in vivo colonization of bladder mucosa by E. coli by >99% 
and elicited a long-term immune response to FimH.62 
Instead of studying individual adhesins, Schneewind and coworkers attempted to identify 
chemical reactions or binding steps that are shared by a large majority of surface proteins.29, 63  
Sortases are membrane enzymes present in many Gram-positive strains that catalyze the covalent 
anchoring of surface proteins to the outer peptidoglycan layer, making them an excellent target for 
anti-adhesion agents with broad clinical applications.63-65  Several sortase inhibitors have been 
identified to date, including methane-thiosulfonate and mercurial p-hydroxymercuribenzoic acid, 
which block Cys184 residues in the active pocket of sortase A.66, 67  However, these compounds 
exhibit poor therapeutic value due to their high toxicities.29   
1.2.2  Exopolysaccharide matrix disruption 
As the EPS matrix contributes significantly to the resistance of bacteria within biofilms to 
antimicrobial agents, strategies to enzymatically or chemically disrupt the biofilm matrix have 
become a popular approach for enhancing biofilm eradication.13, 36  Hatch et al. demonstrated that 
although the production of alginate, a major component of the P. aeruginosa EPS matrix, inhibits 
the dissemination of antibiotics, treatment with the enzyme alginate lyase facilitated the diffusion 
of gentamicin and tobramycin through P. aeruginosa biofilms.68  Similarly, Alipour et al. reported 
that the co-administration of alginate lyase with DNase enhanced the activity of aminoglycosides 
and reduced P. aeruginosa biofilm growth.69  For many bacterial species (e.g., S. epidermidis, S. 
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aureus, P. aeruginosa, E. coli), iron (Fe3+) is crucial for bacterial growth and metabolic enzyme 
function.11  Gallium (Ga), alternatively, exhibits many similar features as Fe3+ (i.e., ionic radius) 
but does not perform the same functions critical for proper enzyme performance; as such, the 
uptake of Ga over Fe3+ by biological systems renders the enzymes non-functional.11, 70  Kaneko et 
al. found that while P. aeruginosa grown in Ga concentrations >2 µM displayed a dose-dependent 
decrease in growth rate, sub-inhibitory Ga concentrations (1 µM) allowed for uninhibited P. 
aeruginosa growth but prevented biofilm formation.71 
One of the most studied components of the Gram-positive EPS matrix is the polysaccharide 
intercellular adhesion (PIA) protein synthesized by the icaADBC operon in staphylococci, which 
is required for staphylococcal biofilm development.36  The ica gene thus represents a viable 
potential target for the development of biofilm inhibitors.  Sub-inhibitory concentrations of the 
common antibacterial agent povidone-iodine have exhibited anti-biofilm activity against S. 
epidermidis by reducing the transcription of the icaADBC operon through activation of the icaR 
transcriptional repressor.72  The inhibition of PIA synthesis and staphylococcal biofilm disruption 
have also been demonstrated using the organosulfur compound allicin against S. epidermidis and 
sulfhydryl compounds (i.e., dithiothreitol, beta-mercaptoethanol, cysteine) against S. aureus.36, 73, 
74  As dimerization of specific protein domains in the presence of zinc (Zn2+) are required for 
biofilm formation by both S. epidermidis and S. aureus, Zn2+ chelation was similarly shown to 
prevent biofilm formation by both staphylococcal bacteria, including antibiotic-resistant strains.75 
1.2.3  Quorum sensing inhibition 
Quorum sensing was introduced in Section 1.1.2 as a contributing factor in biofilm 
resistance to antimicrobial agents through the regulation of virulence factor release by effective 
cell-to-cell communication.  As QS systems have been implicated in both biofilm formation and 
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infection, QS inhibitors have been developed to reduce bacterial pathogenicity.28, 29  Quorum 
sensing inhibition is achieved through the binding of the inhibitor molecule to the QS receptor 
proteins, displacing the QS regulation center.36 
Two of the leading classes of QS inhibitor candidates are furanones and RNA III inhibiting 
peptide (RIP).29  Furanones in particular have been investigated for their broad-spectrum QS 
inhibitory mechanisms and ability to inhibit the QS centers in both Gram-negative and Gram-
positive pathogens.  Additionally, furanones incapable of QS inhibition have been determined to 
increase biofilm susceptibility to antibiotics and antiseptics.  Hentzer et al. treated P. aeruginosa 
biofilms with several natural furanone compounds and found the furanones specifically targeted 
QS systems, inhibited virulence factor expression, and increased bacterial susceptibility to 
tobramycin and certain detergents.76  The QS inhibitor RIP has also been shown to suppress 
pathogenic virulence, biofilm formation, and antibiotic resistance in certain staphylococcal 
strains.77-80  Although RIP exhibited promising results as a QS inhibitor during studies with in vivo 
animal models, clinical applications have been limited due to concerns over in vivo stability and 
drug toxicity.29  These concerns notwithstanding, several in vitro studies have established the 
potential of QS inhibitors as surface-immobilized anti-biofilm agents, qualifying their ability to 
disrupt biofilm formation on surfaces.81, 82 
1.2.4  Development of novel anti-biofilm agents 
Conventional therapies for eradicating bacterial biofilms are frequently ineffective, 
resulting in the persistence of bacterial subpopulations that exhibit increased resistance to 
antibacterial agents.29, 36  Accordingly, new anti-biofilm strategies have been proposed to promote 
more complete killing of pathogenic biofilms.  The encapsulation of traditional antibiotics within 
various delivery systems, including liposomes, micelles, and polymeric nanoparticles, represents 
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one such area.25, 29, 36  While antibiotic delivery vehicles demonstrate several advantages, including 
more efficient antibiotic delivery, in vivo drug retention, and bacterial killing, fostering bacterial 
resistance continues to be a major drawback of these systems. 
Ionic silver (Ag+) has historically been used as an antimicrobial agent because it offers 
broad-spectrum activity at relatively low concentrations (0.05 ppm in PBS, ~50 ppm in biological 
fluids).83-86  The antimicrobial activity of silver ions stems from a number of biocidal mechanisms, 
including surface binding to and damaging of bacterial cell membranes, interfering with DNA 
replication, poisoning respiratory enzymes, and denaturing proteins (including DNA and RNA).83, 
84, 87  Although wide-spread resistance to silver is unlikely due to its multi-mechanistic biocidal 
activity, bacterial resistance to silver has been observed clinically.84, 86, 87  Several different types 
of silver-resistant clinical strains, mostly Gram-negative bacteria, have been recently isolated.84-86, 
88, 89  Bacterial resistance to silver is observed in two predominant forms: 1) the binding of silver 
by cells in the form of an intracellular complex; and, 2) the excretion of silver from 
microorganisms using cellular efflux pumps.86, 89  In addition to potential bacterial resistance, 
silver use is associated with several clinical disadvantages.  The use of silver products often leads 
to potential irritation or discoloration of the surrounding tissue (argyria), especially when using 
silver nitrate.87  Silver-based products also poorly discriminate between healthy cells and 
pathogenic bacteria, resulting in toxicity to both keratinocytes and fibroblasts at bactericidal silver 
levels.87, 89   
Antimicrobial peptides (AMPs) have recently been proposed as promising anti-biofilm 
agents.  As fairly large, cationic macromolecules, AMPs exhibit broad-spectrum antimicrobial 
activity by binding to negatively-charged structural molecules on the microbial membrane, leading 
to membrane disruption and cell death.29, 36  The ability of AMPs to permeate and damage cell 
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membranes makes them potentially effective against slow-growing or resistant bacteria embedded 
within biofilms; the development of resistance to this kind of mechanical disruption is rare.90, 91  
Unfortunately, AMPs are both difficult and expensive to synthesize in large quantities, have low 
specificity, and are sensitive to protease digestion, limiting current therapeutic utility.29 
Modification of AMPs has led to the development of selectively targeted antimicrobial 
peptides (STAMPs), which represent a novel strategy for species-specific biofilm control.  A 
typical STAMP contains a species-specific targeting peptide connected to an antimicrobial peptide 
via a 2 to 20 amino acid peptide chain.29  This configuration allows for specific microbe targeting 
without reducing antibacterial activity.  Eckert et al. first synthesized a P. aeruginosa-specific 
STAMP with increased bactericidal action and faster killing against P. aeruginosa than the non-
targeted, general-killing peptide control.92  The development of STAMPs has been extended to 
selectively remove both Gram-positive and Gram-negative bacterial strains from multi-species 
planktonic cultures.92, 93  To date, however, the use of STAMPs alone has only resulted in 
inhibitory effects against P. aeruginosa and various cariogenic biofilms, though the co-
administration of STAMPs with tobramycin has enhanced their biofilm eradication capabilities.94    
1.3 Nitric oxide 
Nitric oxide (NO) is an endogenously produced diatomic free radical that regulates several 
biological functions in the cardiovascular, respiratory, and nervous systems, including 
neurotransmission, angiogenesis, vasodilation, wound healing, and the immune response.7, 95-103  
The multifaceted roles of NO in the immune response to invading pathogenic bacteria, in 
particular, have led to countless investigations into the effects of exogenous NO delivery to 
promote bacteria killing and biofilm eradication, ultimately lessening the incidence of infection.  
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This section will consider the physiological roles of endogenously produced NO, including its 
innate antimicrobial action. 
1.3.1  Physiological roles of nitric oxide 
Nitric oxide is produced endogenously through the oxidation of L-arginine to L-citrulline 
via nitric oxide synthase (NOS).9, 95, 96, 98  The three distinct isoforms of NOS are divided into two 
classes – constitutive (cNOS) and inducible (iNOS).  The constitutive class encompasses the 
endothelial (eNOS) and neuronal (nNOS) isoforms with regulation by Ca2+ fluxes and binding to 
the messenger protein calmodulin.95, 96  iNOS is present in epithelial, endothelial, and 
inflammatory cells (e.g., macrophages and neutrophils) and upregulates upon cytokine expression 
and/or inflammatory stimuli.9, 95, 96  Although the three isoforms catalyze the same reaction to 
produce NO, they vary greatly with respect to regulation, concentration, and duration of NO 
production.  The lowest levels of NO are produced by eNOS (pM), an enzyme located in the 
vascular endothelium, neurons, epithelial cells, and cardiac myocytes.98  The low, intermittent 
levels of NO generated by eNOS help maintain basal vascular tone and proper blood flow and 
pressure.95  Similarly, nNOS rapidly produces low, transient levels of NO (pM–nM) in neurons, 
skeletal muscle, and epithelial cells, allowing NO to function as a neurotransmitter in neuronal 
tissue.95, 98  As might be expected, iNOS has the highest capacity for NO generation, yielding 
significantly greater quantities of NO (µM) per mole of enzyme per minute than either of the cNOS 
isoforms.95, 98  The iNOS isoform is expressed in several cell types, particularly neutrophils and 
macrophages, as part of the innate immune response against invading pathogens and will be 
detailed further in Section 1.3.2.95, 96, 98 
The low levels of NO produced by the cNOS isoforms readily diffuse across cell 
membranes to act as regulatory and signaling molecules.  Within the vascular endothelium, NO 
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reacts with the iron center of guanylate cyclase, activating the production of cyclic guanosine 
monophosphate (cGMP).95  The upregulation of cGMP leads to smooth muscle relaxation and 
vasodilation.  Nitric oxide production in the cardiovascular system also regulates vascular tone, 
myocardial contractility, endothelial-leukocyte interactions, and antithrombotic effects, while NO 
deficiencies due to endothelium injury can lead to cardiovascular conditions such as 
atherosclerosis, hypertension, coronary heart disease, and stroke.7, 95  Additionally, cNOS-derived 
NO acts as an intracellular messenger and neurotransmitter in the central nervous system through 
the stimulation of neuronal cGMP production.97, 99  The cGMP-dependent nervous system 
functions of NO include regulating the firing of neurons in various areas of the brain and spinal 
cord, the release of specific neurotransmitters (e.g., acetylcholine, serotonin), and membrane 
depolarization.99  The roles of endogenous NO span a wide range of functions in various biological 
systems, demonstrating its significance as a regulatory and signaling molecule. 
1.3.2  Antimicrobial properties of nitric oxide 
Nitric oxide production has been implicated in contributing to the innate host response to 
infectious pathogens.8, 9, 96  Both iNOS and eNOS have been found in immune-system cells (e.g., 
macrophages, dendritic cells).8  Infections in both humans and animal models are often associated 
with significant increases in endogenous NO.96  The production of NO by iNOS is stimulated by 
the presence of pro-inflammatory cytokines as well as microbial byproducts (e.g., 
lipopolysaccharide, lipoteichoic acid).8, 9  Low concentrations of NO (such as those released from 
macrophages after cytokine stimulation) upregulate the activation of iNOS, while substantially 
higher concentrations suppress iNOS and help prevent NO overproduction.96  Nitric oxide 
demonstrates remarkably extensive antimicrobial activity with an ability to eradicate a broad range 
of pathogenic microorganisms, including both Gram-negative and Gram-positive bacteria, viruses, 
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Figure 1.3 Schematic representation of the multi-mechanistic killing pathways of NO and its 
byproducts through the exertion of both nitrosative and oxidative stresses on bacteria.  Reprinted 
with permission from Hetrick et al.104 Copyright 2008, American Chemical Society. 
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fungi, and parasites.8, 9, 105-107  The broad-spectrum antimicrobial action of NO is attributed to its 
multi-mechanistic killing pathways, exerting both nitrosative and oxidative stresses on pathogens 
through the formation of reactive nitrogen and oxygen intermediates (Figure 1.3).7, 8, 104  Reactive 
nitrogen intermediates (e.g., N2O3) apply nitrosative stress to bacterial cells, modifying DNA, 
proteins, and lipids.8  DNA targeting results in deamination, abasic sites, and strand breaks.9  While 
nitrosation of protein thiols is one of the most important protein targets of NO, nitrosative stress 
can occur at heme groups, iron-sulfur clusters, or amines in addition to reactive thiols.8, 9  Reaction 
of NO with superoxide (O2
-) to form peroxynitrite (ONOO-) leads to oxidative DNA and protein 
damage as well as lipid peroxidation.8, 104, 108, 109  This multi-mechanistic action not only allows 
NO to exhibit broad-spectrum antimicrobial activity but also makes it unlikely to foster bacterial 
resistance.7  Indeed, Gram-positive, Gram-negative, and antibiotic-resistant bacteria that survived 
exposure to lethal exogenous NO doses after several passages (20 d) demonstrated minimal 
increases in inhibitory NO concentrations, rendering the development of NO release a viable 
option for designing novel antibacterial agents that do not foster bacterial resistance.10 
Along with potent antimicrobial action, NO shows selectivity towards invading pathogens 
over host mammalian cells due to their endogenous production of NO.  Eukaryotic cells have 
developed several protective measures against NO’s biocidal mechanisms at elevated 
concentrations.  One notable means of protection is the production of metallothionein, which is 
upregulated by eukaryotic cells in response to oxidative stress, a major contributing mechanism to 
the bactericidal action of NO.9  The expression of superoxide dismutase, an endogenously 
produced enzyme that removes superoxide (O2
-) and limits peroxynitrite (ONOO-) formation, also 
reduces the toxic side effects of NO in mammalian cells.8, 110  However, superoxide dismutase is 
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less efficient than NO at scavenging superoxide, making it only partially effective at mitigating 
toxicity at high NO concentrations.111 
1.4 Nitric oxide-releasing materials 
Exogenous NO donors have displayed substantial antibacterial and anti-biofilm activity 
against a broad range of microorganisms.  Indeed, applying gaseous NO to infected dermal wounds 
was found to reduce the microbial burden and improve wound healing.112, 113  Both Gram-negative 
and Gram-positive bacteria, including antibiotic-resistant strains, have been found to be 
susceptible to gaseous NO.114  Unfortunately, the rapid reactivity of gaseous NO makes its use 
impractical in a clinical setting, limiting any potential therapeutic utility.  A number of NO donors 
have been developed to allow for the controlled storage and delivery of NO, with the hope of 
expanding the range of potential clinical applications.  Several classes of NO donors exist, 
including metal nitrosyls, organic nitrites and nitrates, oximes, S-nitrosothiols (RSNOs), and N-
diazeniumdiolates.7, 115  To date, however, none have been translated to the clinic primarily due to 
challenging manufacturing issues.7  S-nitrosothiol and N-diazeniumdiolate NO donors represent 
the most extensively researched NO-release agents with the greatest potential as therapeutics, 
though still only in the development stages.115  
1.4.1  Nitric oxide donors  
S-Nitrosothiols (RSNO) are the endogenous NO delivery vehicles within biological 
systems.116, 117  On the bench, small molecule exogenous RSNO donors are synthesized through 
nitrosation of thiols with nitrous acid.  Nitric oxide release is achieved through a number of 
decomposition pathways (Figure 1.4A), including homolytic cleavage of the S-NO bond by light 
or heat, copper ion-mediated catalytic decomposition, and reaction with reducing agents (e.g., 
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ascorbate).118  The multiple decomposition pathways and triggers to liberate NO results in certain 
stability issue in vivo, complicating the progression of RSNO-based therapies to the clinic.115 
N-Diazeniumdiolate NO donors form on secondary amines under high pressures of NO gas in 
basic conditions to yield zwitterionic dialkylamino diazeniumdiolate salts (Figure 1.4B).119-121  The 
resulting NO-releasing materials are generally stable in basic solutions or as solids at room 
temperature or below.120  In aqueous solutions at neutral or acidic pH, protonation of the secondary 
amine nitrogen initiates NO donor breakdown, yielding two moles of NO for every mole of NO 
donor.120, 122  As such, N-diazeniumdiolate moieties undergo spontaneous dissociation to yield 
biologically active NO under physiological conditions (i.e., pH 7.4), facilitating the therapeutic 
utility of this NO donor class.  The rate of NO release is dependent on solution pH, with increasing 
solution acidity resulting in faster NO release.122  Moreover, the rate and duration of NO release 
can be tuned by varying the identity of the amine precursor, allowing for chemical control of the 
NO-release kinetics.121, 122  Similar to RSNO-based applications, no N-diazeniumdiolate-
containing compounds have been clinically approved; however, a variety of animal studies have 
demonstrated the biomedical utility of N-diazeniumdiolate NO donors as a therapeutic source of 
NO.115  Due to their increased stability and spontaneous NO release under physiological 
conditions, this work will primarily focus on N-diazeniumdiolate NO donor storage and delivery 
chemistries. 
1.4.2  Macromolecular nitric oxide-release scaffolds 
Initial investigations into the antibacterial action of NO donors were focused on the 
modification of low molecular weight small molecules.  For example, the amino acid proline was 
modified with N-diazeniumdiolates to yield PROLI/NO, which is capable of storing large  
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Figure 1.4 (A) Possible decomposition mechanisms for S-nitrosothiol (RSNO) NO donors, 
including heat, light, and copper-mediated decomposition. (B) Formation of N-diazeniumdiolate 
NO donors on secondary amines followed by proton-initiated decomposition to yield two moles 
of NO for every mole of NO donor. 
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quantities of NO (7.24 µmol/mg) due to the accessibility of secondary amines.123  Poor NO donor 
stability triggers rapid NO release (t1/2 = 1.8 s), however, resulting in NO liberation prior to 
association with bacteria and necessitating greater PROLI/NO doses for effective therapeutic 
action.124  In contrast, the small molecule N-diazeniumdiolate-modified diethylenetriamine 
(DETA/NO) exhibits slower NO donor breakdown, allowing for greater broad-spectrum 
antibacterial activity.125  Nevertheless, the antibacterial action of low molecular weight donors 
remains limited by uncontrolled NO release initiation and insufficient bacterial targeting, 
warranting the development of macromolecular scaffolds for NO delivery.   
Modifying macromolecular scaffolds with NO-release capabilities has several advantages 
over small molecule NO donors, including more controllable NO payloads and release rates, 
modifiable surface chemistries, and reduced toxicity to mammalian cells.  Several types of 
macromolecular scaffolds have been investigated for their NO-release capabilities, including 
liposomes,126-129 metal nanoparticles,130 metal organic frameworks,126, 131-133 chitosan,127, 134, 135 
silica nanoparticles,104, 136-140 and dendrimers.141-143  The use of NO-releasing macromolecular 
vehicles improves both control over NO release and bacterial targeting/association.  For example, 
the inhibitory concentration of S-nitrosated human serum albumin was decreased against bacteria 
by a factor of 5000 compared to two small molecule RSNO donors as a result of scaffold-bacteria 
association.144  Hetrick et al. also observed that NO-releasing silica eradicated planktonic P. 
aeruginosa cultures at NO doses 20x lower than those required from the small molecule NO donor 
PROLI/NO.104  The increase in bactericidal action was attributed to more efficient (targeted) NO 
delivery by the NO-releasing silica particles to the bacteria compared to PROLI/NO.   
Bacterial targeting and bactericidal efficacy are also dependent on the structural 
characteristics of the macromolecular scaffold, including size, shape, and exterior 
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functionalization.  Backlund and coworkers reported that NO-releasing silica nanoparticles with 
greater surface charge facilitated increased bacterial association, NO delivery efficiency, and 
bactericidal action over particles with lower zeta potential but similar NO totals and kinetics.136  
Carpenter et al. evaluated the ability of NO-releasing silica nanoparticles to reduce planktonic P. 
aeruginosa bacterial viability as a function of particle size through the synthesis of 50, 100, and 
200 nm silica nanoparticles, independent of total NO payload.137  Smaller (50 nm) particles were 
more effective at killing P. aeruginosa than larger (200 nm) particles, which was attributed to 
faster particle-bacteria association.  In a similar study, Slomberg et al. found that 14 and 50 nm 
NO-releasing silica particles were more effective at killing planktonic P. aeruginosa than 150 nm 
particles.140  Interestingly, the 50 and 150 nm NO-releasing particles exhibited similar action 
against planktonic Gram-positive S. aureus cultures, with increased bactericidal action observed 
for the 14 nm particles, demonstrating a dependence of Gram designation on NO antibacterial 
activity.  Lu and coworkers expanded these studies to investigate the effects of particle shape on 
bactericidal activity.  Nitric oxide-releasing silica nanorods were synthesized with varied aspect 
ratios, maintaining the same particle volume and NO release while increasing the rod length.145  
Greater antibacterial action against planktonic P. aeruginosa was observed with increasing aspect 
ratio due to more efficient NO delivery by the longer silica nanorods that associated with the 
bacteria longitudinally. 
1.4.3  Effect of nitric oxide-releasing scaffold properties on biofilm eradication  
Nitric oxide also exhibits anti-biofilm activity, including biofilm dispersion and 
eradication.  Lancaster hypothesized that the rapid diffusion properties of NO may enhance 
penetration into biofilms, increasing the efficacy of NO against biofilm-encapsulated bacteria.146  
Barraud and coworkers demonstrated the ability of small molecule NO donors (i.e., sodium 
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nitroprusside, SNAP, GSNO) to disperse bacterial cells using P. aeruginosa, E. coli, S. 
epidermidis, and multi-species biofilms.147, 148  To fully harness the anti-biofilm capabilities of 
NO, the development of NO-releasing scaffolds has focused on understanding the 
physicochemical properties of the scaffold with respect to enhanced biofilm eradication. 
Hetrick et al. reported broad-spectrum anti-biofilm activity for NO-releasing MAP3 silica 
nanoparticles against Gram-negative, Gram-positive, and pathogenic fungus biofilms.139  Further, 
the MAP3/NO silica nanoparticles demonstrated ~1000-fold greater efficacy against P. aeruginosa 
biofilms than the slower NO-releasing AHAP3/NO particles.  This dramatic increase in anti-
biofilm action was attributed to a combination of larger NO storage, faster NO-release kinetics, 
and the smaller size of the MAP3/NO scaffold.  To further assess the effects of particle size on 
biofilm eradication, Slomberg et al. evaluated the anti-biofilm efficacy of NO-releasing silica 
nanoparticles as a function of particle size independent of NO payloads, with only a slight variation 
in release kinetics.140  Smaller (14 nm) NO-releasing silica nanoparticles were more effective at 
eradicating both P. aeruginosa and S. aureus biofilms than larger (150 nm) particles.  The greater 
anti-biofilm action observed for the 14 nm particles was attributed to faster association of the 
smaller particles with the biofilm leading to more efficient NO delivery.  This study also evaluated 
the effects of particle shape on anti-biofilm action, with rod-like scaffolds being more effective at 
biofilm eradication versus the spherical particles.140  Similar to planktonic studies, the longer, rod-
shaped silica nanoparticles resulted in more efficient NO delivery and thus improved bactericidal 
action than spherical particles.  Unfortunately, many of the NO-releasing silica scaffolds were 
toxic to L929 fibroblast cells at concentrations required to eradicate biofilms.139, 140  However, the 
exhibited anti-biofilm efficacy of NO-releasing silica nanoparticles demonstrates the utility of NO 
for biofilm eradication. 
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1.5 Designing dual-action therapeutics 
The use of antibiotic combinations has become common in clinical practice in efforts to increase 
the spectrum of antimicrobial activity, lower doses to circumvent toxicity, and minimize the 
likelihood of emerging bacterial resistance.149  Combination therapies can be classified into four 
modes of action that allow for enhanced antimicrobial activity (Figure 1.5).150  The first three 
modes combine a secondary adjuvant compound that augments activity of the primary drug by 
either 1) preventing its degradation or modification, 2) allowing for its accumulation and retention, 
or, 3) inhibiting the repair or tolerance mechanism of microbial cells to the primary drug.  The 
fourth mode involves the combination of two or more mechanistically different biocides.  
Employing multiple compounds that work through different biocidal pathways should not only 
increase the bactericidal action and antibacterial sphere of influence, but also lessen the emergence 
of resistance due to the improbability of bacteria developing resistance to both biocidal 
mechanisms.150, 151  Further, combining two or more antibacterial agents can result in synergy, 
where the bactericidal efficacy of the combination is more effective than their individual sums.149, 
150  As such, the design of dual-action therapeutics has become a viable option for the development 
of novel antibacterial agents. 
Several antibiotic combinations have been successfully implemented to treat resistant 
bacterial infections.150-152  A major category of combination therapy is the coupling of β-lactam 
class antibiotics with lactamase inhibitors (or inactivators), where the β-lactam targets the cell wall 
while the inhibitor prevents antibiotic degradation by the β-lactamase enzyme.153  Combining the 
antibiotics trimethoprim and sulfamethoxazole, two inhibitors of folic acid metabolism, has been 
shown to promote synergistic bactericidal action as each inhibits a different step on the nucleotide 
biosynthesis pathway.150  Other work has centered on developing compounds that render  
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Figure 1.5 Modes of combination therapies.  In the first three modes, the adjuvant (i) prevents 
degradation of the antibacterial agent, (ii) allows accumulation of the antibacterial agent by 
inhibiting efflux pumps, or (iii) inhibits cellular tolerance mechanisms.  In the fourth mode (iv), 
both agents exhibit antibacterial activity through different biocidal mechanisms.  Reprinted with 
permission from Cottarel et al.150 Copyright 2007, Elsevier Ltd. 
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bacteriostatic drugs bactericidal.  For example, the bactericidal drug Synercid (King 
Pharmaceuticals; Bristol, Tennessee) is the combination of two static antibacterial compounds.152  
More recent work has focused on the development of dual-action compounds on a single scaffold.  
For example, Oxaquin (BioVertis; Vienna, Austria) combines the therapeutic components of two 
different compounds in one molecule.150, 154, 155   
The majority of dual-action antibacterial agents utilize a non-depleting, contact-based 
biocide as the base scaffold.  Quaternary ammonium (QA) compounds are a popular non-depleting 
biocide due to their broad-spectrum efficacy and ability to kill bacteria without altering the QA 
structure, allowing for continued bactericidal activity.156-158  The antibacterial action of QA 
compounds is derived from the attractive electrostatic interactions between the cationic QA group 
and the negatively charged bacterial cell membrane, in turn disrupting natural chemical balances 
by replacing essential metal cations (Figure 1.6).156, 159  Adding alkyl chain groups to the QA 
moiety increases the biocidal action by promoting bacterial membrane penetration and 
disruption.156, 157, 159, 160  Although their simple structure has allowed for the facile incorporation 
of QA moieties into a variety of systems (e.g., polymers, films, particles), tethering QAs to 
polymers or particles limits their action to only the bacteria that come into contact with the QA-
modified surface.  As a result, combining QA moieties with releasable antibacterial agents should 
increase the biocidal sphere of influence in addition to improving the overall bactericidal action. 
To prevent biofilm formation on surfaces, Wong et al. developed layer-by-layer coatings 
comprised of a permanently biocidal QA-modified structure topped with hydrolytically-
degradable films that allowed for the release of gentamicin.161  Antibiotic release increased the 
zone of inhibition (ZOI) for the dual-functionalized films over the QA-modified base, while the 
biocidal QA structure resisted biofilm formation even after gentamicin depletion.  In other work, 
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Hu et al. fabricated dual-action cellulose fibers by co-grafting N-halamine and QA salt monomers, 
allowing for the release of oxidative chlorine (Cl+) from QA-modified cellulose.162  The resulting 
dual-action fibers exhibited rapid and increased bactericidal action against Gram-negative and 
Gram-positive bacterial strains over the single-action QA-modified or Cl+-releasing cellulose 
alone. 
The efficacy of combining tethered QA moieties with releasable silver is another area of active 
research.  Multi-layer antibacterial coatings capable of both release- and contact-based killing were 
produced by incorporating QA moieties and silver in a layer-by-layer method.44, 163  For example, 
Grunlan et al. fabricated multi-layer films by dipping substrates into solutions containing either 
cetyltrimethylammonium bromide (QA moiety) or silver nitrite.  The resulting dual-action films 
exhibited increased ZOIs against both E. coli and S. aureus versus the single-action silver-releasing 
films.44  Alternatively, the antibacterial films developed by Li et al. were composed of a functional 
reservoir for silver ion release capped with QA-modified nanoparticles.  The bactericidal action of 
the dual-action coatings was greater than the single-action films, with the QA nanoparticles 
allowing for retained antibacterial action even after silver depletion.163  Similarly, Song et al. 
formed QA-modified polymer fibers doped with silver nanoparticles that were more bactericidal 
against E. coli and S. aureus than silver sulfadiazine.164 
Carpenter et al. reported the synthesis of NO-releasing QA-functionalized silica 
nanoparticles containing methyl, butyl, octyl, or dodecyl alkyl chains.138  All of the NO-releasing 
particles stored similar NO totals (~0.3 µmol NO/mg) regardless of QA modification, allowing for 
the evaluation of bactericidal action as a function of alkyl chain length independent of NO storage.  
Although the NO-releasing, QA-modified silica particles exhibited similar antibacterial action 
against planktonic cultures of P. aeruginosa as the single-action NO-releasing particles, the dual- 
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Figure 1.6 Mechanisms of action for quaternary ammonium (QA) compounds.  (B, C) QA 
compound associate with the cell membrane, replacing essential metal cations at the cell surface. 
(D) Intercalation of long alkyl chains into the cell membrane leads to membrane disruption and 
cell death. Reprinted with permission from Gilbert et al.159 Copyright 2005, John Wiley & Sons. 
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action particles were more effective at eradicating planktonic S. aureus than controls.  Further, the 
bactericidal action of the NO-releasing, QA-modified particles against S. aureus increased with 
increasing alkyl chain length, establishing the benefit of combining biocidal moieties with NO 
release.  Despite the improved antibacterial efficacy against Gram-positive bacteria, the NO-
releasing, QA-modified silica particles demonstrated toxicity to L929 fibroblast cells at 
concentrations required to eradicate planktonic bacteria, necessitating the development of an 
alternative dual-action macromolecular scaffold with improved bactericidal action and negligible 
toxicity to mammalian cells. 
1.6 Dendrimers as scaffolds for dual-action antibacterial agents 
Dendrimers are a family of hyperbranched macromolecular scaffolds exhibiting unique 
multivalent architectures and modifiable exterior functional groups (Figure 1.7).165, 166  Generally 
small in size (<5 nm) and monodisperse, dendrimers have recently been investigated as dual-action 
antibacterial scaffolds.167-169  Increasing the dendrimer generation allows for synthetic control over 
size and the number of terminal functional groups.170  Much work has focused on the modification 
of the dendrimer exterior with antibacterial functional groups, allowing for both the specific 
targeting of bacterial cell membranes and the combination of multiple biocides on a single 
scaffold.167, 171  The ability of dendrimers to associate with, cross, or even disrupt bacterial cell 
membranes, combined with their small scaffold size, makes dendrimers an attractive scaffold for 
developing combination therapeutics.172-174 
1.6.1  Antibacterial dendrimer scaffolds 
The antibacterial action of dendrimer scaffolds is dependent on the number of bactericidal end 
groups and the dendrimer’s ability to associate with and/or cross the bacterial cell membrane.175  
Both unmodified amino-terminated and modified (e.g., anionic, cationic, amphiphilic) 
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poly(amidoamine) (PAMAM) and poly(propyleneimine) (PPI) dendrimers have been shown to 
elicit antibacterial activity against Gram-negative and Gram-positive bacteria.167, 168, 171-174  Xue et 
al. reported the ability of amino-terminated PAMAM dendrimers to inhibit the growth of S. aureus 
and E. coli as a function of dendrimer generation.176  They found that the higher generations 
(generations 2 to 4) were more effective than the generation 1 (G1) scaffold.  S. aureus bacteria 
that survived exposure to G2 PAMAM dendrimers after several passages (15 d) displayed minimal 
increases in inhibitory concentration, indicating a lack of induction of bacterial resistance by the 
dendrimer scaffold. 
Amphiphilic compounds are known to perturb and disrupt bacterial cell membranes.  
Meyers et al. synthesized an anionic amphiphilic dendrimer scaffold that possessed efficient 
antibacterial activity against Gram-positive bacteria with minimal toxicity to eukaryotic cells.171  
Unfortunately, studies evaluating the effect of alkyl chain length on amphiphile bactericidal action 
resulted in no improvement in antimicrobial action with increasing alkyl chain length.  Similarly, 
Tulu et al. observed antibacterial action against Gram-negative and Gram-positive pathogens with 
both anionic- and cationic-terminated PAMAM dendrimers, with the cationic dendrimers 
generally demonstrating greater bactericidal efficacy.177   
As bacterial cell membranes are often hydrophobic and negatively charged, the use of 
cationic scaffolds allows for bacterial targeting leading to enhanced membrane disruption and 
permeation.178  Chen et al. reported that PPI dendrimers modified with QA moieties containing 
alkyl chains of eight or more carbons displayed the greatest antibacterial action, with activity 
against E. coli being dependent on both dendrimer size (i.e., generation) and alkyl chain length.160, 
179  Similarly, Charles et al. observed an increased ZOI for dodecylQA-modified generation 3 (G3) 
PAMAM dendrimers against E. coli and S. aureus compared to butylQA and hexylQA  
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Figure 1.7 Structure of poly(amidoamine) (PAMAM) dendrimer scaffold.  With each increase in 
generation (G0, G1, G2), dendrimer size increases linearly while the number of terminal functional 
groups (-NH2) increases exponentially. 
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modifications, with the latter systems exhibiting negligible antibacterial action at the 
concentrations tested.180  The antibacterial activity of cationic carbosilane dendrimers containing 
QA moieties was also reported by Javier de la Mata and coworkers.181-183  Increasing the number 
of QA moieties at the exterior of the carbosilane dendrimer scaffold improved the bactericidal 
action against both Gram-negative and Gram-positive bacteria over amine- and single QA-
functionalized dendrimers.183  Despite establishing the potential of QA-modified dendrimers for 
use as antibacterial agents, these initial investigations lacked a mechanistic understanding of 
bactericidal efficacy as a function of bacterial Gram designation and QA alkyl chain length. 
1.6.2  Nitric oxide-releasing dendrimers 
Previous work in the Schoenfisch lab demonstrated the ability to modify both PPI and 
PAMAM dendrimers with N-diazeniumdiolate and S-nitrosothiol NO donors.142, 143  Stasko et al. 
first reported the modification of PPI dendrimers with N-diazeniumdiolate moieties at primary 
amine sites.143  Due to the instability of primary amine N-diazeniumdiolates, the dendrimers were 
further functionalized to impart secondary amines on the scaffold prior to NO donor formation.  
Functionalizing the dendrimer scaffold altered the NO-release kinetics, with the more hydrophobic 
modifications resulting in longer NO-release half-lives than their hydrophilic counterparts.143  
Increasing the dendrimer generation from G3 to G5 within the same exterior modification slightly 
extended the NO-release half-life, although the statistical significance is unclear.   
These investigations were later expanded to include four PPI dendrimer generations (G2 – 
G5) and aromatic, hydrophilic, and hydrophobic functional groups.141  Similar to the initial work, 
the NO-release storage and kinetics were highly dependent on exterior modification, with the more 
hydrophobic functional groups (e.g., benzene rings, long alkyl chains) exhibiting longer NO-
release kinetics than the more hydrophilic functionalities (e.g., PEG, methyl groups).  Increasing 
34 
 
the dendrimer generation had an indiscriminate effect on NO-release kinetics.  While the more 
hydrophilic modifications demonstrated an increase in NO-release half-life at higher generations, 
little variance in the NO-release kinetics was observed for the hydrophobic groups; however, the 
statistical significance of these variations is again unclear.141  Alternatively, Lu et al. modified G1 
and G3 PAMAM scaffolds with a ratio of methyl and decene alkyl chains.  The resulting 
amphiphilic dendrimers were then tuned to exhibit similar NO-release totals and half-lives 
regardless of the hydrophobicity ratio or dendrimer generation (though dendrimers containing only 
hydrophilic methyl groups still maintained slightly faster NO-release kinetics).184  Based on these 
studies, the NO-release kinetics were observed to be more dependent on the hydrophobicity of the 
modification than the dendrimer generation. 
Nitric oxide-releasing dendrimers have displayed antibacterial action against both Gram-
negative and Gram-positive bacteria, including antibiotic-resistant strains.  For example,  Sun et 
al. reported the bactericidal action of G2 and G5 PPI dendrimers against planktonic cultures of P. 
aeruginosa and S. aureus as a function of dendrimer generation, exterior modification, and NO-
release capabilities.185  As expected, the more hydrophobic functionalities (e.g., benzene rings) 
were more effective at killing planktonic cultures than other modifications (e.g., PEG, methyl 
groups) due to increased association with the hydrophobic bacterial cell membrane.  The addition 
of NO-release generally improved the antibacterial action of the dendrimer scaffolds against both 
bacterial strains.  Additionally, the higher dendrimer generations exhibited greater bactericidal 
action than the lower generations, corresponding with more efficient NO delivery.   
Lu et al. also reported on the antibacterial action of amphiphilic NO-releasing dendrimers 
against planktonic and biofilm-based cultures of P. aeruginosa.184  Similar to previous 
observations, the dendrimers containing hydrophobic functional groups were more bactericidal 
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against planktonic P. aeruginosa than the hydrophilic methyl-modified dendrimers due to more 
rapid bacterial-association.  The most hydrophobic amphiphilic compositions also resulted in 
greater biofilm eradication.  Interestingly, the dendrimer structure exhibiting slight amphiphilicity 
(i.e., small ratio of hydrophilic side chains) was more effective than the purely hydrophobic-
modified dendrimers at eradicating P. aeruginosa biofilms.  This amphiphilic composition also 
resulted in faster and greater association of the dendrimer scaffold with the biofilm than the purely 
hydrophobic modification, suggesting that greater hydrophobicity may reduce the penetration of 
these scaffolds into the biofilm EPS matrix.    Despite the greater biofilm eradication observed for 
the more hydrophobic long alkyl chain modifications, these dendrimers were highly toxic to L929 
mouse fibroblast cells.  In contrast, the less hydrophobic amphiphiles had lower toxicity to 
mammalian cells at their anti-biofilm concentrations, with NO release increasing the antibacterial 
action, highlighting the benefit of combining multiple biocides on a single dendrimer scaffold. 
1.7 Summary of Dissertation Research 
The goal of my dissertation research was to design NO-releasing therapeutics for the 
eradication of biofilm-based infections.  First, I sought to develop dual-action antibacterial agents 
through the modification of poly(amidoamine) dendrimer scaffolds with various exterior 
functionalities and N-diazeniumdiolate NO donors.  The antibacterial and anti-biofilm actions of 
the resulting scaffolds were next evaluated as a function of exterior modification, dendrimer 
generation, and NO-release capabilities.  These dual-action antibacterial dendrimers were also 
incorporated into electrospun polyurethane fibers to produce polymers with potential utility as 
antibacterial wound dressings.  In summary, my research aimed to: 
1. Synthesize dual-action dendrimer biocides of varying dendrimer generation with 
distinct exterior modifications and tunable NO storage; 
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2. Assess the antibacterial action of dual-action dendrimers against planktonic 
bacteria as a function of dendrimer generation and exterior modification; 
3. Evaluate the ability of dual-action dendrimers to eradicate pathogenic biofilms and 
determine the corresponding anti-biofilm mechanism; and,  
4. Fabricate electrospun polyurethane fibers capable of antibacterial dendrimer and 
NO release as potential wound dressings. 
In this introductory chapter, I sought to describe how the formation and protective 
mechanisms of bacterial biofilms allows for the persistence of infection despite treatment with 
antibiotics.  The poor success of current anti-biofilm agents drives research related to the design 
of antibacterial agents capable of eradicating biofilms without fostering bacterial resistance.  The 
synthesis and characterization of a wide range of dual-action antibacterial dendrimers exhibiting 
biocidal exterior modifications (i.e., quaternary ammonium moieties, alkyl chains) and tunable NO 
storage are described in Chapter 2.  These dual-action, NO-releasing systems allowed for the 
detailed microbiological studies described in subsequent chapters.  In Chapter 3, the antibacterial 
action of dual-action dendrimers was evaluated against planktonic cultures of pathogenic bacteria 
such as those commonly isolated in clinical infections.  The ability of dual-action dendrimers to 
eradicate pathogenic biofilms, including Pseudomonas aeruginosa, Staphylococcus aureus, and 
methicillin-resistant Staphylococcus aureus, both alone and in concert with traditional antibiotics 
(i.e., vancomycin) is described in Chapter 4.  Chapter 5 outlines the fabrication of single-
component electrospun polyurethane fibers doped with antibacterial dendrimers modified with 
diverse exterior functionalities.  Chapter 6 describes the study of electrospun composite 
polyurethane fibers as a function of polyurethane composition and dendrimer dopant. The resulting 
antibacterial action of these materials was evaluated against model Gram-negative and Gram-
37 
 
positive pathogens.  Lastly, Chapter 7 provides a final summary of my research and suggests future 
investigations for the further development and evaluation of NO-releasing, dual-action 
antibacterial agents. 
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CHAPTER 2: 
Dual-Action Nitric Oxide-Releasing Poly(amidoamine) Dendrimers 
2.1 Introduction 
Nitric oxide (NO) is an endogenously produced free radical that regulates several 
biological functions in the cardiovascular, respiratory, and nervous systems.1, 2  Further, the up-
regulation of NO production in activated macrophages and monocytes is associated with host 
defenses against foreign pathogens.2-5  While the increased NO output in macrophages allows for 
a nonspecific defense mechanism to protect the host, the host cells themselves have evolved a 
detoxification mechanism against NO cytotoxicity.6  The broad-spectrum antibacterial activity of 
NO is derived from the production of reactive byproducts (e.g., dinitrogen trioxide and 
peroxynitrite) that compromise the bacterial membrane and cell function through both nitrosative 
and oxidative stresses.3, 7  The multi-mechanistic biocidal action of NO makes it effective against 
a multitude of infectious pathogens while minimizing its risk of fostering bacterial resistance.8   
The potential antibacterial activity of NO in vivo calls for efficient methods to chemically 
store and controllably release NO due to its short half-life in physiological milieu.  As such, several 
classes of NO donors have been developed to store and deliver NO, including organic nitrates, 
metal nitrosyls, S-nitrosothiols, and N-diazeniumdiolates.9  Of these NO donors, N-
diazeniumdiolates are well-suited for in vivo applications as they spontaneously dissociate under 
physiological conditions (pH 7.4, 37 °C) to produce two moles of NO for every mole of NO 
donor.10  Several small molecule N-diazeniumdiolate NO donors have been developed yielding a 
range of NO-release half-lives (i.e., PROLI/NO t1/2 ~ 1.8 s, DETA/NO t1/2 ~ 20 h).
10  
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Unfortunately,  the large doses of low molecular weight NO donors generally required to kill 
bacteria due to inefficient bacterial-association combined with the toxicity of the parent amine to 
healthy mammalian cells necessitates the development of more efficient methods for NO delivery.7   
Large molecular frameworks capable of storing and controllably releasing NO have been 
developed as novel antibacterial agents.  For example, our laboratory has reported the synthesis 
and bactericidal efficacy of both NO-releasing silica nanoparticles and dendrimers against several 
strains of bacteria.7, 11-13  Similar to small molecule NO donors, these scaffolds spontaneously 
release NO under physiological conditions; however, there are several advantages in using larger 
NO-release scaffolds over small molecules.  First, the rate and duration of NO release can be 
controlled as a function of size, structure, composition, and/or surface hydrophobicity of the 
scaffold.11, 13  These scaffolds can also be tailored using specific functional groups to target specific 
cells or reduce the toxicity of the scaffold while maintaining therapeutic levels of NO release.7   
Of the NO-releasing macromolecular scaffolds pioneered by our lab, dendrimers are a 
particularly promising candidate for the development of novel antibacterial agents.  Dendrimers 
are hyperbranched macromolecular polymers exhibiting unique multivalent architectures and 
modifiable peripheral functional groups, making them excellent scaffolds for drug delivery.14-16  
The chemical environment surrounding the dendrimer can be altered by modifying the terminal 
primary amines with various functional groups, allowing for specific targeting of bacterial cell 
membranes.14, 17  Increasing the dendrimer generation allows for facile synthetic control over 
scaffold size and increases the number of terminal primary amines, resulting in greater functional 
group density.15, 16  Combining these factors with their ability to associate with and/or cross 
bacterial cell membranes makes dendrimers ideal candidates for use as antibacterial agents.18, 19   
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Previous work in our lab has established the ability to modify both poly(amidoamine) 
(PAMAM) and poly(propylene imine) (PPI) dendrimers with N-diazeniumdiolate and S-
nitrosothiol NO donors.  Stasko et al. demonstrated the ability to tune NO-release characteristics 
by modifying the dendrimer scaffold with either primary or tertiary S-nitrosothiol donors.20  
Further work demonstrated the increased stabilization of N-diazeniumdiolate NO donors on 
secondary amine-functionalized PPI dendrimers over unmodified dendrimer primary amines.21  Lu 
et al. expanded on this work through the modification of generation 2 (G2) through generation 5 
(G5) PPI dendrimers with diverse exterior functionalities (e.g., aromatic, hydrophilic, 
hydrophobic) that were further modified with N-diazeniumdiolate NO donors on the resultant 
secondary amine sites.22  It was found that both NO-release totals and kinetics were dependent on 
the exterior modification of the dendrimer scaffold, with hydrophobic modification resulting in 
slightly longer dendrimer NO-release half-lives than those functionalized with hydrophilic groups.   
To further expand our toolbox of NO-releasing dendrimers capable of efficient 
antibacterial action, we modified PAMAM dendrimers with both biocidal functional groups and 
NO-release capabilities.  Poly(amidoamine) dendrimers of varying generation were first modified 
with contact-based biocides (i.e., quaternary ammonium moieties or alkyl chains) before N-
diazeniumdiolate modification.  In this chapter, we describe the synthesis and characterization of 
these dual-action dendrimer biocides prior to antibacterial evaluation. 
2.2 Materials and Methods 
Triethylamine (TEA), trimethylsilanolate, glycidyltrimethylammonium chloride, 
epichlorohydrin, dimethylbutylamine, dimethyloctylamine, and dimethyldodecylamine, were 
purchased from Sigma-Aldrich (St. Louis, MO).  Methyl acrylate, 1,2-epoxybutane, 1,2-
epoxyhexane, 1,2-epoxyoctane, 1,2-epoxydodecane, and ethylenediamine (EDA) were purchased 
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from the Aldrich Chemical Company (Milwaukee, WI).  Sodium methoxide (5.4 M solution in 
methanol) was purchased from Acros Organics (Geel, Belgium). Cellulose ester dialysis 
membranes (500-1000 MWCO) were purchased from Spectrum Laboratories, Inc. (Rancho 
Dominguez, CA).  Common laboratory salts and solvents were purchased from Fisher Scientific 
(Fair Lawn, NJ).  Nitrogen (N2), argon (Ar), and nitric oxide (NO) calibration (25.87 PPM, balance 
N2) gases were purchased from National Welders (Raleigh, NC).  Pure nitric oxide (NO) gas 
(99.5%) was purchased from Praxair (Sanford, NC).  Distilled water was purified using a Millipore 
Milli-Q UV Gradient A-10 system (Bedford, MA), resulting in a total organic content of ≤6 ppb 
and a final resistivity of 18.2 mΩ·cm.  All materials were analytical-reagent grade and used as 
received without further purification. 
2.2.1  Synthesis of quaternary ammonium-modified PAMAM dendrimers 
Poly(amidoamine) (PAMAM) scaffolds were synthesized as described previously,15, 16, 23 
by repeated alkylation/amidation steps using methyl acrylate and EDA from an EDA core.  The 
addition of QA functionalities to the dendrimer scaffold necessitated the synthesis of quaternary 
ammonium epoxides (QA-epoxides), as described previously.11  Briefly, 0.04 mmol 
epichlorohydrin was reacted with 0.01 mmol N,N-dimethylbutylamine, N,N-dimethyloctylamine, 
or N,N-dimethyldodecylamine at room temperature overnight (~18 h).  The mixture was then 
added dropwise to cold ether while sonicating, and the solid/viscous liquid QA-epoxides were 
collected via centrifugation (810×g, 5 min).  The supernatant was decanted, and the QA-epoxides 
were washed with 50 mL of cold ether and sonicated extensively.  This washing procedure was 
repeated three times before drying the product in vacuo. 
A ring-opening reaction was then carried out between the QA-epoxides and the terminal 
primary amines of the PAMAM dendrimers.  G1 or G4 PAMAM (50 mg) was dissolved in 5 mL 
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of methanol.  One equivalent of triethylamine (e.g., with respect to the molar amount of primary 
amines) and 2.5 molar equivalents of QA-epoxide were then added to the vial.  The solution was 
stirred at room temperature for 4 d.  Solvent was then removed in vacuo.  The dendrimers were 
subsequently dissolved in water and purified by dialysis against water overnight.  The pure product 
was recovered via lyophilization. 
Representative 1H NMR data of QA-modified dendrimers via the reactions of G4 PAMAM 
with glycidyltrimethylammonium chloride (methylQA), glycidyldimethylbutylammonium 
chloride (butylQA), glycidyldimethyloctylammonium chloride (octylQA), and 
glycidyldimethyldodecylammonium chloride (dodecylQA) included the following peaks.  G4 
methylQA: 1H NMR (400 MHz, D2O, δ) 3.07 (s, CH2N+(CH3)3), 2.31 (s, NCH2CH2C(O)NH).  G4 
butylQA: 1H NMR (400 MHz, CD3OD, δ) 2.30 (s, NCH2CH2C(O)NH), 1.81 (s, CH2N+(CH3)2CH2-
CH2CH2CH3), 1.36–1.30 (q, CH2N+(CH3)2CH2CH2CH2CH3), 0.93 (t, CH2N+(CH3)2CH2-
CH2CH2CH3).  G4 octylQA: 
1H NMR (400 MHz, CD3OD, δ) 2.31 (s, NCH2CH2C(O)NH), 1.80 
(s, CH2N
+(CH3)2CH2CH2(CH2)5CH3), 1.31–1.23 (m, CH2N+(CH3)2CH2CH2(CH2)5CH3), 0.83 (t, 
CH2N
+(CH3)2CH2CH2(CH2)5CH3).  G4 dodecylQA: 
1H NMR (400 MHz, CD3OD, δ) 2.31 (s, 
NCH2CH2C(O)NH), 1.81 (s, CH2N
+(CH3)2CH2CH2(CH2)9CH3), 1.32–1.22 (m, 
CH2N
+(CH3)2CH2CH2(CH2)9CH3), 0.83 (t, CH2N
+(CH3)2CH2CH2(CH2)9CH3). 
2.2.2 Synthesis of alkyl chain-modified PAMAM dendrimers 
To form alkyl chain-functionalized dendrimers without a QA moiety, G1 PAMAM 
dendrimers were modified with butyl, hexyl, octyl, and dodecyl alkyl chains.  Briefly, G1 PAMAM 
(100 mg) was dissolved in either 2 mL (butyl and hexyl modifications) or 5 mL (octyl and dodecyl 
modifications) methanol, and one equivalent of triethylamine (e.g., with respect to the molar 
amount of primary amines) and 1 molar equivalent of epoxide (i.e., epoxybutane, epoxyhexane, 
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epoxyoctane, or epoxydodecane) were then added to the vial.  The solution was stirred at room 
temperature for 3 d.  After reaction completion, solvent and excess epoxide was removed in vacuo.  
To ensure the removal of any unreacted epoxide, the single-action dendrimers were re-dissolved 
in 5 mL methanol and kept under vacuum overnight.  Complete removal of the epoxide was 
verified via 1H NMR spectroscopy. 
To investigate the effects of dendrimer generation, a ring-opening reaction was carried out 
between either epoxybutane or epoxyhexane and the terminal primary amines of the PAMAM 
dendrimers to yield single-action butyl- or hexyl-modified dendrimers.  Briefly, G2, G3, or G4 
PAMAM (100 mg) was dissolved in 2 mL of methanol, and one equivalent of triethylamine (e.g., 
with respect to the molar amount of primary amines) and 1 molar equivalent of epoxide were then 
added to the vial.  The solution was stirred at room temperature for 3 d.  After reaction completion, 
excess epoxide was removed in vacuo.  To ensure the removal of any unreacted epoxide, the single-
action dendrimers were re-dissolved in 5 mL methanol before being kept under vacuum overnight.  
Complete removal of the epoxide was verified via 1H NMR spectroscopy. 
Representative 1H NMR data of butyl- and hexyl-modified G4 PAMAM via the reaction 
of G4 PAMAM with epoxybutane and epoxyhexane included the following peaks.  G4 butyl: 1H 
NMR (400 MHz, MeOD, δ) 2.28 (s, NCH2CH2C(O)NH), 1.41–1.35 (m, 
NHCH2CH(OH)CH2CH3), 0.87–0.85 (t, NHCH2CH(OH)CH2CH3).  G4 hexyl: 1H NMR (400 
MHz, MeOD, δ) 2.28 (s, NCH2CH2C(O)NH), 1.34–1.20 (m, NHCH2CH(OH)C(H2)3CH3),  0.85–
0.81 (t, NHCH2CH(OH)C(H2)3CH3).  
2.2.3 N-Diazeniumdiolation of QA- and alkyl chain-modified PAMAM dendrimers 
To form N-diazeniumdiolate NO donors on the QA-functionalized dendrimer scaffold, 
QA-modified G1 and G4 PAMAM (20 mg) were added to varying ratios of anhydrous methanol 
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(MeOH) to tetrahydrofuran (THF) (1.5 mL solvent) depending on QA modification as follows: 
100% MeOH (methylQA, butylQA); 3:1 MeOH:THF (octylQA); 1:1 MeOH:THF (dodecylQA).  
Trimethylsilanolate was added in a 10-fold excess relative to secondary amines.   
To form N-diazeniumdiolate NO donors on the alkyl chain-modified dendrimer scaffold, 
single-action alkyl chain-modified G1 – G4 PAMAM (30 mg) were added to varying ratios of 
anhydrous MeOH to THF (1 mL solvent) depending on the alkyl chain modification and dendrimer 
generation as follows: 100% MeOH (G1 butyl, G2 butyl); 9:1 MeOH:THF (G3 butyl, G2 hexyl, 
G3 hexyl); 8.5:1.5 MeOH:THF (G4 butyl, G1 hexyl); 8:2 MeOH:THF (G4 hexyl); 3:2 MeOH:THF 
(G1 octyl); 2:3 MeOH:THF (G1 dodecyl).  The solutions were vortexed and then one molar 
equivalent (e.g., with respect to the molar amount of primary amines) of sodium methoxide was 
added. 
The dendrimer solutions were placed in a stainless steel reactor with continuous magnetic 
stirring and connected to an in-house NO reactor.  The vessel was flushed with Ar three times to a 
pressure of 7 bar, followed by three longer Ar purges (10 min) to remove trace oxygen from the 
solutions.  Following deoxygenation, the reactor was then pressurized to 10 bar with NO gas 
purified over KOH.  The pressure was maintained at 10 bar NO for 4 d, after which the solutions 
were again purged with Ar three times at short durations followed by extended purges (3 × 10 min) 
to remove unreacted NO.  Solvent was removed in vacuo, and the resulting NO-releasing 
dendrimers were dissolved in anhydrous methanol in a 1 dram glass vial, capped and parafilmed, 
and stored at -20 °C. 
2.2.4 Characterization of single- and dual-action PAMAM dendrimers 
1H nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker (400 MHz) 
spectrometer.  X-ray photoelectron spectroscopy (XPS) analysis was performed on a Kratos Axis 
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Ultra DLD X-ray Photoelectron Spectrometer with a monochromatic Al Kα X-ray source (150W).   
Electrons were collected at an angle of 90 degrees from the sample surface from a 300 x 700 µm2 
area on the sample.  The pass energy was set to 20 eV to obtain high resolution spectra.  All spectra 
were acquired with a step size of 0.1 eV and calibrated to the C1s peak at 284.6 eV.  Surface 
tension measurements were made using an Attension Sigma 701 tensiometer with a standard Du 
Noüy ring.  All UV measurements were obtained in methanol using an Evolution Array UV-
Visible Spectrophotometer (Thermo Scientific, Waltham, MA).  Infrared spectra were obtained 
using a Bruker Alpha FT-IR spectrometer operating in ATR mode and signal averaging over 18 
spectra. 
2.2.5 Characterization of NO storage and release 
Real-time NO release in deoxygenated PBS (pH 7.4, 37 °C) was monitored using a Sievers NOA 
280i chemiluminescence NO analyzer (NOA, Boulder, CO).  Prior to analysis, the NO analyzer 
was calibrated with air passed through a NO zero filter (0 ppm NO) and a 25.87 ppm NO standard 
gas (balance N2).  One milligram aliquots (or 0.5 mg for G1 octyl and dodecyl) of N-
diazeniumdiolate-functionalized PAMAM in methanol were added to 30 mL deoxygenated PBS 
to initiate NO release.  Nitrogen was flowed through the solution at a flow rate of 80 mL/min to 
carry the liberated NO to the analyzer.  Additional nitrogen flow was supplied to the flask to match 
the collection rate of the instrument at 200 mL/min.  Nitric oxide analysis was terminated when 
NO levels decreased to below 10 ppb NO/mg dendrimer.   
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Scheme 2.1 Reaction of PAMAM scaffold with either (A) QA or (B) alkyl chain epoxides to yield 
single-action dendrimers, followed by reaction with high pressures of NO to yield dual-action, 
NO-releasing dendrimers. 
 
  
65 
 
2.3 Results and Discussion 
2.3.1 Synthesis and characterization of quaternary ammonium-modified PAMAM Dendrimers  
Generation 1 (G1) and generation 4 (G4) PAMAM dendrimers were modified with QA 
moieties via a ring-opening reaction between the peripheral primary amines (n) and QA epoxides 
(Scheme 2.1 A).  To investigate the role of QA alkyl chain length on NO release, PAMAM 
dendrimers were functionalized with QA moieties containing methyl, butyl, octyl, and dodecyl 
alkyl chains.  While glycidyltrimethylammonium chloride (methylQA epoxide) is available 
commercially, butylQA, octylQA, and dodecylQA epoxides were synthesized through the reaction 
of epichlorohydrin with dimethylbutylamine, dimethyloctylamine, or dimethyldodecylamine, 
respectively.11  
The resulting QA epoxides were reacted with G1 (n=8) and G4 (n=64) PAMAM 
dendrimers in a 2.5-fold excess to the number of peripheral primary amines in methanol.  The 
number of QA moieties added to the dendrimer scaffold was determined using 1H NMR 
spectroscopy.  On average, 4 and 32 QA moieties were tethered to the G1 and G4 PAMAM 
scaffolds, respectively, resulting in approximately 50% functionalization of the peripheral primary 
amines (Table 2.1).  The addition of the quaternary ammonium to the dendrimer scaffold was 
confirmed using IR spectroscopy and X-ray photoelectron spectroscopy (XPS).  A weak IR stretch 
at 970 cm-1 indicative of the QA functional group was present for all QA-modified dendrimers 
(Figure 2.1 A).24  The N 1s binding energies of the PAMAM dendrimer amines ranged from 397 
– 399 eV, with an additional peak at 402 eV, corresponding to the quaternary ammonium group, 
present after modification with the QA moiety (Figure 2.1 B).25  Additionally, a doublet at 198 eV, 
absent for the PAMAM scaffold, was observed for the QA-modified dendrimers, signifying the 
presence of the chloride counter ion (Figure 2.1 C). 
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Table 2.1 Percent functionalization and corresponding molecular weight for QA-modified G1 and 
G4 PAMAM dendrimers.  
Dendrimer Average # QAs % Functionalized Molecular Weight (Da) 
G1 methylQA 4 ± 1 48 2006.2 
G1 butylQA 4 ± 1 53 2243.5 
G1 octylQA 4 ± 1 53 2479.2 
G1 dodecylQA 5 ± 1 58 2867.7 
G4 methylQA 35 ± 4 55 19522.1 
G4 butylQA 35 ± 7 55 20994.5 
G4 octylQA 30 ± 3 46 21709.0 
G4 dodecylQA 36 ± 3 56 25227.4 
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Figure 2.1 Representative (A) Fourier transform infrared spectra of G1 QA-modified dendrimers.  
Representative (B) N 1s and (C) Cl 2p XPS spectra for G1 QA-modified dendrimers. 
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Table 2.2 Nitric oxide-release properties for G1 and G4 QA-modified dendrimers in PBS (pH 7.4, 
37 °C) as measured by a chemiluminescence NO analyzer.a 
 
[NO]max
b 
(ppb/mg) 
tmax
c                   
(s) 
t[NO]d 
(µmol/mg) 
t[NO]4h
e 
(µmol/mg) 
t1/2
f          
(h) 
G1 methylQA/NO 15000 ± 3372 48 ± 7 1.50 ± 0.11 0.73 ± 0.07 4.4 ± 1.1 
G1 butylQA/NO 8675 ± 8182 61 ± 9 1.35 ± 0.30 0.78 ± 0.19 3.0 ± 0.5 
G1 octylQA/NO 3400 ± 1249 64 ± 5 1.30 ± 0.05 0.69 ± 0.06 3.6 ± 0.9 
G1 dodecylQA/NO 5016 ± 1379 71 ± 8 1.07 ± 0.16 0.72 ± 0.12 1.9 ± 0.8 
G4 methylQA/NO 5170 ± 252 52 ± 4 1.69 ± 0.22 0.77 ± 0.08 4.9 ± 0.6 
G4 butylQA/NO 4550 ± 3097 62 ± 13 1.48 ± 0.32 0.78 ± 0.18 3.8 ± 1.2 
G4 octylQA/NO 7721 ± 5372 62 ± 10 1.49 ± 0.41 0.86 ± 0.23 2.9 ± 0.4 
G4 dodecylQA/NO 3550 ± 1909 84 ± 4 1.17 ± 0.11 0.78 ± 0.06 1.9 ± 0.1 
aFor all measurements, n ≥ 3 pooled experiments. bMaximum flux of NO release. cTime required 
to reach maximum flux. dTotal NO payload released. eNO payload released after 4 h. fNO release 
half-life.  
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Figure 2.2 Representative UV-vis spectra for NO-releasing QA-modified dendrimers.  
Absorbance peak at ~253 nm is indicative of N-diazeniumdiolate NO donor. 
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Both G1 and G4 QA-modified dendrimers were exposed to high pressures of NO in the 
presence of a base to form N-diazeniumdiolate NO donors on secondary amines.  N-
diazeniumdiolate formation was confirmed by the presence of an absorbance maximum at 253 nm, 
a peak that was not observed in the absorbance spectra of QA-modified PAMAM dendrimer prior 
to diazeniumdiolate formation (Figure 2.2).7  Nitric oxide storage was tunable by adjusting the 
polarity of the charging solvent (i.e., by increasing the ratio of THF:methanol with increasing alkyl 
chain length).  The resulting NO-releasing QA-modified dendrimers exhibited similar 4 h NO 
payloads of approximately 0.76 µmol/mg (Table 2.2).  In this regard, the effects of both dendrimer 
generation and QA alkyl chain length on bactericidal efficacy could be evaluated independent of 
NO release totals. 
The N-diazeniumdiolated QA-modified dendrimers were characterized by an initial 
maximum burst of NO ([NO]max) after introducing the dendrimers into solution, followed by a 
steady decline in NO release.  For each generation, the time required to reach this maximum flux 
(tmax) increased as the QA alkyl chain length increased from methyl to dodecyl, with a concomitant 
decrease in the [NO]max values.  The increase in tmax with increasing alkyl chain length is attributed 
to the presence of the hydrophobic QA alkyl chains that decrease the rate of water diffusion to the 
secondary amine-bound NO donors.11  However, a decrease in NO-release half-life was also 
observed with increasing alkyl chain length, an opposite phenomenon than what might be expected 
from reduced water diffusion.  The observed decrease in half-life for longer (i.e., octylQA and 
dodecylQA) QA alkyl chains is likely due to the formation of dendrimer vesicles in aqueous 
solution, in which the hydrophobic alkyl chains of neighboring dendrimers face inwards (i.e., 
towards each other), exposing the portion of the dendrimer scaffold containing the N-
diazeniumdiolate to aqueous solution (Figure 2.3).  Indeed, Schenning et al. reported the formation 
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of dendrimer bilayers at pH 7.4 for hydrophobic alkyl chain-modified scaffolds.26  In this scenario, 
the hydrophobic alkyl chains align perpendicularly to the dendrimer scaffold, which faces the 
aqueous phase.26  To determine if the QA-modified dendrimers were in fact forming 
supramolecular structures in aqueous solution, the surface tension of phosphate buffered saline 
(pH 7.4) solutions with increasing concentrations of QA-modified dendrimers was measured to 
determine the critical vesicle concentration (CVC) for the dendrimer biocides (Figure 2.4 A-B).  
The CVCs of G4 octylQA and G4 dodecylQA were determined to be 29 ± 11 and 22 ± 4 µg/mL, 
respectively, suggesting the formation of vesicles in solution above these concentrations.  In 
comparison, the CVC of G4 butylQA was > 5 mg/mL due to the inability of the shorter QA alkyl 
chains to readily form vesicles at the concentrations employed herein.  Transmission electron 
microscopy further confirmed the formation of G4 dodecylQA vesicles (Figure 2.4 C). 
2.3.2 Synthesis and characterization of alkyl chain-modified PAMAM dendrimers 
Due to the inherent cationic nature of PAMAM dendrimers and their natural ability to 
associate with bacteria, we hypothesized that alkyl chain modification without QA moieties would 
reduce the synthetic burden to produce dual-action dendrimer biocides while still allowing us to 
evaluate the effects of alkyl chain length.  Thus, PAMAM dendrimers were functionalized with 
alkyl chains via a ring-opening reaction at the peripheral primary amines (Scheme 2.1 B).  We first  
synthesized single- and dual-action G1 PAMAM dendrimers modified with butyl, hexyl, octyl, or 
dodecyl alkyl chains to investigate the effects of alkyl chain length on NO release and bactericidal 
action without the presence of a quaternary ammonium.  To further evaluate the effects of 
dendrimer generation (i.e., size and functional group density) on antibacterial activity, we prepared  
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Figure 2.3 Formation of dendrimer vesicles at pH 7.4.  The hydrophobic alkyl chains of 
neighboring dendrimers face towards each other, exposing the N-diazeniumdiolate ions to aqueous 
solution. 
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Figure 2.4 Surface tension plots for (A) G4 dodecylQA and (B) G4 butylQA, demonstrating the 
decrease in surface tension with increasing dendrimer concentration.  Plot (A) indicates the 
leveling off of surface tension indicative of the CVC.  Error bars represent standard deviation of 
the mean. Transmission electron microscopy images (C) of G4 dodecylQA dendrimer vesicles 
(500 µg/mL in milli-Q water). 
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G1 (n = 8), G2 (n = 16), G3 (n = 32), and G4 (n = 64) butyl- and hexyl-modified PAMAM 
dendrimers with and without NO-release capabilities. 
After modification, the number of alkyl chains added to the G1 dendrimer scaffold was 
determined using 1H NMR spectroscopy.  On average, 5–6 functional groups were tethered to the 
G1 scaffold, resulting in approximately 65% functionalization (Table 2.3).  The addition of the 
alkyl chain modification was further verified with IR spectroscopy with a stronger IR stretch 
observed at 2900 cm-1 with increasing alkyl chain length, corresponding to the greater number of 
C–H bonds in the alkyl chain (Figure 2.5).  As longer alkyl chains resulted in vesicle formation 
for the QA-modified dendrimers, CVC values were also determined for each of the alkyl chain-
modified G1 PAMAM dendrimers by measuring the surface tension of solutions containing 
increasing concentrations of dendrimer.27  As expected, lower CVC values were measured for the 
longer chain G1 octyl and dodecyl dendrimers than the shorter G1 butyl or hexyl dendrimers 
(Table 2.3), indicating the formation of dendrimer vesicles at significantly lower concentrations.  
As such, chemiluminescent NO analysis for G1 octyl and dodecyl dendrimers was performed at 
concentrations below these CVC values to prevent vesicle formation from influencing the NO-
release kinetics. 
Alkyl chain-modified G1 dendrimers were exposed to high pressures of NO under basic 
conditions to form N-diazeniumdiolate NO donors on secondary amines.  Nitric oxide storage was 
tuned by increasing the ratio of THF:methanol with increasing alkyl chain length, resulting in  
similar NO payloads of ~1 µmol/mg.  The N-diazeniumdiolated alkyl chain-modified dendrimers 
were characterized by an initial maximum burst of NO after introducing the dendrimers into 
solution, followed by a steady decline in NO release.  Contrary to the QA-modified dendrimers, 
the time to reach this maximum flux was relatively constant regardless of alkyl chain length (Table  
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Table 2.3 Percent functionalization, corresponding molecular weight, and critical vesicle 
concentrations for alkyl chain-modified PAMAM dendrimers.  
 
No. Modified 
End Groups 
% 
Molecular 
Weight (Da) 
CVC 
(µg/mL) 
G1 butyl 5 ± 1 60 1776.1 3193 ± 3 
G1 hexyl 6 ± 1 73 2010.9 553 ± 11 
G1 octyl 5 ± 1 61 2058.3 31 ± 7 
G1 dodecyl 5 ± 1 63 2351.6 28 ± 7 
G2 butyl 11 ± 1 67 4026.4 3604 ± 2 
G2 hexyl 11 ± 1 69 4359.4 661 ± 5 
G3 butyl 24 ± 3 76 8667.3 2979 ± 3 
G3 hexyl 25 ± 2 78 9423.0 725 ± 4 
G4 butyl 43 ± 4 68 17330.2 3066 ± 2 
G4 hexyl 51 ± 4 80 19323.2 653 ± 10 
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Figure 2.5 Fourier transform infrared spectra of G1 alkyl chain-modified dendrimers. 
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2.4).  Further, a slight increase in NO-release half-life was observed for the longer octyl- and 
dodecyl-modified G1 dendrimers than the shorter butyl and hexyl chains (~21 to 37 min), 
indicating that the longer alkyl chains slightly impede water diffusion to the proton-labile N-
diazeniumdiolate NO donors.  Of note, the half-lives observed for the alkyl chain modifications 
were substantially lower than those of the QA-modified dendrimers (~0.5 h versus 2–5 h), 
suggesting that the quaternary ammonium group plays a significant role in determining NO-release 
kinetics.  Indeed, the presence of the permanent positive charge of the QA moiety may stabilize 
the N-diazeniumdiolate group, extending NO release.7, 22 
To evaluate the effects of dendrimer generation on NO release and bactericidal efficacy, 
epoxybutane or epoxyhexane was reacted with G1–G4 PAMAM dendrimers to yield butyl- and 
hexyl-modified PAMAM dendrimers.  The number of alkyl chains added to the dendrimer scaffold 
was determined using 1H NMR spectroscopy.  For each generation, approximately 70% of the 
terminal primary amines were modified with either butyl or hexyl chains (Table 2.3).  The surface 
tension of phosphate buffered saline (pH 7.4) solutions with increasing concentrations of alkyl 
chain-modified dendrimers were again measured to examine vesicle formation by the butyl- and 
hexyl-modified dendrimers at each generation.26  The CVCs of the butyl- and hexyl-modified 
dendrimers were ~3 mg/mL and ~650 µg/mL, respectively, with no dependence on dendrimer 
generation.  Based on these results, we concluded that vesicle formation does not occur at the 
concentrations required for NO release analysis.  As such, any differences in NO-release kinetics 
are solely due to dendrimer generation or alkyl chain length. 
Butyl- and hexyl-modified dendrimers were exposed to high pressures of NO under basic 
conditions to form N-diazeniumdiolate NO donors at secondary amines sites.  Nitric oxide storage 
was tunable by adjusting the ratio of THF to methanol in the N-diazeniumdiolate modification  
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Table 2.4.  Nitric oxide-release properties of alkyl chain-modified dendrimers in PBS (pH 7.4, 37 
°C) as measured by a chemiluminescence NO analyzer.a  
 
t[NO]b 
(µmol/mg) 
tmax
c 
(min) 
t1/2
d       
(min) 
td
e 
(h) 
G1 butyl/NO 1.06 ± 0.10 1.9 ± 0.4 21 ± 5 7 ± 2 
G1 hexyl/NO 0.98 ± 0.11 2.0 ± 0.8 24 ± 6 7 ± 1 
G1 octyl/NO 1.07 ± 0.13 2.8 ± 0.6 30 ± 5 9 ± 2 
G1 dodecyl/NO 1.12 ± 0.10 1.8 ± 0.4 37 ± 6 9 ± 1 
G2 butyl/NO 1.07 ± 0.15 1.2 ± 0.1 31 ± 5 10 ± 1 
G2 hexyl/NO 1.04 ± 0.12 1.3 ± 0.1 31 ± 8 10 ± 2 
G3 butyl/NO 0.93 ± 0.11 1.4 ± 0.6 26 ± 3 9 ± 1 
G3 hexyl/NO 0.90 ± 0.11 1.5 ± 0.4 25 ± 4 9 ± 1 
G4 butyl/NO 0.91 ± 0.09 1.5 ± 0.5 20 ± 3 8 ± 4 
G4 hexyl/NO 0.94 ± 0.07 1.3 ± 0.3 20 ± 1 10 ± 4 
aFor all measurements, n ≥ 3 pooled experiments. bTotal NO payload released. cTime required to 
reach maximum flux. dNO release half-life. eDuration of NO release. 
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Figure 2.6 Representative UV-vis spectra for NO-releasing alkyl chain-modified dendrimers.  
Absorbance peak at ~253 nm is indicative of N-diazeniumdiolate NO donor. 
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solvent.  N-diazeniumdiolate formation was confirmed by UV-vis spectroscopy with the presence 
of an absorbance maximum at 253 nm (Figure 2.6).7  Of note, little to no nitrosamine formation 
was observed after NO exposure, as evidenced by no absorbance maximum at 350 nm.28   
Chemiluminescence was used to evaluate real-time NO release in PBS (pH 7.4).  The alkyl 
chain-modified dendrimers released NO for approximately 10 h, yielding total NO payloads of ~1 
µmol/mg (Table 2.4).  Proton-initiated NO release was characterized by an initial burst of NO 
upon dendrimer introduction into aqueous solution, followed by a steady decline in NO release.  
The time required to reach the maximum NO flux (tmax) was similar for both the butyl- and hexyl-
modified dendrimers regardless of generation, indicating that the butyl and hexyl chains do not 
greatly influence water diffusion to the scaffold or N-diazeniumdiolate dissociation to NO.  
Similarly, each dendrimer system exhibited similar NO-release kinetics, with NO-release half-
lives (t1/2) of 20–30 min.  In this regard, the effects of generation and alkyl chain modification on 
antibacterial and anti-biofilm action could be evaluated independent of both NO-release totals and 
kinetics. 
2.4 Conclusions 
Poly(amidoamine) dendrimers of varying generation were successfully modified with 
either QA moieties or alkyl chains of varying length.  Nitric oxide-release kinetics were dependent 
on the type of modification (e.g., QA moiety or alkyl chain) and alkyl chain length but independent 
of dendrimer generation.  Quaternary ammonium-modified PAMAM dendrimers exhibited much 
longer NO-release half-lives than their alkyl chain-modified counterparts, suggesting the presence 
of the cationic QA moiety stabilizes the diazeniumdiolate and extends NO-release kinetics.  While 
the alkyl chain-modified G1 PAMAM dendrimers exhibited a slight increase in half-life with 
increasing alkyl chain length, the formation of vesicles at lower concentrations for the QA-
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modified dendrimers resulted in a significant decrease in NO-release half-life for the longer 
dodecylQA modifications at each generation.  Despite these differences in NO-release kinetics, 
altering the NO donor modification conditions allowed the total NO payloads to be tuned for each 
modification.  As such, bactericidal action can be evaluated independent of NO-release totals (QA 
modifications) and both NO-release totals and kinetics (alkyl chain modifications). 
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CHAPTER 3: 
Antibacterial Action of Dual-Action Dendrimers against Planktonic Bacteria 
3.1 Introduction 
Although antibiotics remain the gold standard in the treatment of bacterial infections, the 
increased occurrence of antibiotic-resistant bacteria coupled with a decline in the development of 
new antibiotics necessitates the development of alternative antibacterial agents.1  The co-
administration of two mechanistically different biocides has been demonstrated to reduce the 
emergence of bacterial resistance and can be synergistic, where the bactericidal efficacy of the 
combination is more effective than their individual sums.2, 3    Combining multiple biocides on a 
single macromolecular scaffold (e.g., nanoparticles, dendrimers) is expected to further increase 
bactericidal efficacy.4  Importantly, enhancing the bactericidal efficacy of a scaffold should lower 
the required therapeutic dose and concomitantly reduce any toxicity to healthy cells and tissue. A 
promising option for multimodal therapeutics is to modify non-depleting, contact-based 
antibacterial agents with chemistries that allow for spontaneous release of a secondary biocide, 
therefore increasing the antibacterial sphere of influence.  Further, the use of mechanistically 
different biocides reduces the emergence of resistance as bacteria are less likely to develop 
resistance to all of the employed mechanisms.2 
Nitric oxide (NO) is an endogenously produced, reactive free radical that plays a central 
role in the host defense against microbial pathogens.5, 6  The broad-spectrum antibacterial activity 
of NO is derived from the production of reactive byproducts (e.g., dinitrogen trioxide and 
peroxynitrite) that compromise the bacterial membrane and cell function through both nitrosative 
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and oxidative stresses.5, 7  The ability of NO to act through more than one bactericidal mechanism 
makes it effective against a multitude of infectious pathogens.  To harness the bactericidal actions 
of NO, large molecular frameworks capable of storing and controllably releasing NO have been 
developed as novel antibacterial agents.  Our laboratory has reported the synthesis and bactericidal 
efficacy of both NO-releasing silica nanoparticles and dendrimers against several strains of 
bacteria, including antibiotic-resistant strains.7-10  Benefits of these macromolecular scaffolds 
include controllable NO payloads and release rates, modifiable surface chemistries (e.g., to allow 
for the combination of multiple biocides on a single scaffold), and reduced toxicity to mammalian 
cells.8, 10  
Quaternary ammonium (QA) compounds, widely used as antiseptic and disinfectant 
agents, are popular non-depleting biocides due to their broad-spectrum efficacy.11  The bactericidal 
activity of QA compounds stems from the attractive electrostatic interactions between the cationic 
QA group and the negatively charged bacterial cell membrane, disrupting natural chemical 
balances by replacing essential metal cations.11  The addition of long alkyl chains to the QA group 
promotes bacterial membrane penetration, further amplifying biocidal activity.  The bactericidal 
efficacy of QA compounds is highly dependent on the length of this alkyl chain, with alkyl chains 
of at least eight carbon atoms demonstrating the greatest bactericidal activity due to increased 
penetration into the cell membrane.11-13  The combination of long chain QA moieties with a 
releasable biocide such as nitric oxide would thus be anticipated to increase antibacterial action.  
For instance, it has been demonstrated that QA-functionalized polymers capable of releasing silver 
ions (Ag+) exhibit a wider zone of inhibition than QA polymers alone.14, 15  Carpenter et al. 
similarly reported on NO donor-modified QA-functionalized silica nanoparticles with enhanced 
bactericidal efficacy against both Gram-positive and Gram-negative bacteria.8  Despite improved 
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antibacterial efficacy, however, the NO-releasing QA-modified silica particles demonstrated 
significant toxicity to mammalian cells at concentrations required to eradicate bacteria, motivating 
further development of these dual-action NO-releasing therapeutics. 
Dendrimers are a family of macromolecular scaffolds with hyper-branched architecture 
and multivalent surfaces that have been widely investigated for use as drug delivery and 
therapeutic vehicles.16, 17  The ability to functionalize the dendrimer exterior through 
straightforward chemical methods allows for their modification with specific biocidal end groups.  
This capability, combined with the ability of dendrimers to associate with and/or cross bacterial 
membranes, provides a potentially effective scaffold for the development of combination 
therapeutics.18, 19  Cooper and co-workers demonstrated that PPI dendrimers modified with QA 
moieties containing alkyl chains of eight or more carbons exhibited antibacterial activity as a 
function of dendrimer size and QA alkyl chain length.12, 20  Likewise, Charles et al. found that 
dodecylQA-modified G3 PAMAM dendrimers exhibited an increased zone of inhibition against 
Gram-negative Escherichia coli and Gram-positive Staphylococcus aureus compared to butylQA 
and hexylQA modifications.21   
Herein, we report the antibacterial action of single- and dual-action generation 1 (G1) and 
generation 4 (G4) QA-modified PAMAM dendrimers against planktonic cultures of both Gram-
negative and Gram-positive bacteria.  The effects of QA alkyl chain length, dendrimer generation, 
and bacterial Gram designation on dendrimer bactericidal action were evaluated.  To further 
elucidate the effects of alkyl chain length on antibacterial activity independent of a QA moiety, 
the bactericidal efficacies of G1 PAMAM dendrimers modified with butyl, hexyl, octyl, and 
dodecyl alkyl chains were also assessed.  Finally, we report on the effects of dendrimer generation 
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on antibacterial action through the evaluation of G1–G4 butyl- and hexyl-modified PAMAM 
dendrimers against planktonic bacteria. 
3.2 Materials and Methods 
Phenazine methosulfate (PMS), fetal bovine serum (FBS), trypsin, 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), penicillin 
streptomycin (PS), triethylamine (TEA), rhodamine B isothiocyanate (RITC), and propidium 
iodide (PI) were purchased from Sigma-Aldrich (St. Louis, MO).  Dulbecco's modified Eagle's 
medium (DMEM) and Dulbecco’s phosphate buffered saline (PBS) were obtained from Lonza 
Group (Basel, Switzerland).  4,5-Diaminofluorescein diacetate (DAF-2 DA) was purchased from 
Calbiochem (San Diego, CA).  Tryptic soy broth (TSB) and tryptic soy agar (TSA) were obtained 
from Becton, Dickinson and Company (Franklin Lakes, NJ).  Pseudomonas aeruginosa (P. 
aeruginosa; ATCC #19143), Staphylococcus aureus (S.aureus; ATCC #29213), and methicillin-
resistant S. aureus (MRSA; ATCC #33591) were obtained from American Type Tissue Culture 
Collection (Manassas, VA).  L929 mouse fibroblasts were obtained from the UNC Tissue Culture 
Facility (Chapel Hill, NC).  Carbon dioxide (CO2) was purchased from National Welders (Raleigh, 
NC).  Glass bottom microscopy dishes were received from MatTek Corporation (Ashland, MA).  
Common laboratory salts and solvents were purchased from Fisher Scientific (Fair Lawn, NJ).  
Distilled water was purified using a Millipore Milli-Q UV Gradient A-10 system (Bedford, MA), 
resulting in a total organic content of ≤6 ppb and a final resistivity of 18.2 mΩ·cm.  Unless noted 
otherwise, these and all other materials were analytical-reagent grade and used as received without 
further purification. 
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3.2.1  Planktonic bactericidal assays 
Lyophilized P. aeruginosa, S. aureus, and MRSA were reconstituted in tryptic soy broth 
(TSB) and cultured overnight at 37 °C.  A 0.5 mL aliquot of culture was grown in 50 mL TSB to 
a concentration of 108 colony forming units per mL (cfu/mL), collected by centrifugation 
(2355×g), resuspended in 15% glycerol (v/v in PBS), and stored at -80 °C in 1 mL aliquots.  For 
daily experiments, colonies of bacteria culture were inoculated in 2 mL TSB overnight at 37 °C 
and recultured in fresh TSB (50 mL) the next day. 
To assess the antibacterial action of QA-modified dendrimers, P. aeruginosa and S. aureus 
were cultured in tryptic soy broth to a concentration of 108 cfu/mL, collected by centrifugation 
(2355×g), resuspended in sterile phosphate buffered saline (PBS, pH 7.4), and diluted to 106 
cfu/mL.  Premeasured samples of QA-modified or NO-releasing QA-modified dendrimer in 
methanol were added to a 1 dram glass vial and dried under vacuum for 2 h prior to the bacteria 
assays.  Corresponding volumes of 106 cfu/mL bacteria were added to obtain a range of dendrimer 
concentrations (37 °C).  Untreated controls (blanks) were included in each experiment to ensure 
the bacteria remained viable (at 106 cfu/mL) over the 4 h assay.  The blanks and dendrimer-treated 
bacteria were then spiral-plated at 10- and 100-fold dilutions on tryptic soy agar plates using an 
Eddy Jet spiral plater (IUL; Farmingdale, NY).  Bacterial viability was assessed by counting the 
number of colonies formed on the agar plate using a Flash & Go colony counter (IUL; 
Farmingdale, NY).  Minimum bactericidal concentrations (MBC4h) were determined to be the 
minimum concentration of dendrimer that resulted in a 3-log reduction in bacterial viability 
compared to untreated cells after 4 h (i.e., reduced bacterial counts from 106 to 103 cfu/mL).  Of 
note, the plate counting method used has an inherent limit of detection of 2.5 x 103 cfu/mL.22 
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To test the antibacterial action of the alkyl chain-modified dendrimers, P. aeruginosa, S. 
aureus, and MRSA were cultured in TSB to a concentration of 108 colony forming units per mL 
(cfu/mL), collected by centrifugation (2355×g), resuspended in sterile PBS, and diluted to 106 
cfu/mL in pH 7.4 PBS.  For S. aureus and MRSA assays, the 106 cfu/mL solution in PBS was 
supplemented with 1% glucose and 0.5% TSB to ensure bacteria viability throughout the assay 
duration.  Of note, the addition of TSB did not influence the NO-release totals (i.e., NO totals were 
4.5 ± 1.8% lower in TSB-supplemented PBS; n ≥ 3).  Premeasured samples of single- or dual-
action dendrimer in methanol were added to a 1 dram glass vial and dried under vacuum for 2 h 
prior to the bacteria assays.  Corresponding volumes of 106 cfu/mL bacteria were added to obtain 
a range of dendrimer concentrations.  Untreated controls (blanks) were included in each 
experiment to ensure the bacteria remained viable (at 106 cfu/mL) over the 24 h assay at 37 °C.  
The blanks and dendrimer-treated bacteria were then spiral-plated at 10- and 100-fold dilutions on 
tryptic soy agar plates using an Eddy Jet spiral plater.  Bacterial viability was assessed by counting 
the number of colonies formed on the agar plate using a Flash & Go colony counter.  Minimum 
bactericidal concentrations (MBC24h) were determined to be the minimum concentration of 
dendrimer that resulted in a 3-log reduction in bacterial viability compared to untreated cells after 
24 h (i.e., reduced bacterial counts from 106 to 103 cfu/mL). 
3.2.2 Confocal microscopy to assess dendrimer-bacteria association 
Fluorescently-tagged G4 PAMAM dendrimers were synthesized as described 
previously.10, 23, 24  Briefly, 100 mg G4 PAMAM were added to a vial containing one molar 
equivalent of RITC (3.8 mg) in 2 mL methanol.  One equivalent of triethylamine (with respect to 
the molar amount of primary amines) was then added to the vial.  The solution was stirred for 24 
h in the dark, after which solvent was removed in vacuo.  Dendrimers were dissolved in water, 
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dialyzed against water (3 d), and then lyophilized.  The procedure for QA functionalization 
described in Section 2.2.1 was performed in the dark to modify the fluorescently-tagged G4 
PAMAM with methylQA, butylQA, and dodecylQA moieties.  P. aeruginosa and S. aureus were 
cultured as described above and diluted to 106 cfu/mL.  Aliquots of the bacteria solutions were 
incubated in a glass bottom confocal dish for 45 min at 37 °C.  A Zeiss 510 Meta inverted laser 
scanning confocal microscope with a 543 nm HeNe excitation laser (1.0 mW, 25.0% intensity) 
and a 560 – 615 nm band pass (BP) filter was used to obtain fluorescence images of the RITC-
modified dendrimers.  Both bright field and fluorescence images were collected using an N.A. 
(numerical aperature) 1.2 C-apochromat water immersion lens with a 40× objective.  Solutions of 
RITC-tagged dendrimers (100 µg/mL) in PBS (1.5 mL) were added to 1.5 mL of the bacteria 
solution in the glass confocal dish to achieve a final concentration of 50 µg/mL.  Images were 
collected every 2 min to temporally monitor association of the dendrimers with the bacteria. 
3.2.3 Confocal microscopy for detection of intracellular NO and cell death 
P. aeruginosa and S. aureus were cultured as described above and diluted to 106 cfu/mL in 
PBS containing 10 µM DAF-2 DA and 30 µM PI.  Aliquots of the bacteria solution were incubated 
in a glass bottom confocal dish for 45 min at 37°C.  A Zeiss 510 Meta inverted laser scanning 
confocal microscope with a 488 nm Ar excitation laser (30.0 mW, 2.0% intensity) and a BP 505 – 
530 nm filter was used to obtain DAF-2 (green) fluorescence images.  A 543 nm HeNe exciation 
laser (1.0 mW, 25.0% intensity) with a BP 560 – 615 nm filter was used to obtain PI (red) 
fluorescence images.  Both bright field and fluorescence images were collected using an N.A. 1.2 
C-apochromat water immersion lens with a 40× objective.  Solutions of G4 methylQA/NO, G4 
butylQA/NO, G4 octylQA/NO, or G4 dodecylQA/NO (40 µg/mL) in 1.5 mL PBS (containing 10 
µM DAF-2 DA and 30 µM PI) were added to 1.5 mL of the bacteria solution in the glass confocal 
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dish to achieve a final concentration of 20 µg/mL.  Images were collected every 5 min to 
temporally observe intracellular NO concentrations and bacteria cell death. 
3.2.4 In vitro cytotoxicity 
L929 mouse fibroblasts were grown in DMEM supplemented with 10 vol% FBS and 1 
wt% PS and incubated in 5 vol% CO2 under humidified conditions at 37 °C.  After reaching 80% 
confluency, the cells were trypsinized, seeded onto tissue culture-treated polystyrene 96-well 
plates at a density of 2 x 104 cells/mL, and incubated at 37 °C for 72 h.  The supernatant was then 
aspirated and replaced with 200 µL of fresh growth medium and either 50 µL of QA-modified 
dendrimer in PBS at the determined MBC4h against P. aeruginosa or S. aureus or 50 µL of alkyl 
chain-modified dendrimer in PBS at the lowest and highest planktonic MBC24h values.  Dimethyl 
sulfoxide (10%) and 50 µL PBS were used as positive and negative controls, respectively.  After 
incubation for 4 or 24 h at 37 °C, the supernatant was aspirated and 120 µL of a mixture of 
DMEM/MTS/PMS (105/20/1, v/v/v) was added to each well.  After 1.5 h incubation at 37 °C, the 
absorbance of the colored solutions was quantified at 490 nm using a Thermoscientific Multiskan 
EX plate reader (Waltham, MA).  The mixture of DMEM/MTS/PMS and untreated cells were used 
as a blank and control, respectively.  Results were expressed as percentage of relative cell viability 
as follows: 
                    % Cell Viability = [(Abs490 – Absblank)/(Abscontrol – Absblank)] x 100%              Eq. 3.1 
3.3 Results and Discussion 
3.3.1 Antibacterial action of QA-modified PAMAM dendrimers  
As P. aeruginosa and S. aureus represent two of the most commonly isolated species in 
chronic wounds, they were selected to test the antibacterial efficacy of the QA-modified 
dendrimers.25  Further, their use allowed us to examine the effect of Gram designation (i.e., Gram-
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positive or Gram-negative) on the bactericidal efficacy of these antibacterial agents.  Planktonic 
bacteria viability assays were performed under static conditions to determine the minimum 
dendrimer concentration required to elicit a 3-log reduction in bacterial viability over 4 h (MBC4h).  
The bactericidal NO dose for the NO-releasing QA-modified dendrimers was determined by 
multiplying the 4 h NO payload (t[NO]4h) by the corresponding MBC4h.   
The bactericidal efficacy of single-action (i.e., non-NO-releasing) QA-modified dendrimers was 
first assessed to determine the effects of QA alkyl chain length, dendrimer generation, and bacteria 
Gram designation on antibacterial activity prior to evaluating the effects of NO release.  All QA 
alkyl chain lengths exhibited a generation dependence on bactericidal efficacy against P. 
aeruginosa, with G4 QA-modified dendrimers resulting in improved killing (i.e., decreased 
MBC4h values) relative to their G1 counterparts (Table 3.1).  The generation-dependent increase 
in antibacterial activity against P. aeruginosa is attributed to the greater alkyl chain density of the 
G4 scaffold over the more sparsely functionalized G1 dendrimers.  Alternatively, only the 
methylQA-modified dendrimers exhibited a generation dependence against S. aureus.  While the 
bactericidal concentration of G1 methylQA against S. aureus was greater than 8.0 mg/mL, G4 
methylQA dendrimers resulted in complete bacterial killing at one-fourth that concentration (2.0 
mg/mL).  Although the shortest QA alkyl chain (methylQA) seemed to benefit from the increased 
functional group density of the G4 scaffold, no generation effect was observed for the remaining 
QA alkyl chain lengths, indicating that for antibacterials containing these longer QA alkyl chains 
(i.e., butylQA to dodecylQA), the mechanism of action against the Gram-positive pathogen S. 
aureus is not influenced by functional group density.  
Both dendrimer generation and QA alkyl chain length influenced bactericidal efficacy and 
were dependent on bacterial Gram designation.  While Gram-negative bacteria possess a lipid-rich  
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Table 3.1 Minimum bactericidal concentrations (MBC4h) and bactericidal NO doses for single- 
and dual-action QA-modified dendrimers against S. aureus and P. aeruginosa.a  
 S. aureus P. aeruginosa 
 
MBC4h 
(µg/mL) 
NO dose 
(µmol/mL) 
MBC4h 
(µg/mL) 
NO dose 
(µmol/mL) 
G1 PAMAM >8000  250  
G4 PAMAM 1000  30  
G1 methylQA >8000  1500  
G1 methylQA/NO 500 0.37 300 0.22 
G1 butylQA 3500  1500  
G1 butylQA/NO 500 0.39 300 0.23 
G1 octylQA 30  75  
G1 octylQA/NO 30 0.02 50 0.03 
G1 dodecylQA 10  20  
G1 dodecylQA/NO 10 0.01 10 0.01 
G4 methylQA 2000  500  
G4 methylQA/NO 300 0.23 250 0.19 
G4 butylQA 3500  1000  
G4 butylQA/NO 500 0.39 250 0.20 
G4 octylQA 30  30  
G4 octylQA/NO 20 0.02 30 0.03 
G4 dodecylQA 10  10  
G4 dodecylQA/NO 10 0.01 10 0.01 
aEach parameter was analyzed with multiple replicates (n ≥ 3). 
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outer membrane and a thin peptidoglycan sheet, the outer wall of Gram-positive bacteria is 
comprised of a thicker and more resistant peptidoglycan layer.26  For the short alkyl chains, both 
G1 and G4 scaffolds were more effective against Gram-negative P. aeruginosa than Gram-positive 
S. aureus.  The antibacterial activity of the short alkyl chain QAs is attributed to positively charged 
ammonium groups interacting with the negatively charged bacterial cell membranes.  Once 
associated, the QA functionality can induce cell death through a number of pathways, including 
disrupting membrane functions, replacing essential metal cations, interrupting protein activity, and 
damaging bacterial DNA.11, 13  The increased bactericidal action toward P. aeruginosa indicates 
greater association of the dendrimers with the outer membrane layers present in the Gram-negative 
bacterium, while the thick peptidoglycan layer of Gram-positive S. aureus likely reduced 
associated and QA-induced cell death.  Indeed, RITC-tagged G4 methylQA dendrimers associated 
with P. aeruginosa more rapidly than with S. aureus bacterial cells (Figures 3.1 and 3.2).  While 
association with P. aeruginosa was noted at 10 min, G4 methylQA dendrimer association with S. 
aureus was not observed until after 28 min.  In contrast, G1 dendrimers modified with longer QA 
alkyl chains more effectively killed S. aureus than P. aeruginosa, but neither modification 
demonstrated a Gram dependence with the G4 scaffold.  We believe that the penetration of the 
longer QA alkyl chains tethered to the G1 scaffold exerts greater physical damage to the thicker 
peptidoglycan layer of S. aureus compared to the outer membrane of P. aeruginosa.  This 
hypothesis, however, does not hold true for the G4 dendrimers, where the increased functional 
group densities afforded by the G4 scaffold result in similar killing against both strains of bacteria. 
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Figure 3.1.  Confocal microscopy images of P. aeruginosa exposed to 50 µg/mL RITC-tagged G4 
methylQA and G4 dodecylQA dendrimers at (A) 0, (B) 4, (C) 6, (D) 8, and (E) 10 min after 
dendrimer addition. Threshold reversed for clarity. 
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Figure 3.2.  Confocal microscopy images of S. aureus exposed to 50 µg/mL RITC-tagged G4 
methylQA and G4 dodecylQA dendrimers at (A) 0, (B) 20, (C) 24, (D) 28, and (E) 32 min after 
dendrimer addition.  Threshold reversed for clarity. 
  
98 
 
As expected, longer QA alkyl chains (i.e., octylQA, dodecylQA) were significantly more 
bactericidal than the shorter alkyl chains (i.e., methylQA, butylQA) for both dendrimer generations 
regardless of bacterial strain.  The increased efficacy of octylQA- and dodecylQA-modified 
dendrimers against S. aureus and P. aeruginosa is likely due to insertion of the longer alkyl chain 
groups into the peptidoglycan layer, resulting in physical disruption of the cell membrane.11  
Furthermore, the greater hydrophobicity of the octyl and dodecyl groups versus the shorter alkyl 
chains may allow for enhanced association of the dendrimers with the bacteria cell membranes.  
This is evident in the confocal microscopy images of RITC-tagged dendrimers with both P. 
aeruginosa and S. aureus, with G4 dodecylQA dendrimers associating to a greater extent in a 
shorter period of time than the G4 methylQA dendrimers (Figures 3.1 and 3.2).  The increased 
association efficiency combined with the potential for greater membrane damage results in 
dramatically enhanced killing for these biocides.  While the dodecylQA-modified dendrimers are 
slightly more effective than the octylQA-modified dendrimers for both generations, this trend does 
not apply to the methylQA- and butylQA-modified dendrimers.  For G1 dendrimers, the butylQA 
modification was more effective than methylQA against S. aureus, with a decrease in MBC4h from 
>8.0 to 3.5 mg/mL, respectively.  These results indicate that the slight increase in alkyl chain length 
may allow for better association of the G1 butylQA dendrimers, resulting in greater antibacterial 
activity against S. aureus.   
The same trend in bactericidal efficacy was not observed for the G4 scaffold.  In fact, G4 
methylQA dendrimers were almost twice as effective as G4 butylQA against both S. aureus and 
P. aeruginosa.  The lowered bactericidal efficacy is attributed to decreased dendrimer-bacteria 
association for the G4 butylQA dendrimers relative to the G4 methylQA system (Figure 3.3).  A 
number of factors may play a role in this decreased association.  Normally, the positively charged 
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ammonium group enhances association of the biocide with the bacteria membrane.  However, 
back-folding of the peripheral functional groups toward the dendrimer interior may shield the QA 
from the bacterial membrane, resulting in less membrane damage.27  Shielding effect are often 
further amplified for the G4 scaffold (as compared to G1) due to the closer proximity of terminal 
functional groups.  Although the bactericidal concentration of G4 butylQA was below the CVC 
(>5.0 mg/mL), a decrease in surface tension was still observed at these concentrations, which may 
be indicative of dendrimers assembling at the air-water interface instead of associating with 
bacteria in solution.28, 29  We hypothesize that the slightly longer alkyl chain amplifies both QA 
shielding and the formation of supramolecular assemblies for the G4 butylQA scaffold, reducing 
its bactericidal action from that of the methylQA system. 
The co-administration of active-releasing antibacterial agents with contact-based QA 
biocides has been shown to result in a more effective antibacterial treatment.14, 15  We thus sought 
to combine active NO release, itself a multi-mechanistic antimicrobial, with the contact-based 
biocidal attributes of QA-modified dendrimers.  The combination of NO release with the short QA 
alkyl chains dramatically increased the bactericidal efficacy for both G1 and G4 scaffolds, 
resulting in a 2 – 7 fold decrease in MBC4h values over single-action QA-modified dendrimers.  
For most of the scaffolds, the bactericidal NO doses required to kill S. aureus was nearly twice 
that required for P. aeruginosa (Table 3.1).  The larger NO dose for S. aureus killing is attributed 
to the more robust peptidoglycan layer inhibiting NO diffusion into the bacteria, while for P. 
aeruginosa the outer membrane and thinner peptidoglycan layer do not impede NO diffusion as 
efficiently.  The addition of NO release to the octylQA- and dodecylQA-modified G1 dendrimers 
resulted in increased bactericidal efficacy against P. aeruginosa compared to their non-NO-
releasing counterparts, but had no effect on their bactericidal action against S. aureus.  Imparting   
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Figure 3.3.  Confocal microscopy images of P. aeruginosa exposed to 50 µg/mL RITC-tagged 
(A) G4 methylQA and (B) G4 butylQA dendrimers after 20 min exposure.  Threshold reversed for 
clarity. 
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Figure 3.4.  Confocal microscopy images of P. aeruginosa and S. aureus exposed to 20 µg/mL 
G4 dodecylQA/NO dendrimers at (A) 0, (B) 25, (C) 35, (D) 45, and (E) 60 min after dendrimer 
addition. DAF-2 green fluorescence designates the presence of intracellular NO, while PI red 
fluorescence indicates compromised membranes (cell death). 
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NO release to the G4 dodecylQA dendrimers did not affect the efficacy against either pathogen; 
both the single- and dual-action dendrimers exhibited bactericidal action against S. aureus and P. 
aeruginosa at equivalent concentrations (10 µg/mL).  For this system, the long dodecyl chains 
likely cause increased physical disruption of the cell membrane, precluding intracellular NO 
buildup.  Intracellular NO levels and membrane disruption caused by the scaffolds were 
qualitatively assessed via confocal microscopy of bacterial suspensions stained with specific 
fluorescence probes (i.e., DAF-2 and PI).  In cases where NO serves as the lone antibacterial, a 
bright green fluorescent signal from DAF-2 (indicative of intracellular NO buildup) is generally 
observed prior to red fluorescence (PI), signifying membrane disruption and subsequent cell 
death.7  As this red fluorescence increases, the green fluorescence is concomitantly diminished as 
the DAF-2 diffuses out of the membrane-compromised bacteria.  Bacteria incubated with G4 
dodecylQA/NO, however, exhibited considerable membrane disruption before any significant NO 
accumulation (Figure 3.4).  For both P. aeruginosa and S. aureus, some intracellular NO was 
briefly observed after 25 min, but the significant membrane disruption observed for both strains 
shortly thereafter (at 35 min) supports our hypothesis that the dodecylQA modification 
compromises the cell membrane to such an extent it precludes the buildup of intracellular NO.   
Finally, we compared the bactericidal action of NO-releasing QA-modified dendrimers 
against unmodified G1 and G4 PAMAM scaffolds to determine if the combinatorial effects were 
indeed more efficacious.  The unmodified G1 and G4 dendrimers were significantly more effective 
against P. aeruginosa than S. aureus (Table 3.1).  For the G1 scaffold, both individual and dual 
action octylQA- and dodecylQA-modified dendrimers were more bactericidal than G1 PAMAM 
against both pathogens.  A similar result was obtained for the G4 modifications, with the exception 
of the individual and dual action G4 octylQA dendrimers, which exhibited equivalent bactericidal 
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efficacy as the G4 scaffold against P. aeruginosa.  Modifying the G1 and G4 scaffolds with short 
QA alkyl chains (i.e., methylQA and butylQA) greatly decreased their antibacterial action, with 
only G1 butylQA dendrimers exhibiting greater bactericidal efficacy against S. aureus than their 
corresponding PAMAM scaffold.  Efficacy of the NO-releasing methylQA and butylQA systems 
compared to the G1 and G4 scaffolds was dependent on bacterial Gram designation.  G4 
methylQA/NO and G4 butylQA/NO exhibited an almost 10-fold reduction in bactericidal action 
against P. aeruginosa from the G4 scaffold, while G1 methylQA/NO and G1 butylQA/NO 
maintained relatively similar antibacterial efficacy as G1 PAMAM.  However, all of the dual action 
QA-modified dendrimers displayed significantly greater bactericidal efficacy against Gram-
positive S. aureus than the unmodified PAMAM scaffolds, demonstrating the utility of these dual 
action dendrimers as broad-spectrum antibacterial agents. 
3.3.2 Antibacterial action of alkyl chain-modified PAMAM dendrimers 
As the bactericidal action of the QA-modified dendrimers was found to be highly dependent on 
alkyl chain length, we sought to investigate the effects of dendrimer hydrophobicity (i.e., alkyl 
chain length) on antibacterial action in the absence of the positively charged quaternary 
ammonium.  The antibacterial action of the alkyl chain-modified dendrimers was evaluated against 
the nosocomial pathogens P. aeruginosa, S. aureus, and methicillin-resistant S. aureus (MRSA).  
The use of these bacteria allowed us to further understand the effects of bacterial Gram class and 
antibiotic resistance on the bactericidal efficacy of the dendrimer biocides.  Similar to evaluation 
of QA-modified dendrimer antibacterial action, planktonic bacteria viability assays were 
performed under static conditions to determine the minimum dendrimer concentration required to 
elicit a 3-log reduction in bacterial viability over 24 h (MBC24h). 
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Table 3.2 Minimum bactericidal concentrations (MBC24h) for single- and dual-action alkyl chain-
modified dendrimers against planktonic P. aeruginosa, S. aureus, and MRSA.a  
 P. aeruginosa S. aureus MRSA 
 
MBC24h 
(µg/mL) 
MBC24h 
(µg/mL) 
MBC24h 
(µg/mL) 
Vancomycin  25 12.5 
G1 butyl 2000 3000 6000 
G1 butyl/NO 1000 2000 1000 
G1 hexyl 50 100 100 
G1 hexyl/NO 25 100 100 
G1 octyl 25 25 25 
G1 octyl/NO 25 25 25 
G1 dodecyl 25 25 25 
G1 dodecyl/NO 25 25 25 
G2 butyl 25 1000 1000 
G2 butyl/NO 50 2000 1000 
G2 hexyl 25 100 100 
G2 hexyl/NO 25 100 100 
G3 butyl 25 500 250 
G3 butyl/NO 50 1000 250 
G3 hexyl 10 50 50 
G3 hexyl/NO 25 50 100 
G4 butyl 50 500 500 
G4 butyl/NO 50 500 500 
G4 hexyl 25 100 100 
G4 hexyl/NO 25 50 100 
  aEach parameter was analyzed with multiple replicates (n ≥ 3). 
 
  
105 
 
Both the butyl- and hexyl-modified G1 dendrimers were more effective at eradicating 
planktonic P. aeruginosa than either S. aureus or MRSA (Table 3.2), corroborating our previous 
observations in which QA-modified dendrimers containing short alkyl chains exhibited greater 
bactericidal action against P. aeruginosa over S. aureus.30  The more effective killing was 
attributed to faster dendrimer association with P. aeruginosa bacteria and the inability of the 
shorter alkyl chains to effectively disrupt the thick peptidoglycan layer of Gram-positive S. aureus 
bacterial cells.26  As expected, the longer octyl and dodecyl alkyl chain modifications were more 
bactericidal than the shorter alkyl chains, especially against the Gram-positive bacterial strains.  
However, the G1 octyl and dodecyl dendrimers were equally effective at eradicating all three 
bacterial strains regardless of Gram designation, a discernable difference than the QA-modified 
system.  Of note, no increase in efficacy was observed for the dodecyl modifications over the octyl-
modified dendrimers.  G1 hexyl dendrimers exhibited similar efficacy against P. aeruginosa as the 
longer alkyl chain modifications, suggesting a limit to the benefits of increasing alkyl chain length, 
particularly for these longer bactericidal assays. 
Similar to previous observations, the addition of NO release was more beneficial for the 
shorter butyl and hexyl modifications than the longer octyl- and dodecyl-modified dendrimers.  
Indeed, G1 butyl/NO dendrimers exhibited greater bactericidal efficacy against all three bacterial 
strains compared to single-action G1 butyl, while G1 hexyl/NO dendrimers were slightly more 
effective at killing P. aeruginosa than G1 hexyl.  Neither the octyl nor dodecyl modifications 
benefited from the addition of NO-release capabilities against any of the strains tested.  Similar to 
the QA-modified dendrimers, this was attributed to these longer alkyl chains causing sufficient 
membrane damage to preclude the buildup of intracellular NO to bactericidal concentrations.30 
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The antibacterial action of G2 though G4 butyl- and hexyl-modified dendrimers was next 
evaluated to determine the effects of dendrimer generation on bactericidal action.  Following the 
trend observed for the G1 dendrimers, single-action (i.e., non-NO-releasing) butyl and hexyl 
modifications were more efficacious against P. aeruginosa regardless of generation.  The majority 
of the single-action biocides were equally effective against both Gram-positive bacteria strains, 
with only the G1 and G3 butyl biocides exhibiting dissimilar biocidal concentrations between S. 
aureus and MRSA.  The bactericidal concentration for G1 butyl was found to be double for MRSA 
over S. aureus (6 and 3 mg/mL, respectively) while the MBC24h for G3 butyl was greater for S. 
aureus over MRSA (500 and 250 µg/mL, respectively).  As such, bacterial antibiotic resistance 
was determined to have little effect on the bactericidal action of alkyl chain-modified dendrimers, 
most likely due to the contact-based killing mechanism of membrane disruption exhibited by the 
hydrophobic dendrimers.   
The hexyl-modified dendrimers were characterized by increased bactericidal activity over 
the butyl modifications against all three bacteria strains, likely due to greater membrane 
intercalation and cell membrane damage by the slightly longer hexyl chains.  Further, while the 
butyl-modified dendrimers exhibited a sizeable increase in antibacterial action at higher 
generations, the bactericidal action of the hexyl-modified dendrimers varied little with dendrimer 
generation.  G2–G4 butyl dendrimers proved more biocidal against each bacterial strain than G1 
butyl, suggesting that short alkyl chain modifications benefit substantially from greater functional 
group density.  Within the higher generations, G3 butyl dendrimers exhibited the greatest 
bactericidal action, requiring the lowest concentrations to eradicate each bacterial strain.  Likewise, 
the G3 hexyl dendrimers were more effective at eradicating planktonic bacteria compared to other 
generations, even though the hexyl-modified dendrimers demonstrated little variation in biocidal 
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activity with generation.  These observations suggest that the G3 scaffold may represent an optimal 
balance between size and functional group density, maximizing bactericidal action against both 
Gram-positive and Gram-negative bacteria. 
With the addition of NO release, the resultant biocidal action of the now dual-action 
dendrimer biocides was largely dependent on dendrimer generation.  The G1 scaffold benefited 
most from NO donor modification, with both G1 butyl/NO and G1 hexyl/NO dendrimers 
exhibiting greater efficacy than their non-NO-releasing counterparts.  In contrast, a slightly 
antagonistic effect was observed upon the addition of NO release to the G2 and G3 scaffolds.  
Indeed, G2 butyl/NO, G3 butyl/NO, and G3 hexyl/NO dendrimers all required similar or greater 
dendrimer concentrations to eradicate Gram-positive and Gram-negative bacteria versus controls 
(i.e., single-action biocides).  Little difference in bactericidal efficacy was observed between the 
single- and dual-action G4 dendrimers against any of the bacteria strains, suggesting that the 
increased functional group density of the larger scaffolds results in significant membrane damage, 
precluding any beneficial effects of NO release.   
3.3.3 In vitro cytotoxicity  
The relative toxicity against mammalian cells at bactericidal doses is critical to the design 
of any new antibacterial agent.  Although the clinical utility of long chain quaternary ammonium 
salts has been somewhat limited to topical applications due to their inherent toxicity, tethering QA 
moieties to larger scaffolds has been shown to mitigate their toxic effects.13, 31  The toxicity of the 
QA-modified dendrimers prepared herein was thus evaluated against L929 mouse fibroblast cells.  
The resulting dendrimer cytotoxicity was dependent on dendrimer generation, QA alkyl chain 
length, and biocide concentration (Figure 3.5).  While the G4 methylQA dendrimers were non-
toxic at 500 µg/mL (4% decrease in cell viability), increasing the biocide concentration four-fold 
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to 2.0 mg/mL reduced L929 cell viability by 20%.  In contrast, the toxicity of G4 butylQA 
dendrimers was generally independent of concentration (both 1.0 and 3.5 mg/mL reduced cell 
viability by 40%).  However, the toxicity of the butylQA functionality was generation dependent, 
with the G4 scaffold causing an additional 10% decrease in cell viability versus the G1 butylQA 
system at 3.5 mg/mL.  Of significance, the low (but highly antibacterial) concentrations (i.e., 10 
µg/mL) of the dodecylQA-modified dendrimers were relatively non-toxic, only reducing L929 cell 
viability by 15 and 2% for G1 and G4, respectively.   
While the large initial NO burst characteristic of these macromolecular scaffolds may yield 
toxic levels of NO at higher concentrations (i.e., those required to eradicate biofilms), the 
concentrations tested herein did not exhibit significant toxicity to mammalian cells.  Indeed, the 
NO-releasing QA-modified dendrimers proved to be relatively non-toxic, exhibiting >80% L929 
cell viability at the effective bactericidal concentrations.   Furthermore, NO release resulted in 
increased cell viability versus controls for nearly all of the QA modifications, demonstrating a 
substantial improvement over previously reported silica-based systems.8    For several of the 
scaffolds that exhibited the same bactericidal concentration for both the single- and dual-action 
QA-modified dendrimers, the addition of NO release resulted in increased fibroblast cell viability.  
For example, the G4 octylQA and G4 octylQA/NO dendrimers resulted in cell viabilities of 90 
and 101%, respectively, at 30 µg/mL doses.  These results indicate that the combination of low 
NO concentrations with QA moieties may be beneficial in decreasing the overall toxicity of QA 
scaffolds to mammalian cells.  It is important to note that the bactericidal doses for all of the NO-
releasing QA-modified dendrimers resulted in greater L929 cell viability than the unmodified G1 
and G4 PAMAM dendrimers, demonstrating the advantage of dual action therapeutics in reducing 
scaffold toxicity. 
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Figure 3.5.  Viability (%) of L929 mouse fibroblast cells following 4 h exposure to single- (blue) 
and dual-action (green) QA-modified dendrimers, as well as unmodified PAMAM dendrimers 
(red), at the MBC4h against (A) S. aureus and (B) P. aeruginosa compared to untreated control 
cells. For all measurements, n ≥ 3 pooled experiments with error bars representing standard 
deviation of the mean.  
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Figure 3.6.  Viability (%) of L929 mouse fibroblast cells following 24 h exposure to single- (blue) 
and dual-action (green) alkyl chain-modified dendrimers compared to untreated control cells.  
Values in parenthesis represent dendrimer concentration in µg/mL. For all measurements, n ≥ 3 
pooled experiments with error bars representing standard deviation of the mean.  
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The toxicity of alkyl chain-modified dendrimers was evaluated against L929 fibroblast 
cells at the highest and lowest bactericidal concentrations over 24 h.  In general, the alkyl chain-
modified dendrimers were overall less toxic than their QA counterparts.  All of the G1 alkyl chain 
dendrimers were relatively non-toxic at their highest bactericidal concentrations against planktonic 
bacteria, resulting in >80% cell viability compared to untreated controls (Figure 3.6 A).  For the 
most toxic G1 modifications (i.e., 6 mg/mL G1 butyl and 25 µg/mL G1 dodecyl), the addition of 
NO release resulted in improved cell viability.  While the decrease in toxicity for G1 butyl/NO 
dendrimers is likely due to the lower bactericidal concentration required, the dodecyl-modified 
dendrimers were tested at the same concentration with and without NO release.  Similar to the long 
alkyl chain QA modifications, the low levels of NO released by G1 dodecyl/NO dendrimers appear 
to mitigate some of the toxicity inherent to the dodecyl-modified scaffold, decreasing the reduction 
in cell viability from 15% to <1% at 25 µg/mL doses.   
Increasing the dendrimer generation appeared to have little impact on the toxicity of butyl- 
and hexyl-modified dendrimers at bactericidal concentrations.  Indeed, single-action butyl-
modified dendrimers exhibited >90% cell viability at concentrations up to 2 mg/mL regardless of 
dendrimer generation (Figure 3.6 B).  Within the hexyl modifications only the G4 hexyl scaffold 
exhibited significant toxicity, reducing cell viability by 67% at a concentration of 100 µg/mL.  As 
the G1 and G2 hexyl scaffolds reduced cell viability by <5% at similar concentrations, the dramatic 
increase in G4 hexyl toxicity is attributed to the increased functional group density afforded by the 
G4 scaffold.  Of note, butyl- and hexyl-modified G3 dendrimers, which exhibited the greatest 
bactericidal action, were non-toxic to mammalian cells (>94% viability at all concentrations 
tested). 
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The addition of NO release to the alkyl chain-modified scaffolds had mixed effects on 
dendrimer toxicity.  For most of the dendrimer modifications, the single- and dual-action 
dendrimers exhibited similar toxicity at the concentrations tested.  Nitric oxide-releasing G2 butyl 
dendrimers exhibited a concentration-dependent toxicity, with 1 and 2 mg/mL dendrimer 
concentrations resulting in 2 and 37% reductions in cell viability, respectively.  Alternatively, 
adding NO-release capabilities to the G4 hexyl scaffold decreased the toxicity by half, improving 
cell viability from 33 to 69% at 100 µg/mL.  These results suggest that NO toxicity is highly dose-
dependent.  While low NO concentrations help to mitigate some of the toxic effects of the 
dendrimer scaffold, larger NO doses (~2 µmol/mL and greater) detrimentally impact mammalian 
cells.   
3.4 Conclusions 
Both single and dual-action QA-modified PAMAM dendrimers exhibited biocidal activity 
against P. aeruginosa and S. aureus, with longer QA alkyl chains (i.e., octylQA, dodecylQA) 
proving more effective than shorter chain (i.e., methylQA, butylQA) modifications for both G1 
and G4 dendrimer scaffolds.  While previous work has suggested that QA compounds are more 
potent against Gram-positive versus Gram-negative bacteria due to the additional outer membrane 
barrier characteristic of Gram-negative bacteria, this observation has lacked a mechanistic 
understanding.12, 20  This work indicates that the potency of QA moieties against Gram-positive 
and Gram-negative bacteria is highly dependent on both the QA alkyl chain length and functional 
group density.  In contrast to a prior report,21 G4 dendrimers modified with shorter QA alkyl chains 
demonstrate reasonable bactericidal action against both P. aeruginosa and S. aureus, albeit at 
higher concentrations than those required for longer QA alkyl chain lengths.  While the addition 
of NO release markedly improves the bactericidal action of short alkyl chain QA-modified G1 and 
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G4 dendrimers against both bacteria strains, the longer alkyl chain QA dendrimers do not benefit 
from NO release in the same manner.  For these systems, the long alkyl chains induce significant 
damage to the bacteria membrane, greatly increasing their biocidal action but precluding the 
buildup of intracellular NO.   
The alkyl chain-modified dendrimers exhibited similar trends in bactericidal action as the 
QA modifications, with the shorter alkyl chains proving more effective against P. aeruginosa than 
S. aureus.  However, the longer octyl and dodecyl modifications were equally effective against 
each of the strains tested, suggesting the longer assay times allow for greater membrane damage 
to the bacterial cell regardless of Gram designation.  The addition of NO release had mixed effects 
on both the bactericidal action and cytotoxicity of the alkyl chain-modified dendrimers, with short 
alkyl chain-modified G1 dendrimers exhibiting greater bactericidal action with NO-release 
capabilities and the low levels of NO release from G4 hexyl dendrimers mitigating scaffold 
toxicity.  While the dual-action biocides did not exhibit dramatically improved bactericidal 
efficacy over the single-action dendrimers against planktonic bacteria, all systems were carried 
forward into biofilm assays due to the known challenges of eradicating these bacterial 
communities.  The majority of these dual-action QA- and alkyl chain-modified antibacterial agents 
continue to hold great therapeutic potential as they exhibit minimal toxicity to mammalian cells at 
the dendrimer concentrations required to elicit a three-log reduction in bacterial viability. 
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CHAPTER 4: 
Anti-Biofilm Efficacy of Dual-Action Dendrimers  
4.1 Introduction 
Nosocomial infections present a tremendous challenge to society, representing the fourth 
leading cause of death in the U.S. alone and resulting in over $5 billion in medical costs annually.1  
Approximately 10% of hospitalized patients acquire infections from opportunistic pathogens such 
as Pseudomonas aeruginosa and Staphylococcus aureus, which are notorious for forming chronic 
biofilms that resist standard antibiotic treatment.2  Biofilms form after planktonic bacteria 
irreversibly attach to a surface and produce an exopolysaccharide (EPS) matrix that surrounds and 
protects the bacterial community.3-5  Biofilm-based infections exhibit increased resistance to 
antibacterial agents, often requiring therapeutic doses 3–4 orders of magnitude greater than those 
required to eradicate planktonic bacteria.3  The inability of antibiotics to effectively eradicate 
biofilms is attributed to: 1) the EPS matrix limiting the diffusion of antibacterial agents into the 
biofilm; 2) slower bacterial metabolism reducing the efficacy of antibiotics; and, 3) the biofilm 
chemical microenvironment (e.g. pH, pCO2, pO2) adversely affecting antibacterial activity.
3  The 
inherent resistance of biofilms to traditional therapeutics combined with the increasing prevalence 
of antibiotic-resistant bacteria in clinical settings necessitates the development of new antibacterial 
agents that are capable of eradicating biofilms without fostering resistance.1, 6  
Combination therapies, or the co-administration of two mechanistically different 
antibacterial agents, have been demonstrated to increase the bactericidal efficacy of individual 
biocides while reducing the emergence of bacterial resistance.7, 8   Specifically, the combination 
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of a non-depleting, contact-based biocide with releasable antibacterial agents prolongs bactericidal 
action while increasing the overall antibacterial sphere of influence.9, 10  The enhanced bactericidal 
efficacy of the dual-action scaffold should lower the required therapeutic dose and concomitantly 
reduce any toxicity to healthy cells and tissue.7 
Nitric oxide (NO), an endogenously produced free radical, holds great potential as a 
releasable antibacterial agent due to its central role in the body’s immune response to infection.11, 
12  The broad-spectrum antibacterial action of NO is attributed to the production of reactive 
byproducts (e.g., dinitrogen trioxide and peroxynitrite) that compromise bacterial cell function and 
lead to membrane disruption through both nitrosative and oxidative stresses.11-13  Furthermore, the 
multi-mechanistic killing of NO makes it unlikely to foster bacterial resistance.14  Alternatively, 
contact-based biocides such hydrophobic alkyl chains can exert antibacterial activity through 
direct interactions, such as intercalating into and disrupting the hydrophobic cell membrane.15-17  
Our laboratory has developed a toolbox of large molecular frameworks capable of storing and 
controllably releasing NO for use as novel antibacterial agents.13, 18-22  Benefits of these 
macromolecular scaffolds include controllable NO release rates and payloads as well as allowing 
for the combination of multiple biocides on a single scaffold.23, 24   
Of the NO-releasing macromolecular scaffolds pioneered by our lab, poly(amidoamine) 
(PAMAM) dendrimers are a particularly promising candidate for the development of anti-biofilm 
agents.  Dendrimers are hyperbranched macromolecular polymers exhibiting unique multivalent 
architectures and modifiable peripheral functional groups, making them excellent scaffolds for 
drug delivery.25-27  The dendrimer exterior can be altered by modifying the terminal primary 
amines with various functional groups, allowing for specific targeting of bacterial cell 
membranes.25, 28  Increasing the dendrimer generation allows for facile synthetic control over 
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scaffold size and increases the number of terminal primary amines, resulting in greater functional 
group density.26, 27  Combining these factors with their ability to associate with and/or cross 
bacterial cell membranes makes dendrimers ideal candidates for use as anti-biofilm agents.29, 30  
Indeed, initial investigations into the anti-biofilm activity of dendrimer scaffolds have yielded 
promising results.  Johansson et al. functionalized peptide dendrimer scaffolds with LecB ligands 
and found that the multivalency afforded by the dendrimer scaffold increased LecB binding over 
monovalent ligands, inhibiting P. aeruginosa biofilm growth.31  Similarly, Hou et al. found that 
antimicrobial dendrimeric peptides reduced the formation of Escherichia coli biofilms by 93% 
compared to untreated controls.32  In our lab, Lu et al. reported increased killing of P. aeruginosa 
biofilms with hydrophobic dendrimers; unfortunately, these dendrimers were toxic to L929 mouse 
fibroblast cells at low concentrations (i.e., 10–30 µg/mL).33  The use of more hydrophilic 
amphiphiles provided to be less toxic at therapeutic levels while demonstrating greater anti-biofilm 
activity with NO release, indicating the benefit of combining multiple biocides on a single 
macromolecular scaffold.  Herein, we describe the anti-biofilm action of single- and dual-action 
generation 1 (G1) through generation 4 (G4) butyl- and hexyl-modified PAMAM dendrimers to 
determine the effects of exterior hydrophobicity (i.e., alkyl chain length), dendrimer size 
(generation), and NO release against both Gram-positive and Gram-negative biofilms.  We further 
evaluate the efficacy of NO-releasing G3 dendrimers in concert with the traditional antibiotic 
vancomycin against Gram-positive S. aureus and methicillin-resistant S. aureus biofilms. 
4.2 Materials and Methods 
Phenazine methosulfate (PMS), fetal bovine serum (FBS) trypsin, 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), penicillin 
streptomycin (PS), triethylamine (TEA), rhodamine B isothiocyanate (RITC), propidium iodide 
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(PI), and vancomycin hydrochloride (from Streptomyces orientalis) were purchased from Sigma-
Aldrich (St. Louis, MO).  Dulbecco's modified Eagle's medium (DMEM) and Dulbecco’s 
phosphate buffered saline (PBS) were obtained from Lonza Group (Basel, Switzerland).  4,5-
Diaminofluorescein diacetate (DAF-2 DA) was purchased from Calbiochem (San Diego, CA).  
Tryptic soy broth (TSB) and tryptic soy agar (TSA) were obtained from Becton, Dickinson and 
Company (Franklin Lakes, NJ).  Pseudomonas aeruginosa (P. aeruginosa; ATCC #19143), 
Staphylococcus aureus (S.aureus; ATCC #29213), and methicillin-resistant S. aureus (MRSA; 
ATCC #33591) were obtained from American Type Tissue Culture Collection (Manassas, VA).  
L929 mouse fibroblasts were obtained from the UNC Tissue Culture Facility (Chapel Hill, NC).  
The Centers for Disease Control and Prevention (CDC) bioreactor was purchased from BioSurface 
Technologies Corporation (Bozeman, MT).  Medical grade silicone rubber (1.45 mm thick) was 
purchased from McMaster Carr (Atlanta, GA) and doubled in thickness using Superflex Clear 
RTV silicone adhesive sealant (Loctite, Westlake, OH) to fabricate coupons to fit the CDC 
bioreactor (thickness ~4 mm; diameter ~12.7 mm).  Carbon dioxide (CO2) was purchased from 
National Welders (Raleigh, NC).  Collagen-coated glass bottom microscopy dishes were received 
from MatTek Corporation (Ashland, MA).  Common laboratory salts and solvents were purchased 
from Fisher Scientific (Fair Lawn, NJ).  Distilled water was purified using a Millipore Milli-Q UV 
Gradient A-10 system (Bedford, MA), resulting in a total organic content of ≤6 ppb and a final 
resistivity of 18.2 mΩ·cm.  Unless noted otherwise, these and all other materials were analytical-
reagent grade and used as received without further purification. 
4.2.1  Biofilm eradication assays 
Lyophilized P. aeruginosa, S. aureus, and MRSA were reconstituted in tryptic soy broth 
(TSB) and cultured overnight at 37 °C.  A 0.5 mL aliquot of culture was grown in 50 mL TSB to 
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a concentration of 108 colony forming units per mL (cfu/mL), collected by centrifugation 
(2355×g), resuspended in 15% glycerol (v/v in PBS), and stored at -80 °C in 1 mL aliquots.  For 
daily experiments, colonies of bacteria culture were inoculated in 2 mL TSB overnight at 37 °C 
and recultured in fresh TSB (50 mL) the next day. 
A CDC bioreactor was used to grow P. aeruginosa, S. aureus, and MRSA biofilms over 
48 h.34  Growth conditions (e.g., nutrient concentrations, additives, flow rate) were optimized for 
each biofilm system (bacterial strain).  Briefly, medical grade silicone rubber substrates were 
added to the coupon holders within the CDC bioreactor.  After autoclaving, the reactor effluent 
line was clamped and 500 mL sterile media (P. aeruginosa: 0.3 g/L TSB; S. aureus: 3.0 g/L TSB 
+ 0.1% glucose; MRSA: 4.0 g/L TSB) was added aseptically.  Bacteria were cultured in TSB to a 
concentration of 108 cfu/mL.  The bioreactor was then inoculated with either 1 mL (P. aeruginosa, 
S. aureus) or 2 mL (MRSA) of the resulting 108 cfu/mL bacterial suspension.  The completed 
assembly was incubated at 37 °C for 24 h with stirring (150 rpm; Reynolds number: 5000).  
Following this batch phase growth, the effluent line was opened, resulting in an effective volume 
of ~350 mL, and the reactor was continuously refreshed with new media (P. aeruginosa: 0.33% 
(v/v) TSB, 6 mL/min; S. aureus: 1% (v/v) TSB, 2 mL/min; MRSA: 5% TSB, 6 mL/min) for 
another 24 h to complete biofilm growth.  Premeasured samples of single- or dual-action dendrimer 
in methanol were added to a 2 dram glass vial and dried under vacuum for 2 h prior to the bacteria 
assays.  Biofilms grown on silicone rubber substrates were exposed immediately after 48 h growth 
to these single- or dual-action dendrimers in 3 mL PBS supplemented with 1% glucose and 0.5% 
TSB at 37 °C for 24 h with slight agitation.   Of note, the addition of TSB did not influence the 
NO-release totals (i.e., NO totals were 4.5 ± 1.8% lower in TSB-supplemented PBS; n ≥ 3).  For 
each experiment, 3 biofilms were untreated and incubated in glucose- and TSB-supplemented PBS 
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to confirm biofilm viability.  After 24 h incubation, the samples were sonicated (Elma Lab-Line 
9331, Melrose Park, IL;10 min, 60% power) and vortexed to disrupt the biofilm.  The blank and 
dendrimer-treated biofilm solutions were then spiral-plated at 10-, 100-, 1000-, and 10,000-fold 
dilutions on tryptic soy agar plates using an Eddy Jet spiral plater (IUL; Farmingdale, NY).  
Bacterial viability was assessed by counting the number of colonies formed on the agar plate using 
a Flash & Go colony counter (IUL; Farmingdale, NY).  The minimum biofilm eradication 
concentration (MBEC24h) was determined as the minimum concentration of dendrimer to reduce 
the viability of the biofilm to below the limit of detection for the plate counting method (2.5 x 103 
cfu/mL).35  
An adapted checkerboard assay36 was used to evaluate any possible synergistic effects 
between alkyl chain-modified dendrimers and the antibiotic vancomycin against Gram-positive 
biofilms.  Tested concentrations started at half the MBEC24h values for the dendrimer and 
vancomycin and were subsequently halved.  Premeasured samples of single- or dual-action 
dendrimer in methanol were added to a 2 dram glass vial and dried under vacuum for 2 h prior to 
the bacteria assays.  The appropriate amount of vancomycin was weighed out in a separate 2 dram 
glass vial.  To expose biofilms, 1.5 mL of PBS supplemented with 1% glucose and 0.5% TSB were 
added to each vial and then added to the biofilm sample in a 15 mL falcon tube for a final exposure 
volume of 3 mL PBS supplemented with 1% glucose and 0.5% TSB.  After exposure at 37 °C for 
24 h, biofilms were sonicated and plated as described above. 
4.2.2 Confocal microscopy to assess penetration into S. aureus biofilms 
Fluorescently-labeled G1 – G4 PAMAM dendrimers were synthesized as described 
previously.33, 37, 38  Briefly, 100 mg G1 through G4 PAMAM were added to separate vials 
containing one molar equivalent of RITC per mole dendrimer (G1: 37.5 mg; G2: 16.5 mg; G3: 7.8 
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mg; G4: 3.8 mg) in 2 mL methanol.  One equivalent of triethylamine (with respect to the molar 
amount of primary amines) was then added to the vial.  The solution was stirred for 24 h in the 
dark, after which solvent was removed in vacuo.  Dendrimers were dissolved in water, dialyzed 
against water (1–3 d), and then lyophilized.  The procedure for alkyl chain modification described 
in Section 2.2.2 was performed in the dark to modify the fluorescently-labeled G1 – G4 PAMAM 
with butyl and hexyl moieties. 
The visualization of RITC-tagged dendrimers penetrating into S. aureus biofilms was 
adapted from a previously reported assay.39  S. aureus was cultured in TSB to a concentration of 
108 cfu/mL, and 3 mL of the resulting bacteria suspension in TSB was added to a collagen-coated 
glass bottom confocal dish.  The bacteria were then incubated for 48 h at 37 °C with no agitation.  
After 2 d biofilm growth, the remaining TSB solution was removed, and the biofilms were washed 
with 1 mL sterile water and then kept in 1.5 mL PBS until exposure.  Solutions of RITC-labeled 
dendrimers (100 µg/mL) in PBS (1.5 mL) were added to the biofilm solutions to achieve a final 
concentration of 50 µg/mL.  A Zeiss 510 Meta inverted laser scanning confocal microscope with 
a 543 nm HeNe excitation laser (1.0 mW, 25.0% intensity) and a BP 560 – 615 nm filter was used 
to obtain fluorescence images of the RITC-modified dendrimers.  Z-stack fluorescence images 
were collected in 2 µm slices using an N.A. 1.2 C-apochromat water immersion lens with a 40× 
objective.  Images were collected every 10 min to temporally monitor dendrimer penetration into 
the biofilms. 
4.2.3 Confocal microscopy for detection of intracellular NO and cell death 
P. aeruginosa and S. aureus biofilms were grown on glass substrates (Biosurface 
Technologies) in the CDC bioreactor as described above.  P. aeruginosa and S. aureus biofilms 
were exposed to NO-releasing G1 butyl or G1 hexyl dendrimers (100 µg/mL) in PBS containing 
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10 µM DAF-2 DA and 30 µM PI for 1 – 2 h.  S. aureus biofilms were also exposed to NO-releasing 
G1 hexyl or G2 hexyl dendrimers (250 µg/mL) in PBS containing 10 µM DAF-2 DA and 30 µM 
PI for 2 – 3 h.  Before imaging, the substrates were dipped in PBS to remove excess dye and 
loosely adhered cells.  A Zeiss 510 Meta inverted laser scanning confocal microscope with a 488 
nm Ar excitation laser (30.0 mW, 2.0% intensity) and a BP 505 – 530 nm filter was used to obtain 
DAF-2 (green) fluorescence images.  A 543 nm HeNe exciation laser (1.0 mW, 25.0% intensity) 
with a BP 560 – 615 nm filter was used to obtain PI (red) fluorescence images.  Z-stack 
fluorescence images were collected in 5 µm slices using a Zeiss 1.2 C-apochromat lens with a 20× 
objective. 
4.2.4 In vitro cytotoxicity 
L929 mouse fibroblasts were grown in DMEM supplemented with 10 vol% FBS and 1 
wt% PS and incubated in 5 vol% CO2 under humidified conditions at 37 °C.  After reaching 80% 
confluency, the cells were trypsinized, seeded onto tissue culture-treated polystyrene 96-well 
plates at a density of 2 x 104 cells/mL, and incubated at 37 °C for 72 h.  The supernatant was then 
aspirated and replaced with 200 µL of fresh growth medium and 50 µL of varying concentrations 
of dendrimer in PBS.  Dimethyl sulfoxide (10%) and 50 µL PBS were used as positive and negative 
controls, respectively.  After 24 h incubation at 37 °C, the supernatant was aspirated and 120 µL 
of a mixture of DMEM/MTS/PMS (105/20/1, v/v/v) was added to each well.  After 1.5 h 
incubation at 37 °C, the absorbance of the colored solutions was quantified at 490 nm using a 
Thermoscientific Multiskan EX plate reader (Waltham, MA).  The mixture of DMEM/MTS/PMS 
and untreated cells were used as a blank and control, respectively.  Results were expressed as 
percentage of relative cell viability as follows: 
                    % Cell Viability = [(Abs490 – Absblank)/(Abscontrol – Absblank)] x 100%                Eq. 4.1 
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A killing curve was constructed for the single- and dual-action alkyl chain-modified dendrimers 
for each generation by plotting % cell viability vs dendrimer concentration.  IC50 values were 
determined for each curve, corresponding to the dendrimer concentration that resulted in a 50% 
reduction in cell viability. 
To assess the toxicity of single- and dual-action dendrimers in tandem with vancomycin, 
pre-measured samples of dendrimer and vancomycin were added to separate 1 dram glass vials.  
Each sample was dissolved separately in 100 µL PBS.  After aspirating the supernatant, the wells 
were filled with 200 µL of fresh growth medium, 25 µL of dendrimer sample, and 25 µL of 
vancomycin.  The cells were incubated for 24 h at 37 °C, and cell viability was determined as 
described above using Equation 4.1. 
4.3 Results and Discussion 
4.3.1 Anti-biofilm efficacy of alkyl chain-modified PAMAM dendrimers  
Although evaluation of antibacterial action against planktonic bacteria represents a viable 
screening method, the ability to eradicate pathogenic biofilms is more relevant for assessing the 
clinical utility of novel antibacterial agents.  P. aeruginosa, S. aureus, and MRSA biofilms grown 
on medical-grade silicone rubber substrates in a CDC bioreactor were exposed to varying 
concentrations of single- and dual-action dendrimer biocides in PBS (pH 7.4) to determine the 
minimum dendrimer concentration required to eradicate biofilms over 24 h (MBEC24h).  Of note, 
untreated biofilms resulted in average bacterial viabilities of 3 x 109, 7 x 107, and 2 x 107 cfu/mL 
for P. aeruginosa, S. aureus, and MRSA biofilms, respectively.  As the inherent detection limit of 
the plate counting method is 2.5 x 103 cfu/mL,35 total biofilm killing corresponded to 6- and 4-log 
reductions in bacterial viability against P. aeruginosa and S. aureus biofilms, respectively.  
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Analogous to planktonic studies, nearly all of the dendrimer biocides were more effective 
against P. aeruginosa than S. aureus (including MRSA) biofilms, with only the longer alkyl chains 
exhibiting equivalent action regardless of bacterial strain (Table 4.1).  The increased efficacy of 
both NO and short alkyl chain modifications against P. aeruginosa planktonic cultures has 
previously been attributed to both the thicker peptidoglycan layer present in S. aureus bacteria 
inhibiting NO diffusion and membrane disruption and the cytoprotective defenses exhibited by S. 
aureus against NO’s bactericidal activity.38, 40  However, the large disparity between the anti-
biofilm action of the butyl-modified dendrimers against Gram-negative and Gram-positive 
biofilms suggests differences in the biofilm architecture may further contribute to the increased 
NO tolerance of S. aureus biofilms over P. aeruginosa.  To elucidate the mechanism of dendrimer 
action against these biofilms, DAF-2 DA and PI fluorescent probes were utilized to visualize 
intracellular NO and cell membrane damage, respectively, via confocal microscopy.  After only 2 
h, G1 hexyl/NO dendrimers initiated substantial membrane damage to P. aeruginosa biofilms, 
while almost no intracellular NO or compromised membranes were observed for S. aureus 
biofilms (Figure 4.1).  The inability of G1 hexyl/NO dendrimers to cause damage to the S. aureus 
biofilms during a similar exposure to P. aeruginosa biofilms supports the hypothesis that 
differences in the biofilm architecture between these two bacterial strains affect the efficiency of 
dendrimer diffusion into the biofilm.  Of note, S. aureus biofilms produce copious amounts of 
extracellular proteins, DNA, and polysaccharides in their exopolysaccharide matrix,41 which may 
result in slower diffusion of dendrimer biocides into the biofilm.  Specifically, polycationic 
exopolysaccharides characteristically present in S. aureus biofilms may also electrostatically repel 
the cationic dendrimers, inhibiting biofilm penetrations.42  Further, P. aeruginosa and S. aureus 
biofilms exhibit distinct planktonic dispersal mechanisms, likely influencing their susceptibility to 
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antibacterial agents.  For example, several forms of P. aeruginosa biofilms demonstrate swarming 
dispersal, in which the outer wall of the biofilm consists of stationary bacteria exhibiting a biofilm 
phenotype while bacteria deeper within the biofilm remain planktonic cells, making them more 
vulnerable to the action of antibacterial agents.41  In contrast, S. aureus biofilms employ a clumping 
dispersal mechanism, shedding aggregates of bacteria from the biofilms instead of single cells.  
These smaller biofilm aggregates retain their exopolysaccharide matrix, and thus exhibit similar 
resistance to antibacterial agents as the parent biofilms.41  A combination of these architectural 
factors most likely contributes to the increased activity of the dendrimer biocides against P. 
aeruginosa biofilms over S. aureus. 
The hexyl-modified dendrimers exhibited superior anti-biofilm activity against P. aeruginosa 
biofilms regardless of dendrimer generation.  Neither the size of the dendrimer nor the functional 
group density affected hexyl chain-induced membrane damage or cell death against P. aeruginosa 
biofilms.  The hexyl-modified dendrimers also did not exhibit an improvement in anti-biofilm 
efficacy with the addition of NO release, suggesting that significant membrane damage initiated 
by the hexyl chains precludes the buildup of intracellular NO to bactericidal concentrations.38  In 
contrast, the butyl-modified dendrimers demonstrated greater anti-biofilm action with both 
increasing generation and NO-release capabilities, indicating the greater functional group density 
afforded by the higher generations improves the biocidal action of these shorter butyl chains. 
 The addition of NO release enhanced the anti-biofilm capabilities of all of the butyl-
modified dendrimers against P. aeruginosa biofilms.  The improved anti-biofilm efficacy of the 
dual-action butyl-modified dendrimers suggests the lack of membrane damage at lower 
concentrations (i.e., below the biocidal concentrations for single-action butyl-modified 
dendrimers) allows for the buildup of intracellular NO to bactericidal concentrations and NO- 
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Table 4.1 Minimum biofilm eradication concentrations (MBEC24h) for single- and dual-action 
alkyl chain-modified dendrimers against P. aeruginosa, S. aureus, and MRSA biofilms.a  
 
P. aeruginosa 
Biofilms 
S. aureus 
Biofilms 
MRSA 
Biofilms 
 
MBEC24h 
(µg/mL) 
MBEC24h 
(µg/mL) 
MBEC24h 
(µg/mL) 
Vancomycin  2000 5000 
G1 butyl 8000 >30,000 >30,000 
G1 butyl/NO 2000 10,000 20,000 
G1 hexyl 100 1000 2000 
G1 hexyl/NO 100 1000 1000 
G1 octyl 50 100 200 
G1 octyl/NO 50 100 200 
G1 dodecyl 100 100 200 
G1 dodecyl/NO 100 100 200 
G2 butyl 6000 >30,000 >30,000 
G2 butyl/NO 2000 5000 20,000 
G2 hexyl 150 4000 >10,000 
G2 hexyl/NO 150 2000 >10,000 
G3 butyl 2000 >30,000 >30,000 
G3 butyl/NO 1000 5000 20,000 
G3 hexyl 200 100 100 
G3 hexyl/NO 100 100 100 
G4 butyl 2000 >30,000 >30,000 
G4 butyl/NO 1000 20,000 20,000 
G4 hexyl 200 100 100 
G4 hexyl/NO 200 100 100 
aEach parameter was analyzed with multiple replicates (n ≥ 3). 
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Figure 4.1.  Confocal microscopy images of (A) P. aeruginosa and (B) S. aureus biofilms 
exposed to 100 µg/mL G1 hexyl/NO dendrimers for 2 h.  DAF-2 green fluorescence designates 
the presence of intracellular NO, while PI red fluorescence indicates compromised membranes.  
Threshold reversed for clarity.  
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mediated killing.  Confocal microscopy was used confirm this hypothesis by visualizing 
the buildup of intracellular NO and cell membrane damage (Figure 4.2).  A substantial amount of 
intracellular NO was noted after only 1 h upon exposure of P. aeruginosa biofilms to G1 butyl/NO.  
After 2 h, the bacteria membranes appear extensively compromised, indicating substantial cell 
death.  At this point, intracellular NO is no longer observed due to diffusion of DAF-2 out of the 
fully compromised membranes.13  Upon exposure to G1 hexyl/NO dendrimers, however, P. 
aeruginosa biofilms exhibited considerable membrane damage at 1 h, likely the result of the 
intercalation of the hexyl chains and not the bactericidal action of NO. 
Similar to G1 hexyl, octyl- and dodecyl-modified G1 dendrimers proved bactericidal against P. 
aeruginosa biofilms.  While G1 octyl dendrimers were slightly more effective at killing P. 
aeruginosa biofilms (MBEC24h = 50 µg/mL), the dodecyl-modified dendrimers exhibited similar 
efficacy as the hexyl modifications (MBEC24h = 100 µg/mL).  The decrease in anti-biofilm action 
observed for the dodecyl-modified dendrimers corroborates previous reports where hydrophobic 
decene-modified dendrimers were slightly less effective at eradicating P. aeruginosa biofilms than 
amphiphilic dendrimers, which was attributed to the increased hydrophobicity of the longer alkyl 
chains reducing efficient penetration into the biofilm exopolysaccharide matrix.33, 43  The lessened 
anti-biofilm action as a function of hydrophobicity was only apparent against P. aeruginosa 
biofilms, as both octyl- and dodecyl-modified dendrimers exhibited similar action against S. 
aureus (MBEC24h = 100 µg/mL).  The addition of NO release did not improve the anti-biofilm 
action of the octyl and dodecyl modifications against either bacterial strain, likely due to the 
increased membrane damage initiated by the longer alkyl chains precluding the buildup of 
intracellular NO. 
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Figure 4.2.  Confocal microscopy images of P. aeruginosa biofilms exposed to 100 µg/mL G1 
butyl/NO and G1 hexyl/NO dendrimers for (A) 1 h and (B) 2 h.  DAF-2 green fluorescence 
designates the presence of intracellular NO, while PI red fluorescence indicates compromised 
membranes.  Threshold reversed for clarity. 
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Figure 4.3.  Confocal microscopy images of S. aureus biofilms exposed to 50 µg/mL RITC-tagged 
(A) G1 butyl, (B) G2 butyl, (C) G4 butyl, (D) G1 hexyl, (E) G2 hexyl, and (F) G4 hexyl dendrimers 
for 1 h.  Threshold reversed for clarity. 
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The hexyl-modified dendrimers were more effective against S. aureus biofilms than the 
butyl modifications regardless of generation (Table 4.1), exhibiting at least an order of magnitude.  
Indeed, the butyl-modified dendrimers proved incapable of eradicating S. aureus biofilms at 
concentrations up to 30 mg/mL.  To elucidate why the hexyl-modified dendrimers exhibited a 
dramatic enhancement in anti-biofilm action over their butyl counterparts, confocal microscopy 
was used to visualize the extent to which RITC-tagged butyl- and hexyl-modified dendrimers 
associated with and penetrated into S. aureus biofilms.  As expected, both G1 hexyl (Figure 4.3 
D) and G4 hexyl (Figure 4.3 F) dendrimers exhibited extensive biofilm penetration relative to 
either G1 butyl (Figure 4.3 A) or G4 butyl (Figure 4.3 C) dendrimers.  These results indicate at 
least some of the increased anti-biofilm action of the hexyl modifications is due to their ability to 
infiltrate deeper into the biofilm at a faster rate than the butyl-modified dendrimers, in addition to 
hexyl chain-initiated membrane destruction. 
Nitric oxide release greatly improved the biocidal action of the butyl-modified dendrimers 
against S. aureus biofilms.  Increasing the dendrimer generation from G1 to G2 or G3 doubled the 
anti-biofilm action of the butyl system, with an MBEC24h value of 5 mg/mL for G2 and G3 
butyl/NO dendrimers versus 10 mg/mL for G1 butyl/NO.  The enhanced biofilm eradication is 
attributed to the greater functional group density of these larger scaffolds, facilitating more 
membrane disruption and biofilm-dendrimer association than the smaller G1 system.  However, 
the advantages of increased functional group density were mitigated for the G4 butyl/NO 
dendrimers, which demonstrated less anti-biofilm action than any of the dual-action butyl-
modified dendrimers against S. aureus biofilms (MBEC24h = 20 mg/mL).  While initially surprising 
as the G4 butyl/NO scaffold was effective against P. aeruginosa biofilms, the larger size of the 
dendrimers may limit diffusion into the S. aureus biofilms.  Confocal microscopy visualization of 
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biofilm penetration for RITC-tagged G1 butyl, G2 butyl, and G4 butyl dendrimers confirmed this 
hypothesis (Figure 4.3 A-C).  The G2 butyl dendrimers infiltrated the biofilm to a greater extent 
after 1 h, while G1 butyl dendrimers exhibited little dispersion, remaining mostly associated with 
the outermost region of the biofilm.  As such, the biofilm-penetrating G2 butyl scaffold allows for 
both cell membrane damage and internal NO release, resulting in more efficient biofilm 
eradication at lower dendrimer concentrations.  Alternatively, less association with the biofilm and 
decreased biofilm penetration was observed with the G4 butyl dendrimer system.  The 
accumulation of G4 butyl dendrimers at the biofilm surface (Figure 4.3 C) confirms the inability 
of this system to effectively breach the exopolysaccharide matrix. 
While the hexyl-modified dendrimers were more effective at eradicating S. aureus 
biofilms, the overall anti-biofilm action proved dependent on dendrimer generation.  As expected 
for highly antibacterial scaffolds, NO release provided little additional benefits on the anti-biofilm 
action of nearly all the hexyl modifications.  While G1 hexyl and G1 hexyl/NO dendrimers 
exhibited moderate anti-biofilm efficacy (MBEC24h = 1 mg/mL), both single- and dual-action G3 
and G4 hexyl dendrimers were appreciably more bactericidal and eradicated S. aureus biofilms at 
concentrations an order of magnitude lower (MBEC24h = 100 µg/mL).  The enhanced biofilm 
eradication capabilities are attributed to the increased functional group density of the G3 and G4 
scaffolds leading to greater membrane intercalation and biofilm penetration (Figure 4.3 F).  Of 
note, confocal microscopy further reveals the size of the G4 scaffold no longer inhibits its 
penetration into the biofilm when modified with hexyl alkyl chains, likely due to the increased 
hydrophobicity of the hexyl chains enabling improved association with and disruption of the 
exopolysaccharide matrix and bacterial cell membranes. 
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Single-action G2 hexyl dendrimers required a concentration four times greater than G1 hexyl for 
biofilm eradication (MBEC24h = 4 and 1 mg/mL, respectively), making it the least effective hexyl-
modified scaffold for biofilm eradication.  Confocal microscopy using RITC-tagged dendrimers 
revealed comparable biofilm penetration after 1 h between the G1 and G2 hexyl scaffolds (Figure 
4.3 D-E).  Thus, the reduced anti-biofilm activity is more likely the result of poor intercalation or 
membrane damage by the hexyl chains rather than hindered biofilm penetration of the scaffold.  
Further, NO release increased the antibacterial action of the G2 hexyl scaffold, supporting the 
hypothesis that the membrane damage caused by the hexyl chains does not prevent the buildup of 
intracellular NO.  As shown in Figure 4.4 A, biofilms exposed to G1 hexyl/NO dendrimers exhibit 
compromised cell membranes after 3 h with almost no intracellular NO present.  In contrast, 
considerable intracellular NO and negligible membrane damage were noted for biofilms exposed 
to G2 hexyl/NO dendrimers (Figure 4.4 B), verifying decreased membrane damage as the cause 
of reduced anti-biofilm action.  Factors that may be contributing to the decreased biocidal action 
of the G2 hexyl dendrimers include vesicle formation and backfolding of pendant functional 
groups towards the interior of the scaffold, reducing the exterior functional group density.38, 44-46 
Both single- and dual-action dendrimers exhibited similar bactericidal trends against 
MRSA biofilms, albeit mostly at higher bactericidal concentrations than for non-resistant S. 
aureus.  While butyl-modified dendrimers proved ineffective up to 30 mg/mL, the addition of NO-
release capabilities only moderately improved the anti-biofilm action of the butyl systems.  
Contrary to the results observed for S. aureus biofilms a generation dependence was not observed 
for the dual-action scaffolds, with all of the butyl/NO dendrimers eradicating MRSA biofilms at 
20 mg/mL.  The similar anti-biofilm action across all generations for the dual-action butyl 
modifications suggests that neither increased size nor functional group density influences the  
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Figure 4.4.  Confocal microscopy images of S. aureus biofilms exposed to 250 µg/mL (A) G1 
hexyl/NO and (B) G2 hexyl/NO dendrimers for 3 h.  DAF-2 green fluorescence designates the 
presence of intracellular NO, while PI red fluorescence indicates compromised membranes.  
Threshold reversed for clarity. 
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biocidal action of the dendrimers against MRSA biofilms.  Rather, a NO dose of ~20 µmol/mL is 
necessary for MRSA biofilm eradication in the absence of membrane damage. 
The generation dependence of the hexyl-modified dendrimers followed the same general 
trend as observed for S. aureus biofilms, with G3 and G4 hexyl dendrimers exhibiting greater 
efficacy against MRSA biofilms than either the G1 or G2 hexyl systems.  The concentrations of 
single- and dual-action G3 and G4 hexyl were identical for eradicating both MRSA and S. aureus 
biofilms (MBEC24h = 100 µg/mL).  Although G1 hexyl dendrimers were less effective against 
MRSA versus S. aureus (MBEC24h = 2 and 1 mg/mL, respectively), the addition of NO release 
increased their anti-biofilm action to similar levels (MBEC24h = 1 mg/mL).  G2 hexyl and G2 
hexyl/NO again represented the least effective anti-biofilm systems, with both being incapable of 
eradicating MRSA biofilms at concentrations up to 10 mg/mL.  Finally, the anti-biofilm action of 
the octyl- and dodecyl-modified dendrimers was reduced almost two-fold against MRSA biofilms 
from S. aureus (MBEC24h = 200 µg/mL and 100 µg/mL, respectively).  These results suggest that 
biofilms comprised of antibiotic-resistant bacteria decrease the anti-biofilm action of all but the 
most effective dendrimer biocides. 
As biofilms can often require therapeutic doses 3–4 orders of magnitude greater than those 
required to eradicate planktonic bacteria,3 we next compared the biofilm eradication 
concentrations for each strain to their corresponding planktonic bactericidal doses.  Against P. 
aeruginosa biofilms, all of the single- and dual-action G1 dendrimers only exhibited a 2–4-fold 
increase in therapeutic dose from planktonic bacteria.  A more substantial increase was observed 
for the higher generations, ranging from a 4-fold increase for G3 hexyl/NO to 240-fold for single-
action G2 butyl dendrimers.  The G2 butyl/NO dendrimers represented the largest gap in P. 
aeruginosa planktonic and biofilm eradication for the NO-releasing dendrimers with a 40-fold 
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concentration difference.  Similarly, the NO-releasing dendrimers exhibited a 2–40-fold increase 
in concentration against S. aureus biofilms and a 1–100-fold increase against MRSA biofilms.  
Alternatively, treatment of Gram-positive biofilms with vancomycin resulted in 80- and 400-fold 
increases in therapeutic dose over planktonic bacteria for S. aureus and MRSA, respectively, 
indicating another benefit of using NO as an anti-biofilm agent over traditional antibiotics. 
4.3.2 In vitro cytotoxicity  
Regardless of effective biocidal action, the utility of new antibacterial agents is ultimately 
dictated by their toxicity to mammalian cells.  Killing curves were constructed for the single- and 
dual-action alkyl chain-modified dendrimers for each generation by plotting % cell viability vs 
dendrimer concentration, and the concentration corresponding to a 50% reduction in L929 cell 
viability compared to untreated controls represented the inhibitory concentration at 50% viability 
(IC50). Toxicity was assessed using a therapeutic index (TI) by comparing the IC50 against L929 
mouse fibroblasts to the biofilm eradication concentrations for each dendrimer system, allowing 
the evaluation of the clinical utility for each biocide.  A higher TI index indicates a better toxicity 
ratio (i.e., greater bactericidal action with minimal toxicity to mammalian cells), while a TI below 
1 signifies extreme toxicity at biocidal concentrations. 
As expected, G1 octyl and dodecyl dendrimers exhibited significant toxicity (IC50 = 75 and 
40 µg/mL, respectively) due to the increased membrane intercalation and cell damage of the long 
alkyl chains (Table 4.2).  Similarly, hexyl-modified dendrimers were substantially more toxic than 
the butyl modifications, most likely due to the increased membrane disruption caused by the longer 
hexyl chains.  The toxicity of the hexyl-modified dendrimers increased with size (higher 
generations), as G4 hexyl dendrimers exhibited greater toxicity than the G1 scaffold (IC50 = 75 
and 1150 µg/mL, respectively).  Within each generation, however, the addition of NO release had 
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very little effect on the toxicity of the hexyl modifications.  The toxicity of the butyl-modified 
dendrimers was also dependent on dendrimer generation, with the G3 and G4 scaffolds (IC50 ~3 
mg/mL) exhibiting almost twice the toxicity of G1 or G2 butyl (IC50 values of ~8 and ~6 mg/mL, 
respectively).  Despite the generation dependence of the single-action dendrimers, dual-action 
butyl modifications resulted in similar toxicity regardless of dendrimer size (IC50 ~3 mg/mL), 
suggesting an NO dose of ~3 µmol/mL is relatively toxic to mouse fibroblast cells irrespective of 
functional group density. 
The overall therapeutic utility of the dendrimers as broad-spectrum antibacterial agents was 
determined by comparing the IC50 values against L929 cells for each system to their biofilm 
eradication concentrations and determining their TI.  Nearly all of the dendrimer biocides were 
capable of eradicating Gram-negative P. aeruginosa biofilms at non-toxic concentrations (i.e., TI 
> 1.00), with the exception of G1 butyl, G1 dodecyl, G1 dodecyl/NO, G4 hexyl, and G4 hexyl/NO 
(Table 4.3).  The greatest therapeutic utility was demonstrated by the G1 and G2 hexyl-modified 
dendrimers, which demonstrated maximal anti-biofilm action at concentrations well below their 
median inhibitory concentration (TI ≥ 7.50).  In contrast, the biofilm eradication concentrations 
for most of the single- and dual-action dendrimers against Gram-positive biofilms were greater 
than their corresponding IC50 values (TI < 1.00), limiting their clinical utility as broad-spectrum 
antibacterial agents.  The only scaffold capable of eradicating both Gram-negative and Gram-
positive biofilms at non-toxic concentrations was the G3 hexyl dendrimer system, with both single-
action and NO-releasing dendrimers eradicating biofilms at concentrations well below the IC50 
values (G3 hexyl TI ≥ 2.25; G3 hexyl/NO TI = 4.50).  These data suggest that the G3 scaffold, 
combined with the increased biocidal action of the hexyl modification, provides an optimal balance 
between dendrimer size and functional group density to maximize broad-spectrum antibacterial 
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Table 4.2 Inhibitory concentrations at 50% cell viability (IC50) for single- and dual-action alkyl 
chain-modified dendrimers against L929 mouse fibroblast cells.a  
 
IC50 
(µg/mL) 
G1 butyl 7700 
G1 butyl/NO 3000 
G1 hexyl 1150 
G1 hexyl/NO 750 
G1 octyl 75 
G1 octyl/NO 75 
G1 dodecyl 40 
G1 dodecyl/NO 40 
G2 butyl 6000 
G2 butyl/NO 2400 
G2 hexyl 1150 
G2 hexyl/NO 1150 
G3 butyl 2900 
G3 butyl/NO 2700 
G3 hexyl 450 
G3 hexyl/NO 450 
G4 butyl 3100 
G4 butyl/NO 3800 
G4 hexyl 75 
G4 hexyl/NO 150 
aEach parameter was analyzed with multiple replicates (n ≥ 3). 
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Table 4.3 Calculated therapeutic index (TI) for each dendrimer biocide against P. aeruginosa, S. 
aureus, and MRSA biofilms. 
 P. aeruginosa Biofilms S. aureus Biofilms MRSA Biofilms 
G1 butyl 0.96 <0.26 <0.26 
G1 butyl/NO 1.50 0.30 0.15 
G1 hexyl 11.50 1.15 0.58 
G1 hexyl/NO 7.50 0.75 0.75 
G1 octyl 1.50 0.75 0.38 
G1 octyl/NO 1.50 0.75 0.38 
G1 dodecyl 0.40 0.40 0.20 
G1 dodecyl/NO 0.40 0.40 0.20 
G2 butyl 1.00 <0.26 <0.26 
G2 butyl/NO 1.20 0.48 0.12 
G2 hexyl 7.67 0.29 <0.12 
G2 hexyl/NO 7.67 0.58 <0.12 
G3 butyl 1.45 <0.26 <0.26 
G3 butyl/NO 2.70 0.54 0.14 
G3 hexyl 2.25 4.50 4.50 
G3 hexyl/NO 4.50 4.50 4.50 
G4 butyl 1.55 <0.26 <0.26 
G4 butyl/NO 3.80 0.19 0.19 
G4 hexyl 0.38 0.75 0.75 
G4 hexyl/NO 0.75 1.50 1.50 
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action while minimizing toxicity to mammalian cells.  As such, both G3 hexyl and G3 hexyl/NO 
represent the most viable options for developing broad-spectrum anti-biofilm agents against the 
bacterial strains investigated herein. 
4.3.3 Synergy of dual-action dendrimers with vancomycin 
Another important aspect in the evaluation of combination therapies is the ability to 
demonstrate additive or synergistic bactericidal action with established therapeutics, namely 
traditional antibiotics.  The evaluation of potential synergy not only ensures that the combination 
of new and conventional therapies exhibits increased bactericidal activity, but also that the 
combination is not antagonistic, reducing the antibacterial action of the individual biocides.7  
Decreasing the required therapeutic concentration with increased biocidal action should mitigate 
toxic side effects to mammalian cells.  We thus sought to evaluate any possible synergistic effects 
between NO-releasing dendrimers and vancomycin in the eradication of both S. aureus and MRSA 
biofilms.   
Dual-action G3 butyl/NO and G3 hexyl/NO dendrimers were selected as test agents to 
evaluate the combined efficacy of NO release with vancomycin.  Single-action (i.e., non-NO-
releasing) G3 hexyl dendrimers were used as a control as they exhibited similar anti-biofilm 
efficacy as their NO-releasing counterparts,47 allowing us to evaluate any additional benefits of 
NO release.  The Gram-positive biofilms were exposed to single- or dual-action dendrimers 
concurrently with vancomycin using an adapted checkerboard assay, starting with concentrations 
at half the MBEC24h values for the dendrimer and vancomycin, and then subsequently halving 
them.36  Any resulting synergistic effects were determined by calculating the fractional bactericidal 
concentration index (FBC24h) using equation 4.2, where MBEC24hA and MBEC24hB represent the 
individual biofilm eradication concentrations for agents A and B, respectively, and MBEC24hAB 
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and MBEC24hBA are the concentrations of agents A and B constituting the most effective 
bactericidal combination as determined by the adapted checkerboard assay. 
                                    FBC24h =
MBEC24hAB
MBEC24hA
+
MBEC24hBA
MBEC24hB
        Eq. 4.2 
For each strain, FBC24h values between 0.50 and 1.00 indicate greater-than-additive (or moderately 
synergistic) bactericidal action, while an FBC24h ≤ 0.50 is defined as synergistic and FBC24h ≤ 0.25 
is highly synergistic.36, 48-50   
While G3 butyl/NO dendrimers were highly synergistic with vancomycin against S. aureus 
biofilms (FBC24h = 0.18), only moderate synergy with vancomycin was observed for MRSA 
biofilms (FBC24h = 0.63), most likely due to the inability of the G3 butyl scaffold to effectively 
penetrate MRSA biofilms.  Indeed, G3 butyl/NO dendrimers required four times the 
concentrations to eradicate MRSA over S. aureus biofilms.47  Combining G3 butyl/NO dendrimers 
with vancomycin resulted in an 8-fold decrease in dendrimer concentration (20 to 2.5 mg/mL) for 
the eradication of MRSA biofilms, indicating a marked improvement over G3 butyl/NO 
dendrimers alone.  Both G3 hexyl and G3 hexyl/NO demonstrated synergy (FBC24h = 0.50) with 
vancomycin against S. aureus biofilms, though the addition of NO release had no effect on the 
combined efficacy of the dual-action dendrimers (Table 4.4).  Alternatively, only G3 hexyl/NO 
dendrimers resulted in synergy with vancomycin against MRSA biofilms (FBC24h value of 0.50 
compared to 0.75 for G3 hexyl dendrimers), suggesting that NO improves the antibacterial action 
of the hexyl-modified dendrimer scaffold in concert with vancomycin against MRSA biofilms.   
To establish the utility of combining NO-releasing dendrimers and traditional antibiotics 
as anti-biofilm agents, the toxicity of the antibacterial combinations was evaluated against L929 
mouse fibroblast cells and compared to that of the individual biocides.  All of the combined 
dendrimer and vancomycin doses required to eradicate S. aureus biofilms demonstrated negligible 
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Table 4.4 Combined biofilm eradication concentrations and calculated fractional bactericidal 
concentration index (FBC24h) against S. aureus and MRSA biofilms.
a 
S. aureus 
Biofilms 
Dendrimer 
(µg/mL) 
Vancomycin 
(µg/mL) 
FBC24h 
G3 butyl/NO 250 250 0.18 
G3 hexyl 25 500 0.50 
G3 hexyl/NO 25 500 0.50 
MRSA   
Biofilms 
Dendrimer 
(µg/mL) 
Vancomycin 
(µg/mL) 
FBC24h 
G3 butyl/NO 2500 2500 0.63 
G3 hexyl 50 1250 0.75 
G3 hexyl/NO 25 1250 0.50 
  aEach parameter was analyzed with multiple replicates (n ≥ 3). 
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Figure 4.5.  Viability (%) of L929 mouse fibroblast cells following 24 h exposure to individual 
(solid) and combined (hashed) dendrimer and vancomycin biofilm eradication concentrations 
against (A) S. aureus and (B) MRSA biofilms. 
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toxicity (>95% viability) to fibroblast cells (Figure 4.5).  Although the combination of G3 hexyl 
and G3 hexyl/NO dendrimers with vancomycin only improved cell viability by 10–20%, the 
synergistic effects exhibited by G3 butyl/NO with vancomycin significantly reduced the toxicity 
of G3 butyl/NO dendrimers at therapeutic concentrations with an increase in cell viability from ~8 
to ~97%.  For the concentrations required to eradicate MRSA biofilms, both control and NO-
releasing G3 hexyl dendrimers exhibited insignificant toxicity in concert with vancomycin (~100% 
cell viability).  However, the combination of G3 butyl/NO and vancomycin required against 
MRSA biofilms still proved relatively toxic, only improving the cell viability of G3 butyl/NO 
dendrimers from ~6 to 30%.  Such toxicity is attributed to the larger concentrations of G3 butyl/NO 
required to eradicate MRSA biofilms (MBEC24h = 2.5 mg/mL G3 butyl/NO + 2.5 mg/mL 
vancomycin).   
4.4 Conclusions 
The utility of alkyl chain-modified PAMAM dendrimers as broad-spectrum anti-biofilm 
agents was assessed through the systematic evaluation of eradication efficiency as a function of 
dendrimer generation, alkyl chain length, and bacterial Gram class.  The anti-biofilm efficacy of 
alkyl chain-modified dendrimers was highly dependent on the biocide’s ability to penetrate into 
the biofilm and compromise cell membranes.  Hexyl-modified dendrimers were considerably more 
effective at biofilm eradication than the butyl systems, likely a result of greater membrane 
intercalation, cell membrane damage, and biofilm penetration.  While increased membrane 
damage precludes the buildup of intracellular NO to bactericidal concentrations for these 
modifications, the addition of NO release enhanced the anti-biofilm action of dendrimer biocides 
that did not adequately compromise cell membranes, indicating the utility of dual-action 
dendrimers as broad-spectrum antibacterial agents.  The G3 dendrimer scaffold represented the 
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ideal balance of dendrimer size and functional group density for optimal biofilm eradication due 
to its limited toxicity to mammalian cells, making these systems the most promising option for the 
design of broad-spectrum anti-biofilm agents.  Indeed, NO-releasing alkyl chain-modified G3 
dendrimers demonstrated moderate to high synergy with vancomycin in the eradication of Gram-
positive biofilms, indicating the possible clinical utility of these scaffolds. 
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CHAPTER 5: 
Nitric Oxide-Releasing Single-Component Electrospun Polyurethane Fibers 
5.1 Introduction 
Chronic wounds, including diabetic foot ulcers, pressure ulcers, and venous leg ulcers, pose 
a serious health risk, with successful treatment often hindered by inefficient eradication of 
opportunistic infectious pathogens such as Pseudomonas aeruginosa and Staphyloccocus aureus.1-
3  Characteristics of an ideal wound dressing thus include facile gaseous and fluid exchange, the 
absorption of excess wound exudates, and protection against infectious microorganisms.4  
Electrospun fibers are inherently porous and possess high effective surface areas, which protect 
the wound from bacterial infections and allow for increased water absorption capabilities, making 
them excellent alternatives to traditional wound dressings.4  Khil et al. demonstrated improved 
wound healing capabilities of electrospun polyurethane fibers over the commercially-available 
wound dressing Tegaderm (3M Health Care; St. Paul, Minnesota) in adult male guinea pigs.5  The 
electrospun dressings were found to increase the rate of epithelialization, as well as prevent both 
infectious microorganism permeation and fluid accumulation.  Electrospun fibers can also be 
modified to exhibit antibacterial action through the incorporation of therapeutic compounds into a 
blended, all-in-one dressing.4, 6, 7  Initial work in the development of antibacterial electrospun 
wound dressings has investigated the ability to achieve controlled release of antibiotics6-8 or silver 
ions9, 10 from electrospun fibers composed of a range of polymers (e.g., polyurethane, polylactic 
acid, gelatin).  However, the use of such antimicrobial agents continues to pose bacterial resistance 
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concerns that warrant the development of wound dressings capable of delivering antibacterial 
agents that are unlikely to foster resistance.  
Nitric oxide (NO) is a promising antibacterial agent for the treatment of chronic wounds as 
it exhibits broad-spectrum antibacterial activity.11  Further, NO has been shown to play a 
significant role in the wound healing process.12  Indeed, the application of exogenous gaseous NO 
was found to improve the healing of skin wounds in rats from the inflammatory to the reparation 
phase, leading to faster scar tissue remodeling with less inflammation.13  Further, the treatment of 
S. aureus-infected wounds with gaseous NO substantially improved wound healing over untreated 
infected wounds, with complete wound healing occurring nine days faster for the NO-treated 
wound.13  Unfortunately, the direct application of gaseous NO to a wound is not trivial, 
necessitating the development of alternative methods for NO delivery. 
In this regard, Weller et al. applied a NO-generating acidified nitrite cream to incision 
wounds two days after injury and found significant improvements in wound healing in both control 
(i.e., non-diabetic) and diabetic mice.14  Balkus and coworkers have developed zeolite-containing 
and acrylonitrile-based electrospun fibers capable of NO release, but did not evaluate the 
antibacterial activity or wound healing characteristics of these materials.15, 16  Wold et al. 
covalently modified polymers with thiol functionalities prior to electrospinning to yield S-
nitrosothiol-modified electrospun fibers with NO release characteristics dependent on the identity 
of the thiol precursor.17  The NO-releasing fibers were found to reduce Acinetobacter baumannii 
viability by 96% after 2 h.17  Similarly, Vogt et al. reported the design of a light-triggered NO-
releasing nanofibrous gelatin matrix using S-nitrosothiol NO donors that was capable of S. aureus 
growth inhibition.18 
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Our lab has developed macromolecular scaffolds capable of controllable NO storage and 
release, including silica nanoparticles and dendrimers.  Indeed, Koh et al. doped silica 
nanoparticles modified with either N-diazeniumdiolate or S-nitrosothiol NO donors into 
electrospun fibers as a function of polyurethane water uptake capabilities.19  The resulting NO-
releasing fibers exhibited average release durations of ~15 and ~300 h for N-diazeniumdiolate- 
and S-nitrosothiol-containing fibers, respectively.  The incorporation of dual-action dendrimers 
combining a contact-based biocide with NO release instead of the inert silica scaffold may improve 
the antibacterial properties of NO-releasing electrospun fibers.20-23  Herein, we describe the 
fabrication of single-component electrospun polyurethane fibers doped with dual-action 
poly(amidoamine) dendrimers and evaluation of their in vitro antibacterial action as a function of 
dendrimer modification. 
5.2 Materials and Methods 
Triethylamine (TEA), rhodamine B isothiocyanate (RITC), dimethyloctylamine, 
epichlorohydrin, phenazine methosulfate (PMS), fetal bovine serum (FBS), trypsin, 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt 
(MTS), penicillin streptomycin (PS), and glutaraldehyde solution were purchased from Sigma-
Aldrich (St. Louis, MO).  Methyl acrylate, 1,2-epoxyhexane, 1,2-epoxyoctane, 1,2-
epoxydodecane, and ethylenediamine (EDA) were purchased from the Aldrich Chemical 
Company (Milwaukee, WI).  Sodium methoxide (5.4 M solution in methanol) was purchased from 
Acros Organics (Geel, Belgium). Cellulose ester dialysis membranes (500-1000 MWCO) were 
purchased from Spectrum Laboratories, Inc. (Rancho Dominguez, CA).  Tecoflex (SG-80A) 
polyurethane was a gift from Thermedics (Woburn, MA). Hydrothane (AL 25-80A) polyurethane 
was a gift from AdvanSource Biomaterials Corp. (Willmington, MA). Tecoplast (TP-470) 
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polyurethane was a gift from Lubrizol (Cleveland, OH).  Dispensing needles for electrospinning 
(JG22-1.0P) were obtained from Howard Electronic Instruments, Inc (El Dorado, KS).  Dulbecco's 
modified Eagle's medium (DMEM) and Dulbecco’s phosphate buffered saline (PBS) were 
obtained from Lonza Group (Basel, Switzerland).  Tryptic soy broth (TSB) and tryptic soy agar 
(TSA) were obtained from Becton, Dickinson and Company (Franklin Lakes, NJ).  Pseudomonas 
aeruginosa (P. aeruginosa; ATCC #19143) and Staphylococcus aureus (S.aureus; ATCC #29213) 
were obtained from American Type Tissue Culture Collection (Manassas, VA).  L929 mouse 
fibroblasts were obtained from the UNC Tissue Culture Facility (Chapel Hill, NC).  Nitrogen (N2), 
argon (Ar), carbon dioxide (CO2), and nitric oxide (NO) calibration (25.87 PPM, balance N2) gases 
were purchased from National Welders (Raleigh, NC).  Pure nitric oxide (NO) gas (99.5%) was 
purchased from Praxair (Sanford, NC).  Common laboratory salts and solvents were purchased 
from Fisher Scientific (Fair Lawn, NJ).  Distilled water was purified using a Millipore Milli-Q UV 
Gradient A-10 system (Bedford, MA), resulting in a total organic content of ≤6 ppb and a final 
resistivity of 18.2 mΩ·cm.  Unless noted otherwise, these and all other materials were analytical-
reagent grade and used as received without further purification. 
5.2.1 Synthesis of QA- and alkyl chain-modified PAMAM dendrimers 
Poly(amidoamine) (PAMAM) scaffolds were synthesized as described previously20, 24, 25 
by repeated alkylation/amidation steps using methyl acrylate and EDA from an EDA core.  G4 
PAMAM dendrimers were then modified with either hexyl, octyl, and dodecyl alkyl chains or 
octylQA moieties.  To form alkyl-modified dendrimers,22 G4 PAMAM (100 mg) was dissolved in 
either 2 mL (hexyl modifications) or 5 mL (octyl and dodecyl modifications) methanol, and one 
equivalent of triethylamine (e.g., with respect to the molar amount of primary amines) and 1 molar 
equivalent of epoxide (i.e., epoxyhexane, epoxyoctane, or epoxydodecane) were then added to the 
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vial.  The solution was stirred at room temperature for 3 d.  After reaction completion, excess 
epoxide was removed in vacuo.  To ensure the removal of any unreacted epoxide, the single-action 
dendrimers were re-dissolved in 5 mL methanol before being kept under vacuum overnight.  
Complete removal of the epoxide was verified via 1H NMR spectroscopy (Bruker 400 MHz 
spectrometer).   
Representative 1H NMR data of alkyl chain-modified G4 PAMAM included the following 
peaks.  G4 hexyl: 1H NMR (400 MHz, MeOD, δ) 2.28 (s, NCH2CH2C(O)NH), 1.34–1.20 (m, 
NHCH2CH(OH)(CH2)3CH3),  0.85–0.81 (t, NHCH2CH(OH)C(H2)3CH3).  G4 octyl: 1H NMR (400 
MHz, MeOD, δ) 2.29 (s, NCH2CH2C(O)NH), 1.35–1.23 (m, NHCH2CH(OH)(CH2)5CH3),  0.83–
0.80 (t, NHCH2CH(OH)C(H2)5CH3).  G4 dodecyl: 
1H NMR (400 MHz, MeOD, δ) 2.27 (s, 
NCH2CH2C(O)NH), 1.34–1.20 (m, NHCH2CH(OH)(CH2)9CH3),  0.82–0.78 (t, 
NHCH2CH(OH)(CH2)9CH3).   
To form QA-modified dendrimers, quaternary ammonium epoxides (octylQA-epoxide) 
were synthesized as described previously.23, 26  Briefly, 0.04 mmol epichlorohydrin was reacted 
with 0.01 mmol N,N-dimethyloctylamine at room temperature overnight (~18 h).  The mixture 
was then added dropwise to cold ether while sonicating, and the solid/viscous liquid octylQA-
epoxide was collected via centrifugation (810×g, 5 min).  The supernatant was decanted, and the 
octylQA-epoxide was washed with 50 mL of cold ether and sonicated extensively.  This washing 
procedure was repeated three times before drying the product in vacuo.  A ring-opening reaction 
was then carried out between the octylQA-epoxide and the terminal primary amines of the 
PAMAM dendrimers.  G4 PAMAM (100 mg) was dissolved in 5 mL of methanol.  One equivalent 
of triethylamine (e.g., with respect to the molar amount of primary amines) and 2.5 molar 
equivalents of octylQA-epoxide were then added to the vial.  The solution was stirred at room 
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temperature for 4 d.  Solvent was then removed in vacuo.  The dendrimers were subsequently 
dissolved in water, followed by dialysis against water overnight and lyophilization. 
Representative 1H NMR data of QA-modified G4 PAMAM included the following peaks.  
G4 octylQA: 1H NMR (400 MHz, CD3OD, δ) 2.31 (s, NCH2CH2C(O)NH), 1.80 (s, 
CH2N
+(CH3)2CH2CH2(CH2)5CH3), 1.31–1.23 (m, CH2N+(CH3)2CH2CH2(CH2)5CH3), 0.83 (t, 
CH2N
+(CH3)2CH2CH2(CH2)5CH3).   
 5.2.2 N-Diazeniumdiolation of QA- and alkyl chain-modified PAMAM dendrimers 
To form N-diazeniumdiolate NO donors on the modified dendrimer scaffolds, single-action 
G4 PAMAM (30 mg) were dissolved in 1 mL of varying ratios of anhydrous methanol (MeOH) 
and tetrahydrofuran (THF) depending on the modification as follows: 8:2 MeOH:THF (G4 hexyl) 
or 1:1 MeOH:THF (G4 octyl, G4 dodecyl, G4 octylQA).  The solutions were vortexed and then 
one molar equivalent (e.g., with respect to the molar amount of primary amines) of sodium 
methoxide was added. 
The dendrimer solutions were placed in a stainless steel reactor with continuous magnetic 
stirring and connected to an in-house NO reactor.  The vessel was flushed with Ar three times to a 
pressure of 7 bar, followed by three longer Ar purges (10 min) to remove trace oxygen from the 
solutions.  Following deoxygenation, the reactor was then pressurized to 10 bar with NO gas pre-
scrubbed with KOH.  The pressure was maintained at 10 bar for 4 d, after which the solutions were 
again purged with Ar three times at short durations followed by extended purges (3 × 10 min) to 
remove unreacted NO.  Solvent was removed in vacuo, and the resulting dual-action, NO-releasing 
dendrimers were dissolved in anhydrous methanol in a 1 dram glass vial, capped and parafilmed, 
and stored at -20 °C. 
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5.2.3 Fabrication of single-component electrospun polyurethane fibers 
All polyurethane solutions (Tecoplast, Tecoflex, and Hydrothane) used herein were 12 
wt% (120 mg/mL) in 3:1:1 THF:DMF:MeOH.  Polyurethane solutions containing control and NO-
releasing dendrimers (10 mg/mL; 1 wt%) were prepared by first dissolving the polyurethane in 
THF and DMF, followed by the addition of dendrimer solution in the remaining equivalent of 
methanol.  
Electrospun fibrous mats were fabricated using a custom electrospinning apparatus27 
consisting of a ES20P-20W High Voltage power supply (Gamma High Voltage Research, Ormond 
Beach, FL), a Kent Scientific Genie Plus syringe pump (Torrington, CT), and grounded steel 
collector plate covered in aluminum foil.  All fibers were fabricated using an applied voltage of 15 
kV, 15 cm tip-to-collector distance, and 20 µL/min flow rate.  For all Tecoflex and Hydrothane 
fibers, 1.0 mL of polyurethane solution was electrospun and collected on aluminum foil, while 2.0 
mL of solution was required to obtain similar masses for the Tecoplast fibers.  After collection, 
fibers were cut using a 1.27 cm-diameter hole-punch to yield individual samples with a resultant 
surface area of 1.267 cm2. 
5.2.4 Characterization of NO storage and release 
Real-time NO release in deoxygenated PBS (pH 7.4, 37 °C) was monitored using a Sievers 
NOA 280i chemiluminescence NO analyzer (NOA, Boulder, CO).  Prior to analysis, the NO 
analyzer was calibrated with air passed through a NO zero filter (0 ppm NO) and a 25.87 ppm NO 
standard gas (balance N2).  Fibrous mat coupons (surface area: 1.267 cm
2) or 0.5 mg aliquots of 
N-diazeniumdiolate-functionalized PAMAM in methanol were added to 30 mL deoxygenated PBS 
to initiate NO release.  Nitrogen was flowed through the solution at a flow rate of 80 mL/min to 
carry the liberated NO to the analyzer.  Additional nitrogen flow was supplied to the flask to match 
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the collection rate of the instrument at 200 mL/min.  Nitric oxide analysis was terminated when 
NO levels decreased to below 1 pmol/cm2 for fibers (9.7 ppb) or 10 ppb NO/mg dendrimer.  Total 
amount of dendrimer incorporated per milligram of fiber were determined by measuring total NO 
release in 50 mM HCl at 37 °C. 
5.2.5 Characterization of electrospun polyurethane fibers 
Fiber diameter and morphology were assessed using either an environmental scanning 
electron microscope (ESEM; FEI Quanta 200 field emission gun, Hillsboro, OR) or a FEI Helios 
600 Nanolab Dual Beam System (Hillsboro, OR) without additional metal coating.  Fiber 
diameters were determined using NIH ImageJ software (Bethesda, MD) and were averaged for at 
least 150 measurements over three separate fiber samples.   
Water absorption of the electrospun fibrous mats was assessed by comparing weights of 
the dry and hydrated samples.  Dry electrospun fibers were weighed before soaking in Milli-Q 
water overnight at room temperature.  The hydrated samples were removed from water, and the 
excess surface water was removed by dabbing with a Kimwipe before weighing the samples again.  
Water absorption was calculated by the following equation, where WH is the weight of the hydrated 
sample and WD is the initial weight of the dry fibrous mat: 
                      Water Absorption (%) = [(WH – WD)/WD] x 100%              Eq. 5.1 
The porosity of electrospun fibrous mats was determined using the liquid intrusion 
method.28, 29  Fiber mats were weighed prior to immersion in 100% ethanol at room temperature 
overnight to allow diffusion of ethanol into the void volume.  After incubation, fibers were 
removed from ethanol, dabbed with a Kimwipe, and weighed again.  Porosity was calculated by 
dividing the volume of intruded ethanol (determined by the change in mass and the density of 
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ethanol, 0.789 g/mL) by the total volume after intrusion (volume of ethanol + volume of fibers, 
determined by initial fiber mass and polyurethane density, 1.1 g/mL). 
Quantitation of dendrimer delivery was performed using electrospun fibers doped with 
RITC-tagged G4 PAMAM dendrimers.  Fluorescently-labeled G4 PAMAM dendrimers were 
synthesized as described previously.21-23  Briefly, 100 mg G4 PAMAM were added to a vial 
containing one molar equivalent of RITC per mole dendrimer (3.8 mg) in 2 mL methanol.  One 
equivalent of triethylamine (with respect to the molar amount of primary amines) was then added 
to the vial.  The solution was stirred for 24 h in the dark, after which solvent was removed in vacuo.  
Dendrimers were dissolved in water, dialyzed against water (3 d), and then lyophilized.  The above 
procedures for dendrimer modification and fiber mat fabrication were performed in the dark to 
yield RITC-tagged electrospun fibrous mats.  Individual fiber mats were incubated in 500 µL PBS 
(pH 7.4, 37 °C) for 2 h, 1 d, and 7 d.  After incubation, 100 µL of each solution was transferred to 
a black 96-well plate in triplicate and fluorescence intensity was measured using a BMG PolarStar 
Omega fluorescence plate reader (Ortenberg, Germany).  Calibration standards were prepared at 
concentrations ranging from 0 – 100 µg/mL in triplicate.  Dendrimer delivery was reported as 
percent dendrimer leached based on the experimental amount of dendrimer per milligram of fiber 
(calculated from the total dendrimer incorporation determined by NO release in 50 mM HCl) and 
mass of the fiber mat sample.  Fluorescence images of single-component RITC-tagged fibers were 
obtained on a Zeiss 200M inverted microscope with an XBO 75 Xe arc lamp, single band filter set 
(Omega Optical), and cascade 1 K CCD camera (Photometrics) with Micromanager software using 
a 40× objective and 50 ms exposure time.  
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5.2.6 In vitro cytotoxicity 
L929 mouse fibroblasts were grown in DMEM supplemented with 10 vol% FBS and 1 
wt% PS and incubated in 5 vol% CO2 under humidified conditions at 37 °C.  After reaching 80% 
confluency, the cells were trypsinized, seeded onto tissue culture-treated polystyrene 24-well 
plates at a density of 105 cells/mL, and incubated at 37 °C for 72 h.  The supernatant was then 
aspirated and replaced with 1 mL of fresh growth medium and the electrospun fiber mats.  
Dimethyl sulfoxide (10%) and 50 µL PBS were used as positive and negative controls, 
respectively.  After incubation for 2 or 24 h at 37 °C, the supernatant was aspirated and 500 µL of 
a mixture of DMEM/MTS/PMS (105/20/1, v/v/v) was added to each well.  After 1.5 h incubation 
at 37 °C, 100 µL of the colored solution was transferred to a 96-well plate in triplicate and the 
absorbance was quantified at 490 nm using a Thermoscientific Multiskan EX plate reader 
(Waltham, MA).  The mixture of DMEM/MTS/PMS and untreated cells were used as a blank and 
control, respectively.  Results were expressed as percentage of relative cell viability as follows: 
                    % Cell Viability = [(Abs490 – Absblank)/(Abscontrol – Absblank)] x 100%             Eq. 5.2 
5.2.7 In vitro cell proliferation 
L929 mouse fibroblasts were grown in DMEM supplemented with 10 vol% FBS and 1 
wt% PS and incubated in 5 vol% CO2 under humidified conditions at 37 °C.  After reaching 80% 
confluency, the cells were trypsinized, seeded onto electrospun fiber mats in tissue culture-treated 
polystyrene 24-well plates at a density of 105 cells/mL.  After incubation at 37 °C for 24 h, fiber 
mats were dipped once in sterile water to remove non-adhered cells then transferred to a 15 mL 
falcon tube containing 500 µL of a mixture of DMEM/MTS/PMS (105/20/1, v/v/v).  The solutions 
were then sonicated for 5 min at 60% power (Elma Lab-Line 9331, Melrose Park, IL).  For wells 
containing positive (10% DMSO) and negative controls, the supernatant was aspirated and 
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replaced with 500 µL of a mixture of DMEM/MTS/PMS.  After 1.5 h incubation at 37 °C, 100 µL 
of the colored solution was transferred to a 96-well plate in triplicate and the absorbance was 
quantified at 490 nm using a Thermoscientific Multiskan EX plate reader (Waltham, MA).  The 
mixture of DMEM/MTS/PMS and untreated cells (i.e., cells seeded in a well without fibers) were 
used as a blank and control, respectively.  The viability of cells adhered to blank fibers was 
calculated using Equation 5.2 and normalized to 100%.  The viability of cells adhered to control 
and NO-releasing fibers was then reported as a percentage of the cells adhered to blank fibers. 
To prepare fibers for imaging, blank, control, and NO-releasing G4 octyl-doped Tecoflex 
fibrous mats were exposed to L929 mouse fibroblast cells as described above.  After 24 h 
incubation, fibers were dipped once in sterile water then fixed in 1 mL 2.5% glutaraldehyde in 
Milli-Q water for 45 min.  After fixation, fibers were rinsed in sterile water (3 × 10 min) before 
dehydration in solutions of increasing percent ethanol (25, 50, 75, 95, 100%).  Fibers were fully 
dehydrated with a Tousimis Semidri PVT-3 critical point dryer and coated with 5 nm gold using a 
Cressington 108 Auto Sputter Coater.  Images were obtained using a FEI Helios 600 Nanolab Dual 
Beam System (Hillsboro, OR). 
5.2.8 Bacterial adhesion assays on single-component fibers 
Lyophilized P. aeruginosa and S. aureus were reconstituted in tryptic soy broth (TSB) and 
cultured overnight at 37 °C.  A 0.5 mL aliquot of culture was grown in 50 mL TSB to a 
concentration of 108 colony forming units per mL (cfu/mL), collected by centrifugation (2355×g), 
resuspended in 15% glycerol (v/v in PBS), and stored at -80 °C in 1 mL aliquots.  For daily 
experiments, colonies of bacteria culture were inoculated in 2 mL TSB overnight at 37 °C and 
recultured in fresh TSB (50 mL) the next day. 
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To assess the antibacterial action of the electrospun fibrous mats, P. aeruginosa and S. 
aureus were cultured in TSB to a concentration of 108 cfu/mL, collected by centrifugation 
(1045×g), and resuspended in simulated wound fluid (SWF; 25% FBS in PBS, pH 7.4) at 108 
cfu/mL.  Individual fiber mat samples (blank, control, and NO-releasing) were added to 1 dram 
glass vials and sterilized under UV light for 2 h prior to the bacteria assays.  Fibers were exposed 
to 500 µL 108 cfu/mL bacteria in SWF for either 2 or 6 h at 37 °C with light agitation.  Untreated 
controls (blanks) were included in each experiment to ensure the bacteria remained viable over the 
2 or 6 h assays.  After exposure, fibers were removed from the bacteria solutions, dipped once in 
sterile water to remove non-adhered cells, and transferred to a 15 mL falcon tube containing 3 mL 
sterile water.  The solutions were then sonicated for 5 min at 60% power (Elma Lab-Line 9331, 
Melrose Park, IL).  The resulting solutions were vortexed and then spiral-plated at 100-, 1000-, 
and 10,000-fold dilutions on tryptic soy agar plates using an Eddy Jet spiral plater (IUL; 
Farmingdale, NY).  Bacterial viability was assessed by counting the number of colonies formed 
on the agar plate using a Flash & Go colony counter (IUL; Farmingdale, NY).   
5.3  Results and Discussion 
5.3.1 Synthesis and characterization of NO-releasing G4 dendrimers   
To evaluate the effects of dendrimer modification on fiber NO-release characteristics, 
generation 4 (G4) poly(amidoamine) (PAMAM) dendrimers were modified with alkyl chains (i.e., 
hexyl, octyl, dodecyl) or octylQA moieties through a ring-opening reaction at the peripheral 
primary amines as described previously.22, 23  Addition of the functional groups was confirmed 
using 1H NMR spectroscopy.  On average, 46 functional groups were added to the G4 scaffold, 
resulting in ~70% functionalization of the terminal primary amines (Table 5.1).   
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The secondary amines were subsequently converted to N-diazeniumdiolate NO donors 
under high pressures of NO.  Nitric oxide storage was tuned by increasing the ratio of 
THF:methanol with increasing alkyl chain length, resulting in similar NO payloads of ~1 µmol/mg 
(Table 5.1).  All of the alkyl chain-modified dendrimers exhibited similar initial maximum fluxes 
and durations (~10 h).  However, a slight increase in NO-release half-life was observed with 
increasing alkyl chain length (~20 to ~34 min), likely due to decreased water diffusion to the 
proton-labile N-diazeniumdiolate NO donor.  The QA-modified dendrimer (G4 octylQA) 
exhibited an initial max flux about half that of the alkyl chain-modified dendrimers and an 
extended NO-release half-life (115 min) and duration (16 h).  The longer NO-release half-life 
exhibited by the QA-modified dendrimers suggests that the permanent positive charge of the QA 
moiety stabilizes the N-diazeniumdiolate group, extending NO release.  Fabrication of electrospun 
polyurethane fibers doped with dendrimers exhibiting a range of exterior modifications and NO-
release half-lives allows for the evaluation of fiber and NO-release characteristics as a function of 
dendrimer modification. 
5.3.2 Fabrication and characterization of single-component electrospun polyurethane fibers   
We have previously fabricated electrospun polyurethane fibers with NO-release 
capabilities through the incorporation of NO-releasing proline (PROLI/NO), silica nanoparticles, 
and poly(amidoamine) (PAMAM) dendrimers.19, 27, 30, 31  Nitric oxide-release kinetics were 
dependent on the dopant NO-release kinetics (i.e., PROLI/NO-doped fibers exhibited much faster 
release kinetics than either of the macromolecular scaffolds) and polyurethane hydrophobicity.  
Fibers comprised of NO-releasing dendrimers and silica nanoparticles demonstrated similar NO-
release totals and kinetics, but the dendrimer scaffolds were better retained within the polyurethane 
fibers.  Indeed, dendrimer-doped Tecoplast fibers exhibited <20% leaching after one week while  
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Table 5.1 Characterization and NO-release properties of G4 dendrimers in PBS (pH 7.4, 37 °C) 
as measured by a chemiluminescence NO analyzer.a 
 
No. Modified 
End Groupsb 
% 
Modified 
[NO]max
c 
(ppb/mg) 
tmax
d 
(min) 
t[NO]e 
(µmol/mg) 
t1/2
f 
(min) 
td
g 
(h) 
G4 hexyl/NO 51 ± 4 80 ± 6 3800 ± 1160 1.3 ± 0.3 0.94 ± 0.07 20 ± 1 10 ± 4 
G4 octyl/NO 47 ± 3 74 ± 5 4930 ± 780 2.7 ± 0.4 0.93 ± 0.05 23 ± 3 9 ± 1 
G4 dodecyl/NO 46 ± 7 71 ± 11 3880 ± 640 1.8 ± 0.4 0.90 ± 0.07 34 ± 3 10 ± 1 
G4 octylQA/NO 39 ± 5 61 ± 8 1570 ± 150 2.0 ± 0.3 1.03 ± 0.06 115 ± 6 16 ± 1 
aFor all measurements, n ≥ 3 pooled experiments. bDetermined by 1H NMR. cMaximum flux of 
NO release. eTime required to reach maximum flux. eTotal NO payload released. fNO release 
half-life. gDuration of NO release.  
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70–100% of NO-releasing silica nanoparticles leached from electrospun fibers regardless of 
polyurethane hydrophobicity.19, 31   
To fabricate single-component (i.e., composed of one polyurethane) electrospun fibers, 
three polyurethanes (Tecoplast, Tecoflex, and Hydrothane) exhibiting distinct hydrophobicity and 
water uptake properties were chosen for study.  Of these, Tecoplast was the most hydrophobic and 
Hydrothane exhibited the greatest water uptake, allowing us to evaluate the effects of polyurethane 
hydrophobicity on fiber formation and NO-release characteristics.  For these studies, control and 
NO-releasing G4 octyl dendrimers were doped into polyurethane solutions prior to 
electrospinning.  Blank (no dendrimer dopant), control (non-NO-releasing), and NO-releasing 
electrospun fibers were fabricated for each of the individual polyurethanes.  The resulting semi-
porous mats contained fibers exhibiting smooth morphology with little to no bead formation 
(Figure 5.1).  Fiber diameter was dependent on both the polyurethane composition and presence 
of dendrimer dopant (Table 5.2).  Blank Tecoplast and Hydrothane fibers exhibited similar 
diameters of ~630 nm, while blank Tecoflex fibers were larger (~930 nm), demonstrating no trend 
between fiber diameter and polyurethane hydrophobicity.  The effects of dendrimer dopant also 
varied with polyurethane composition.  Although Hydrothane fibers exhibited no significant 
variation in fiber diameter with the addition of control or NO-releasing G4 octyl dendrimers, the 
diameters of dendrimer-doped Tecoplast and Tecoflex fibers were decreased from blank fibers by 
approximately 300 and 150 nm, respectively.   
A critical characteristic for wound dressings is the allowance of gaseous and fluid 
exchanges.4  A porous nanofiber structure with high surface area allows for cell respiration, 
maintains an appropriately moist environment for the wound, and prevents stagnation at the wound 
site by absorbing excess wound exudate.  In this regard, the porosity of dendrimer-doped 
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electrospun fibrous mats was characterized via liquid intrusion by measuring the ability of a non-
wetting liquid to permeate the pores.28, 29  In general, porosity of the electrospun fibers trended 
with polyurethane hydrophobicity.  Blank Tecoplast fibers (most hydrophobic) exhibited the 
greatest porosity (~70%), which decreased upon addition of the dendrimer dopant by ~10% (Table 
5.2).  Blank, control, and NO-releasing electrospun fibers exhibited similar porosities of 
approximately 50 and 43% for Tecoflex and Hydrothane, respectively.  As expected, blank 
electrospun fibers exhibited greater water absorption with decreasing polyurethane 
hydrophobicity, most likely due to the increase in water uptake.  While blank, control, and NO-
releasing electrospun Tecoflex and Hydrothane fibers absorbed water at similar rates, both 
dendrimer-doped Tecoplast fibers exhibited significantly enhanced water absorption values 
(~750%) compared to blank Tecoplast fibers (~100%) (Table 5.2).  This increase in water 
absorption is surprising considering the hydrophobicity of the Tecoplast composition.  Indeed, it 
is likely connected to the decrease in fiber diameter and porosity observed for the dendrimer-doped 
fibers, leading to greater fiber surface area and allowing for increased water absorption.  
Nitric oxide release from electrospun polyurethane fibers was evaluated via 
chemiluminescence in PBS (pH 7.4, 37 °C).  Electrospun fibers were cut into coupons to yield 
fiber samples with a consistent surface area of 1.267 cm2.  Due to the proton-labile nature of N-
diazeniumdiolate NO donors, the maximum NO flux was expected to increase with decreasing 
polyurethane hydrophobicity with a concomitant decrease in the time to reach the maximum.  
Surprisingly, both values were similar for each of the polyurethanes regardless of hydrophobicity 
(Table 5.3).  Similarly, we expected the NO-release half-life (t1/2) to decrease with increasing 
polyurethane water uptake.  However, the most hydrophobic Tecoplast fibers exhibited the fastest 
NO-release half-life (17.5 min) and duration (1.4 h).  Although initially surprising, these values 
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Figure 5.1 Scanning electron micrographs of blank, control, and NO-releasing G4 octyl-doped 
electrospun Tecoplast, Tecoflex, and Hydrothane fibers. 
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Table 5.2 Characterization of single-component electrospun polyurethane fibers.a 
 
Fiber 
Diameter (nm) 
Porosity 
(%) 
Water 
Absorption (%) 
Tecoplast 623 ± 253 71.0 ± 4.5 102 ± 67 
Tecoplast-G4 octyl 342 ± 95 63.1 ± 4.8 765 ± 166 
Tecoplast-G4 octyl/NO 336 ± 107 59.1 ± 5.7 747 ± 149 
Tecoflex 927 ± 310 50.4 ± 7.6 116 ± 37 
Tecoflex-G4 octyl 771 ± 247 54.6 ± 5.6 112 ± 35 
Tecoflex-G4 octyl/NO 798 ± 266 49.4 ± 13.7 89 ± 29 
Hydrothane 636 ± 199 43.0 ± 9.3 173 ± 40 
Hydrothane-G4 octyl 603 ± 237 41.7 ± 10.5 167 ± 49 
Hydrothane-G4 octyl/NO 543 ± 151 44.6 ± 9.9 155 ± 37 
     aFor all measurements, n ≥ 3 pooled experiments. 
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were found to scale proportionally with total NO released (Figure 5.2 A).  Nitric oxide-releasing 
Tecoflex fibers exhibited the longest half-life (36.5 min) and greatest NO payload (0.037 
µmol/mg), while NO-releasing Tecoplast fibers only released 0.018 µmol NO/mg.  Both the half-
life (20.9 min) and total NO storage (0.027 µmol/mg) of NO-releasing Hydrothane fibers fell 
between these two, suggesting that polyurethane hydrophobicity has little effect on the NO-release 
kinetics of single-component electrospun fibers.  As evidenced by the variation in NO storage, the 
amount of dendrimer doped into the electrospun fibers varied greatly with polyurethane identity.  
Total dendrimer incorporation was calculated per mass of electrospun fiber by determining the 
total NO released under acidic conditions (50 mM HCl).  While electrospun Tecoflex-G4 octyl/NO 
fibers incorporated the greatest amount of dendrimer (~60 µg/mg), the more hydrophobic 
Tecoplast fibers exhibited much lower dendrimer incorporation (~20 µg/mg), indicating 
polyurethane hydrophobicity greatly affects dendrimer incorporation during electrospinning. 
While previous reports have attempted to minimize dopant leaching for in vivo applications,19, 31 
active release of dual-action dendrimers is expected to increase the antibacterial action of 
electrospun fibers.  To quantitate the amount of dendrimer delivered from each of the electrospun 
polyurethane fiber compositions, dendrimer leaching into solution over time was determined in 
PBS (pH 7.4, 37 °C) after 2 h, 1 d, and 7 d.  The G4 dendrimer scaffold was labeled with the 
fluorescent tag RITC prior to modification with octyl alkyl chains, and the resulting RITC-tagged 
dendrimers were used to fabricate fluorescent electrospun fibers (Figure 5.3).  Total dendrimer 
delivery (%) was determined after 2 h, 1 d, and 7 d using the total amount of incorporated 
dendrimer determined from NO release totals in acidic conditions.   
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Table 5.3 Nitric oxide-release properties for G4 octyl/NO-doped electrospun polyurethane fibers 
in PBS (pH 7.4, 37 °C).a 
 
[NO]max
b 
(pmol/cm2) 
tmax
c 
(min) 
t[NO]d 
(µmol/cm2) 
t[NO]e 
(µmol/mg) 
t1/2
f 
(min) 
td
g 
(h) 
t(dopant)h 
(µg/mg) 
Tecoplast 13.0 ± 4.0 3.9 ± 1.6 0.017 ± 0.006 0.018 ± 0.002 17.5 ± 2.1 1.4 ± 0.3 22 ± 2 
Tecoflex 11.7 ± 3.6 4.3 ± 2.1 0.036 ± 0.011 0.037 ± 0.008 36.5 ± 4.3 2.3 ± 0.4 61 ± 8 
Hydrothane 15.7 ± 5.4 4.3 ± 2.4 0.027 ± 0.010 0.027 ± 0.006 20.9 ± 4.8 1.6 ± 0.4 52 ± 4 
aFor all measurements, n ≥ 3 pooled experiments. bMaximum flux of NO release. cTime required 
to reach maximum flux. dTotal NO payload released per surface area.  eTotal NO payload released 
per mg. fNO release half-life. gDuration of NO release. hTotal amount of dendrimer incorporated 
as determined by total NO release in 50 mM HCl. 
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Figure 5.2 Representative total NO-release curves for (A) G4 octyl/NO-doped electrospun 
Tecoplast, Tecoflex, and Hydrothane fibers and (B) NO-releasing dendrimer-doped electrospun 
Tecoflex fibers. Representative NO-release curves for (C) G4 hexyl/NO, (D) G4 octyl/NO, (E) G4 
dodecyl/NO, and (F) G4 octylQA/NO-doped electrospun Tecoflex fibers. 
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Although total dendrimer release slightly increased over time, the majority of dendrimer 
delivery occurred in the first 24 hours (Figure 5.4).  As expected, dendrimer delivery was 
dependent on the hydrophobicity of the polyurethane, with the hydrophilic Tecoflex and 
Hydrothane polyurethanes exhibiting greater dendrimer release than the more hydrophobic 
Tecoplast fibers.  After 7 d, control and NO-releasing Tecoplast fibers exhibited 35 and 26% 
dendrimer release, respectively, with both fiber compositions delivering approximately 20% of the 
total dendrimer payload in the first day.  At each timepoint, the NO-releasing Tecoflex and 
Hydrothane fibers exhibited greater drug delivery than control (non-NO-releasing) fibers.  
Although control and NO-releasing Hydrothane fibers demonstrated similar dendrimer delivery 
after 7 d (72 and 76%, respectively), the NO-releasing fibers exhibited more rapid dendrimer 
release than their non-NO-releasing counterparts after 1 d (59 versus 69% for control and NO-
releasing fibers, respectively).  Furthermore, NO-releasing Tecoflex fibers were characterized as 
having faster and greater dendrimer delivery than control fibers after 7 d, exhibiting 48 and 65% 
release for control and NO-releasing fibers, respectively.  The faster release kinetics exhibited by 
the NO- releasing fibers suggests that dendrimer delivery is dependent on charge, with the 
zwitterionic N-diazeniumdiolate resulting in faster release rates. 
5.3.3 Fabrication and characterization of electrospun Tecoflex fibers with various dendrimer 
dopants 
 Due to the lower NO totals and dendrimer incorporation exhibited by Hydrothane and 
Tecoplast fibers, Tecoflex fibers were selected for further study to evaluate the effects of 
dendrimer exterior modification on NO-release and material characteristics.  Control and NO-
releasing G4 PAMAM dendrimers modified with hexyl, octyl, dodecyl, and octylQA functional 
groups were individually doped into electrospun Tecoflex fibers (Figures 5.1, 5.5).  While the  
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Figure 5.3 Electron micrographs of G4 RITC octyl-doped (A) Tecoplast, (B) Tecoflex, and (C) 
Hydrothane fibers.  (D) Fluorescence image of Tecoplast-G4 RITC octyl fibers. 
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Figure 5.4 Dendrimer delivery (%) for control (solid line) and NO-releasing (dashed line) G4 
octyl-doped electrospun Tecoplast (red), Tecoflex (blue), and Hydrothane (green) fibers after 2 h, 
1 d, or 7 d soaking in PBS (pH 7.4, 37 °C).  For all measurements, n ≥ 3 pooled experiments with 
error bars representing standard deviation of the mean.  
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addition of control and NO-releasing dendrimer dopant decreased the average fiber diameter from 
blank Tecoflex fibers (~930 nm), changes in the dendrimer exterior modification had little effect 
on the resulting fiber diameters, with average diameters ranging from 600–800 nm (Table 5.4).   
To evaluate the potential of these fibers to allow for gas and fluid exchange,4 the porosity 
and water absorption of the electrospun Tecoflex fibers were evaluated as a function of dendrimer 
modification.  As expected due to the similarity of the exterior modifications, the porosity of the 
fibrous mats containing alkyl chain-modified dendrimers (i.e., G4 hexyl, G4 octyl, G4 dodecyl) 
were unchanged from blank fibers (Table 5.4).  The QA-containing Tecoflex fibers exhibited the 
greatest porosities (62 and 68% for control and NO-releasing, respectively), possibly due to 
electrostatic repulsions from the QA moiety limiting fiber interactions.  For all modifications, the 
water absorption levels were less for the dendrimer-doped versus blank Tecoflex fibers, with 
almost all of the control and NO-releasing fibers exhibiting less than 100% water absorption (Table 
5.4).  Although control and NO-releasing G4 octyl-doped Tecoflex fibers exhibited >90% water 
absorption values, water uptake by the other modifications (i.e., hexyl, dodecyl, octylQA) was less 
(55–77%).  This result was somewhat unexpected due to the similarity in fiber diameters and 
porosities and identical polyurethane composition (Tecoflex). 
Nitric oxide release from electrospun polyurethane fibers (surface area: 1.267 cm2) was 
evaluated as described above (Figure 5.2 C-F).  The magnitude of the initial NO burst ([NO]max) 
decreased with increasing alkyl chain length (20 to 9 pmol/cm2) (Table 5.5).  Similarly, the time 
required to reach the maximum flux increased with alkyl chain length (3.8 to 13.8 min), suggesting 
the hydrophobicity of the dendrimer exterior influences initial water diffusion to the NO donor 
within the electrospun fibers.  Yet, all of the alkyl chain-doped Tecoflex fibers exhibited similar 
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Figure 5.5 Scanning electron micrographs of control and NO-releasing G4 hexyl-, G4 dodecyl-, 
and G4 octylQA-doped electrospun Tecoflex fibers. 
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Table 5.4 Characterization of electrospun Tecoflex fibers.a 
 
Fiber Diameter 
(nm) 
Porosity 
(%) 
Water Absorption 
(%) 
Tecoflex 927 ± 310 50.4 ± 7.6 116 ± 37 
Tecoflex-G4 hexyl 617 ± 187 57.0 ± 8.7 64 ± 21 
Tecoflex-G4 hexyl/NO 649 ± 202 52.2 ± 8.8 66 ± 27 
Tecoflex-G4 octyl 771 ± 247 54.6 ± 5.6 112 ± 35 
Tecoflex-G4 octyl/NO 798 ± 266 49.4 ± 13.7 89 ± 29 
Tecoflex-G4 dodecyl 691 ± 249 60.9 ± 8.2 77 ± 19 
Tecoflex-G4 dodecyl/NO 564 ± 183 53.1 ± 13.3 73 ± 32 
Tecoflex-G4 octylQA 595 ± 194 62.3 ± 10.1 55 ± 16 
Tecoflex-G4 octylQA/NO 646 ± 202 67.6 ± 13.5 59 ± 18 
      aFor all measurements, n ≥ 3 pooled experiments. 
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NO-release half-lives (30–40 min), totals (~0.038 µmol/mg), and durations (~2.5 h) regardless of 
alkyl chain modification.  In contrast, the QA-containing Tecoflex fibers exhibited a lower max 
flux (4.8 pmol/cm2) with extended NO-release half-life (151 min) and duration (6 h) (Figure 5.2).  
The longer NO release exhibited by G4 octylQA-containing fibers parallels the extended release 
of the QA dendrimers over the alkyl-modification systems in solution, suggesting the NO-release 
kinetics of the NO donor dopant may have greater influence over the NO-release characteristics of 
the electrospun fibers than the polyurethane identity.  While all of the dendrimer modifications 
incorporated similar amounts of dendrimer (60–70 µg/mg), the overall NO-release totals for 
Tecoflex-G4 octylQA/NO fibers were slightly lower than the alkyl chain modifications (0.027 
µmol/mg).  This behavior is most likely the result of unaccounted for NO release below the 
threshold (1 pmol/cm2) due to the extended release kinetics of these fibers at pH 7.4.  Of note, the 
1.267 cm2 fiber mats exhibited similar NO-release totals (~0.36 µmol/cm2).  
Dendrimer delivery into solution was determined in PBS (pH 7.4, 37 °C) at 2 h, 1 d, and 7 d as a 
function of dendrimer modification.  The majority of dendrimer release occurred within the first 
24 h (Figure 5.6).  As expected, the most hydrophobic dendrimer (G4 dodecyl) was better retained 
within the fibers, with control Tecoflex-G4 dodecyl fibers exhibiting only 38% dendrimer release 
after 7 d compared to ~48% for the other dendrimer systems.  Similar to observations in Section 
5.3.2, the NO-releasing fibers demonstrated greater dendrimer release than their non-NO-releasing 
counterparts due to increased instability of the zwitterionic N-diazeniumdiolate within the fibers.  
Of note, the Tecoflex-G4 octylQA/NO fibers exhibited the greatest levels of dendrimer delivery 
after 7 d (~80%), supporting the hypothesis that increased scaffold charged leads to faster and 
greater dendrimer release from electrospun fibers. 
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Table 5.5 Nitric oxide-release properties for NO-releasing electrospun Tecoflex fibers in PBS (pH 7.4, 37 °C).a 
 
[NO]max
b 
(pmol/cm2) 
tmax
c 
(min) 
t[NO]d 
(µmol/cm2) 
t[NO]2h
e 
(µmol/cm2) 
t[NO]f 
(µmol/mg) 
t1/2
g 
(min) 
td
h 
(h) 
t[dopant]i 
(µg/mg) 
G4 hexyl/NO 19.8 ± 6.8 3.8 ± 1.7 0.043 ± 0.014 0.039 ± 0.013 0.038 ± 0.007 30.5 ± 4.4 2.9 ± 0.4 68 ± 1 
G4 octyl/NO 11.7 ± 3.6 4.3 ± 2.1 0.036 ± 0.011 0.034 ± 0.010 0.037 ± 0.008 36.5 ± 4.3 2.3 ± 0.4 61 ± 8 
G4 dodecyl/NO 8.9 ± 2.4 13.8 ± 3.5 0.032 ± 0.010 0.030 ± 0.007 0.039 ± 0.004 38.3 ± 5.1 2.5 ± 0.4 65 ± 8 
G4 octylQA/NO 4.8 ± 1.1 2.3 ± 0.3 0.034 ± 0.010 0.014 ± 0.004 0.027 ± 0.005 151.0 ± 22.1 6.0 ± 0.9 72 ± 4 
aFor all measurements, n ≥ 3 pooled experiments. bMaximum flux of NO release. cTime required to reach maximum flux. 
dTotal NO payload released per surface area.  eNO payload released after 2 h.  fTotal NO payload released per mg. gNO 
release half-life. hDuration of NO release. iTotal amount of dendrimer incorporated as determined by total NO release in 50 
mM HCl.1
8
1
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Figure 5.6 Dendrimer delivery (%) for control (solid line) and NO-releasing (dashed line) G4 
hexyl- (red), G4 octyl- (blue), G4 dodecyl- (green), and G4 octylQA- (purple) doped electrospun 
Tecoflex fibers after 2 h, 1 d, or 7 d soaking in PBS (pH 7.4, 37 °C). For all measurements, n ≥ 3 
pooled experiments with error bars representing standard deviation of the mean.  
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5.3.4 In vitro cytotoxicity and cell proliferation 
The toxicity of blank, control, and NO-releasing electrospun polyurethane fibers was evaluated 
against L929 mouse fibroblast cells over 2 and 24 h.  Each of the G4 octyl-doped polyurethane 
fibers were non-toxic at both timepoints (>80% cell viability compared to untreated controls), with 
variations in toxicity dependent on polyurethane identity (Figure 5.7 A-B).  Blank, control, and 
NO-releasing Tecoflex fibers exhibited no toxicity (~100% viability) regardless of dendrimer 
dopant or NO release (Figure 5.7 C-D).  Control Tecoplast fibers were slightly more toxic at 24 
than 2 h (96 and 88% viability, respectively), while NO-releasing Tecoplast fibers exhibited 
similar toxicity (~95% viability) at both timepoints.  Electrospun Hydrothane fibers were 
characterized as having the highest toxicity, with control and NO-releasing fibers reducing cell 
viability to 87 and 81%, respectively, after 2 h exposure.  This may be attributed to the slightly 
higher dendrimer release exhibited by the Hydrothane fibers.  However, the lack of toxicity 
exhibited by control and NO-releasing Tecoflex fibers despite relatively similar concentrations of 
dendrimer delivery makes this unlikely.  Alternatively, the greater toxicity of the G4 octyl-doped 
Hydrothane fibers is likely due to the bulk characteristics of the fiber mat itself leading to fiber-
cell interactions and cell removal (from the well) upon removal of the fiber mat. 
The ability of L929 cells to proliferate on dendrimer-doped electrospun Tecoflex fibers 
was next evaluated upon direct cell seeding onto the fibrous mats.  While some prior studies have 
correlated the ability of cells to integrate into and proliferate on electrospun fibrous mats with 
wound healing capabilities,7, 32 Lalani et al. reported that a lack of cell adhesion on the fibers is 
more beneficial for use as removable wound dressings.10  Decreased cell adhesion on the wound 
dressings would allow for easier, painless dressing removal without harming the newly formed 
skin underneath.10  Along these lines, the ability of L929 cells to adhere to blank, control, and NO- 
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Figure 5.7 Viability (%) of L929 mouse fibroblast cells following (A,C) 2 h or (B,D) 24 h exposure 
to blank (solid), control (diagonal lines), and NO-releasing (horizontal lines) (A,B) G4 octyl-doped 
electrospun fibers or (C,D) dendrimer-doped electrospun Tecoflex fibers. For all measurements, n 
≥ 3 pooled experiments with error bars representing standard deviation of the mean.  
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Figure 5.8 (A) Viability (%) of L929 mouse fibroblast cells adhered to control (diagonal lines) 
and NO-releasing (horizontal lines) dendrimer-doped Tecoflex electrospun fibers following 24 h 
exposure. For all measurements, n ≥ 3 pooled experiments with error bars representing standard 
deviation of the mean.  (B) Scanning electron micrographs of L929 mouse fibroblast cells adhered 
to blank, control, and NO-releasing G4 octyl-doped Tecoflex electrospun fibers following 24 h 
exposure.   
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releasing electrospun Tecoflex fibers was evaluated with the idea that decreased adhesion would 
indicate greater potential for wound dressing compatibility. 
To assess any reductions in cell adhesion, the number of viable L929 cells adhered to blank 
Tecoflex fibers after 24 h (~10% of the total cells in the well) was normalized to 100%.  The 
percent viability of cells adhered to control and NO-releasing Tecoflex fibers was determined in 
relation to the blank fibers (Figure 5.8 A).  For each of the dendrimer dopants, control Tecoflex 
fibers exhibited a statistically significant decrease in adhered cell viability (~60% compared to 
blank fibers).  With the exception of Tecoflex-G4 hexyl/NO fibers, the remaining NO-releasing 
Tecoflex fibers further decreased cell viability (~50% compared to blank fibers).  While 
statistically significant from the blank Tecoflex fibers (p < 0.05 using two-tailed student’s t-test), 
this behavior was not significant from control fibers.  The lack of toxicity exhibited by the leached 
dendrimer, NO dose, and electrospun fibers to L929 cells above (Figure 5.7) indicates that these 
decreases in cell viability are most likely attributed to reduced cell adhesion and not cell death.  To 
confirm this, L929 cells were fixed with glutaraldehyde after 24 h exposure and imaged via 
scanning electron microscopy.  For both the control and NO-releasing G4 octyl-doped Tecoflex 
fibers, L929 cells appear to be less densely adhered to the electrospun fibers than for the blank 
fibers (Figure 5.8 B).  Of note, the L929 fibroblast cells in contact with NO-releasing fibers 
exhibited a morphology distinct from those adhered to blank or control fibrous mats.  This 
spherical morphology is often indicative of non-adhered cells, as opposed to spread-out, spindle 
shaped cells (as those adhered to the control fibers).33  While both control and NO-releasing 
Tecoflex fibers reduced L929 cell adhesion compared to blank fibers, cells in contact with NO-
releasing fibrous mats exhibited the morphology of non-adhered cells, indicating the benefits of 
NO release in further reducing cell adhesion and integration into electrospun fiber mats. 
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5.3.5 Antibacterial action of NO-releasing single-component electrospun fibers   
P. aeruginosa and S. aureus represent two of the most commonly isolated species in 
chronic wounds.2  Antibacterial action of single-component NO-releasing fibers was thus carried 
out to further assess the potential of these materials as wound dressings.  Electrospun fibers were 
cut into coupons to yield fiber samples with similar surface area (1.267 cm2) and NO payloads.  
Bacterial adhesion studies were performed in simulated wound fluid (SWF) composed of 25% 
fetal bovine serum in PBS (pH 7.4, 37 °C) for 2 or 6 h, corresponding to the duration of NO release 
for the Tecoflex-G4 octyl/NO and Tecoflex-G4 octylQA/NO fibers, respectively.  Log reductions 
in bacterial viability were determined by comparing the bacterial viability on control or NO-release 
fibers to that on blank Tecoflex fibers. 
Both control and NO-releasing electrospun Tecoflex fibers were found to reduce the 
viability of adhered P. aeruginosa and S. aureus compared to blank Tecoflex fibers after 2 and 6 
h exposures (Figure 5.9).  After 2 h exposure, the control G4 octyl-doped Tecoflex fibers proved 
more effective at reducing bacterial adhesion (both strains) than their NO-releasing counterparts, 
(Table 5.6).  In contrast, both control and NO-releasing Tecoflex-G4 octyl fibers exhibited similar 
reductions in adhered bacterial viability at 6 h, likely due to the inability of the dendrimers to 
eradicate the larger concentrations of bacteria resulting from bacterial growth.  Similar trends were 
observed for the G4 octylQA-doped Tecoflex fibers, with control fibers exhibiting greater 
reductions in adhered bacterial viability after 2 h exposure but similar reductions at 6 h as the NO-
releasing fibers against both bacterial strains.  As a result of the negligible killing by both control 
and NO-releasing Tecoflex fibers (≤1-log reduction), the evaluation of single-component 
electrospun fibers was abandoned.  The fabrication of composite electrospun polyurethane fibers  
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Figure 5.9 Viability of (A,B) P. aeruginosa or (C,D) S. aureus adhered to blank (solid), control 
(diagonal lines), and NO-releasing (horizontal lines) dendrimer-doped Tecoflex electrospun fibers 
following 2 or 6 h exposure. For all measurements, n ≥ 3 pooled experiments with error bars 
representing standard deviation of the mean. Asterisk indicates significant differences from blank 
(p < 0.05) using two-tailed student’s t-test. 
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Table 5.6 Average log reduction of adhered bacterial viability.a 
 P. aeruginosa S. aureus 
 2 h 6 h 2 h 6 h 
Tecoflex-G4 octyl 0.9 ± 0.6 0.8 ± 0.4 1.0 ± 0.6 0.6 ± 0.3 
Tecoflex-G4 octyl/NO 0.5 ± 0.2 0.9 ± 0.5 0.5 ± 0.2 0.6 ± 0.3 
Tecoflex-G4 octylQA 1.2 ± 0.5 0.8 ± 0.3 1.1 ± 0.9 0.9 ± 0.5 
Tecoflex-G4 octylQA/NO 0.9 ± 0.8 0.7 ± 0.4 0.4 ± 0.3 0.9 ± 0.3 
aFor all measurements, n ≥ 3 pooled experiments. 
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formed using a co-axial electrospinning setup was thus investigated (Chapter 6), as the distinct 
core-sheath structure of these fibers should allow for greater dendrimer incorporation and control 
over both dendrimer- and NO-release characteristics. 
5.4  Conclusions 
Three distinct polyurethanes were electrospun into single-component fibers doped with 
control or NO-releasing G4 octyl dendrimers.  While the fiber diameter, porosity, water absorption, 
and dendrimer incorporation were dependent on the polyurethane identity, NO-release proved 
independent of polyurethane hydrophobicity.  Electrospun Tecoflex fibers prepared using 
dendrimer dopants with a range of exterior modifications exhibited tunable NO-release kinetics 
and durations, indicating the dendrimer modification greatly influences the NO-release properites.  
Both control and NO-releasing dendrimer-doped electrospun Tecoflex fibers exhibited decreased 
L929 cell adhesion from blank Tecoflex fibers, with the fibroblasts exposed to NO-releasing fibers 
demonstrating non-adhesive morphologies.  However, the low antibacterial action of the NO-
releasing Tecoflex fibers against planktonic bacteria required a new direction for the development 
of electrospun fibers to allow for enhanced dendrimer storage, NO release, and bactericidal action. 
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CHAPTER 6: 
Active Release of Dual-Action Dendrimers from Co-Axial Electrospun Polyurethane Fibers 
6.1 Introduction 
The successful treatment of chronic wounds such as diabetic foot ulcers, pressure ulcers, 
and venous leg ulcers is often hindered by the inefficient eradication of opportunistic pathogens 
such as Pseudomonas aeruginosa and Staphyloccocus aureus.1-3  Left untreated, the proliferation 
of infectious bacteria and biofilms in chronic wounds often leads to significant morbidity (e.g.,  
limb amputation).3  While the use of wound dressings may facilitate some wound healing, the 
presence of bacteria hinders complete wound closure.  An ideal wound dressing wound provide 
facile gaseous and fluid exchange, absorb excess wound exudates, and act as a physical barrier to 
infectious microorganisms, while also reducing the bacterial burden in the wound site.4   
Polyurethane materials are often used as wound dressings because they exhibit adequate 
barrier properties, oxygen permeability, and tissue compatibility.5-8  Commercially-available 
wound dressings such as semi-permeable polyurethane films and foams have demonstrated utility 
as physical barriers, inhibiting the migration of bacteria to the wound and promoting wound 
closure.4, 9, 10  Incorporating silver ions into these polyurethane wound dressings as an active 
release antimicrobial agent further improved wound healing and reduced pain-related symptoms.11-
13  However, significant accumulation of wound fluid beneath the bandage continues to be a 
disadvantage of these dressings, requiring frequent wound aspiration to prevent leakage and 
infection.5, 14, 15  The fabrication of porous wound dressing materials via electrospinning has been 
proposed to further improve the wound healing capabilities of polyurethane wound dressings.  The 
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electrospinning technique, consisting of the application of a high potential difference between the 
head of a syringe needle containing a polymer solution and a grounded collector, produces 
nonwoven nanofibrous polymer webs.4, 16, 17  These mats demonstrate properties essential for 
wound healing due to their inherent porosity and large effective surface area.  Indeed, the high 
surface area to volume ratio allows for increased water absorption, while the semi-permeability 
and porous architecture of such materials allows for cell respiration and protects the wound from 
bacterial infection.4  Khil et al. reported improved wound healing capabilities of electrospun 
polyurethane fibers in adult male guinea pigs over the conventional Tegaderm (3M Health Care; 
St. Paul, Minnesota), a commercially-available polyurethane wound dressing.5  The electrospun 
dressings both increased the rate of epithelialization and prevented the permeation of infectious 
microorganisms with little observed fluid accumulation.   
Electrospun fibers have also been modified to exhibit antibacterial action via the 
incorporation of therapeutic compounds blended into an all-in-one dressing.4, 18, 19  Initial studies 
in the development of antibacterial electrospun wound dressings have demonstrated the controlled 
release of antibiotics18-20 and silver ions21, 22 from electrospun fibers.  However, bacterial resistance 
to both antibiotics and silver23-25 warrants the development of dressings capable of delivering next 
generation antibacterial agents that are unlikely to foster resistance.  
Nitric oxide (NO) is a promising antibacterial agent that exhibits both broad-spectrum 
antibacterial and wound-healing actions.26-28  Our lab has pioneered the development of 
antibacterial macromolecular scaffolds capable of controllable NO storage and release,29, 30 with 
dendrimers representing an excellent scaffold for the design of novel antibacterial agents.31-33  
Combining antibacterial NO release with a non-depleting, contact-based biocide (i.e., quaternary 
ammonium moieties or alkyl chains) has proven especially effective at producing broad-spectrum 
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dual-action antibacterial agents.34-37  The co-administration of two mechanistically different 
biocides in this manner is expected to reduce the emergence of bacterial resistance and improve 
the bactericidal efficacy of the scaffold, thereby lowering the required therapeutic dose.38, 39  We 
have previously reported on the ability of NO-releasing alkyl chain-modified dendrimers to 
eradicate both Gram-negative and Gram-positive biofilms as a function of dendrimer generation 
(i.e., size) and modification.35, 36  Herein, we report both the fabrication of electrospun composite 
polyurethane fibers doped with NO-releasing alkyl chain- or quaternary ammonium (QA)-
modified poly(amidoamine) dendrimers and evaluation of the antibacterial action of the resulting 
dendrimer- and NO-releasing fibers against both Gram-negative and Gram-positive bacteria.  Our 
study investigated the promise of dual-action dendrimer biocide release from electrospun 
polyurethane fibers as potential antibacterial wound dressings. 
6.2 Materials and Methods 
Triethylamine (TEA), rhodamine B isothiocyanate (RITC), dimethyloctylamine, epichlorohydrin, 
phenazine methosulfate (PMS), fetal bovine serum (FBS), trypsin, 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS), penicillin 
streptomycin (PS), and propidium iodide (PI) were purchased from Sigma-Aldrich (St. Louis, 
MO).  Methyl acrylate, 1,2-epoxyoctane, and ethylenediamine (EDA) were purchased from the 
Aldrich Chemical Company (Milwaukee, WI).  Sodium methoxide (5.4 M solution in methanol) 
was purchased from Acros Organics (Geel, Belgium).  Colloidal silica in methanol was obtained 
from Nissan Chemical America Corporation (Houston, TX).  Cellulose ester dialysis membranes 
(500-1000 MWCO) were purchased from Spectrum Laboratories, Inc. (Rancho Dominguez, CA).  
Tecophilic (HP-93A-100) and Tecoflex (SG-80A) polyurethanes were obtained from Thermedics 
(Woburn, MA).  Tecoplast (TP-470) polyurethane was a gift from Lubrizol (Cleveland, OH).  
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Dulbecco's modified Eagle's medium (DMEM) and Dulbecco’s phosphate buffered saline (PBS) 
were obtained from Lonza Group (Basel, Switzerland).  4,5-Diaminofluorescein diacetate (DAF-
2 DA) was purchased from Calbiochem (San Diego, CA).  Tryptic soy broth (TSB), tryptic soy 
agar (TSA), Luria-Bertani (LB) broth, LB, and Mueller Hinton agar were obtained from Becton, 
Dickinson and Company (Franklin Lakes, NJ).  Pseudomonas aeruginosa (P. aeruginosa; ATCC 
#19143), Eschericia coli (E. coli; ATCC #35150), Staphylococcus aureus (S. aureus; ATCC 
#29213), and methicillin-resistant Staphylococcus aureus (MRSA; ATCC #33591) were obtained 
from American Type Tissue Culture Collection (Manassas, VA).  L929 mouse fibroblasts were 
obtained from the UNC Tissue Culture Facility (Chapel Hill, NC).  Nitrogen (N2), argon (Ar), 
carbon dioxide (CO2), and nitric oxide (NO) calibration (25.87 PPM, balance N2) gases were 
purchased from National Welders (Raleigh, NC).  Pure nitric oxide (NO) gas (99.5%) was 
purchased from Praxair (Sanford, NC).  Common laboratory salts and solvents were purchased 
from Fisher Scientific (Fair Lawn, NJ).  Distilled water was purified using a Millipore Milli-Q UV 
Gradient A-10 system (Bedford, MA), resulting in a total organic content of ≤6 ppb and a final 
resistivity of 18.2 mΩ·cm.  Unless noted otherwise, all materials were analytical-reagent grade 
and used as received without further purification. 
6.2.1 Synthesis of QA- and alkyl chain-modified PAMAM dendrimers 
Poly(amidoamine) (PAMAM) scaffolds were synthesized as described previously,35, 40, 41 
by repeated alkylation/amidation steps using methyl acrylate and EDA from an EDA core.  G4 
PAMAM dendrimers were then modified with either octyl or octylQA moieties.  To form octyl-
modified dendrimers,36 G4 PAMAM (100.0 mg) was dissolved in 5 mL methanol, and one 
equivalent of triethylamine (with respect to the molar amount of primary amines) and one molar 
equivalent of epoxyoctane were then added to the vial.  This solution was stirred at room 
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temperature for 3 d.  After reaction completion, excess epoxide was removed in vacuo.  To ensure 
removal of any unreacted epoxide, dendrimers were re-dissolved in 5 mL methanol and kept under 
vacuum overnight.  Complete removal of the epoxide was verified via 1H NMR spectroscopy 
(Bruker 400 MHz spectrometer; Billerica, MA).   
To form octyl QA-modified dendrimers, quaternary ammonium epoxides (octylQA-
epoxide) were first synthesized as described previously.34, 37  Briefly, 0.04 mmol epichlorohydrin 
was reacted with 0.01 mmol N,N-dimethyloctylamine at room temperature overnight (~18 h).  The 
mixture was then added dropwise to cold ether while sonicating, and the solid/viscous liquid 
octylQA-epoxide was collected via centrifugation (810×g, 5 min).  The supernatant was decanted, 
and the octylQA-epoxide was washed with 50 mL of cold ether and sonicated extensively.  This 
washing procedure was repeated three times before drying the product in vacuo.  A ring-opening 
reaction was then carried out between the octylQA-epoxide and the terminal primary amines of 
the PAMAM dendrimers.  G4 PAMAM (100.0 mg) was dissolved in 5 mL of methanol.  One 
equivalent of triethylamine (with respect to the molar amount of primary amines) and 2.5 molar 
equivalents of octylQA-epoxide were then added to the vial.  The solution was stirred at room 
temperature for 4 d.  Solvent was then removed in vacuo.  The dendrimers were subsequently 
dissolved in water, followed by dialysis against water overnight and lyophilization. 
Representative 1H NMR data of modified G4 PAMAM included the following peaks.  G4 
octyl: 1H NMR (400 MHz, MeOD, δ) 2.29 (s, NCH2CH2C(O)NH), 1.35–1.23 (m, 
NHCH2CH(OH)(CH2)5CH3),  0.83–0.80 (t, NHCH2CH(OH)C(H2)5CH3).  G4 octylQA: 1H NMR 
(400 MHz, CD3OD, δ) 2.31 (s, NCH2CH2C(O)NH), 1.80 (s, CH2N+(CH3)2CH2CH2(CH2)5CH3), 
1.31–1.23 (m, CH2N+(CH3)2CH2CH2(CH2)5CH3), 0.83 (t, CH2N+(CH3)2CH2CH2(CH2)5CH3).   
6.2.2 N-Diazeniumdiolation of QA- and alkyl chain-modified PAMAM dendrimers 
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To form N-diazeniumdiolate NO donors on the modified dendrimer scaffold, single-action 
G4 PAMAM (30 mg) were added to 1 mL solutions of 1:1 MeOH:THF.  One molar equivalent 
(e.g., with respect to the molar amount of primary amines) of sodium methoxide was added after 
mixing (vortexing) the solutions.  The resulting dendrimer solutions were placed in a stainless steel 
reactor with continuous magnetic stirring and connected to an in-house NO reactor.  The vessel 
was flushed with Ar three times to a pressure of 7 bar, followed by three longer Ar purges (10 min) 
to remove trace oxygen from the solutions.  Following deoxygenation, the reactor was pressurized 
to 10 bar with NO gas pre-scrubbed with KOH.  The pressure was maintained at 10 bar for 4 d, 
after which the solutions were again purged with Ar three times for short durations followed by 
extended purges (3 × 10 min) to remove unreacted NO.  Solvent was removed in vacuo, and the 
NO-releasing dendrimers were dissolved in anhydrous methanol in a 1 dram glass vial, capped and 
parafilmed, and stored at -20 °C. 
6.2.3 Fabrication of electrospun polyurethane fibers 
All polyurethane solutions used were prepared at a concentration of 10 wt% (100 mg/mL) 
in 3:1:1 THF:DMF:MeOH.  Polyurethane solutions containing control and NO-releasing 
dendrimers (5, 15, or 25 mg/mL) were prepared by first dissolving the polyurethane in THF and 
DMF, followed by the addition of dopant solution in the remaining equivalent of methanol.   
Electrospun fibrous mats were fabricated using a custom electrospinning apparatus42, 43 
consisting of a ES20P-20W High Voltage power supply (Gamma High Voltage Research, Ormond 
Beach, FL), two Kent Scientific Genie Plus syringe pumps (Torrington, CT), and a grounded steel 
collector plate covered in aluminum foil placed at a 45° angle to the needle.  All fibers were 
fabricated using an applied voltage of 15 kV and 15 cm tip-to-collector distance.  Composite 
polyurethane fibers were formed using a co-axial needle (Ramè-Hart; Succasunna, NY) composed 
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of two concentric needles (inner gauge: 22, outer gauge: 13).  The co-axial needle was supplied by 
both individual core and sheath solutions, each connected to a separate syringe pump (Appendix).  
Core solutions were composed of either 10 wt% Tecophilic (HP 93A) or Tecoflex (SG 80A) 
polyurethanes doped with control or NO-releasing dendrimer (blank fibers contained no dendrimer 
dopant in the core solution).  Sheath solutions were composed of 10 wt% Tecoplast (TP 470) or 
Tecoflex (SG 80A) polyurethanes with no dendrimer dopant.  Fibers prepared with a SG 80A 
sheath and HP 93A core were doped with either 5, 15, or 25 mg/mL dendrimer, while the core 
solutions for all fibers prepared using a TP 470 sheath were doped with 25 mg/mL dendrimer.  To 
form fibrous mats, 0.5 mL core solution (10 µL/min flow rate) and 1.5 mL sheath solutions (30 
µL/min flow rate) were electrospun and collected on aluminum foil.  After collection, fibers were 
cut using a 1.27 cm-diameter hole-punch to yield individual “coupon” samples with a resultant 
surface area of 1.267 cm2.  Each fiber sample was weighed, and any sample with a mass below 1 
mg or above 3.5 mg was excluded. 
6.2.4 Characterization of NO storage and release 
Nitric oxide release was evaluated in real-time in deoxygenated PBS (pH 7.4, 37 °C) using 
a Sievers NOA 280i chemiluminescence NO analyzer (NOA, Boulder, CO).44  Prior to analysis, 
the NO analyzer was calibrated with air passed through a NO zero filter (0 ppm NO) and a 25.87 
ppm NO standard gas (balance N2).  Fibrous mat coupons (surface area: 1.267 cm
2) or 0.5 mg 
aliquots of N-diazeniumdiolate-functionalized PAMAM in methanol were added to 30 mL 
deoxygenated PBS to initiate NO release.  Nitrogen was flowed through the solution at a flow rate 
of 80 mL/min to carry the liberated NO to the analyzer.  Additional nitrogen flow was supplied to 
the flask to match the collection rate of the instrument at 200 mL/min.  Nitric oxide analysis was 
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terminated when NO levels decreased to below 1 pmol NO/cm2 for fibers (9.7 ppb) or 10 ppb 
NO/mg dendrimer.   
Nitric oxide release was also measured in 50 mM HCl at 37 °C to calculate the mass of 
dendrimer encapsulated within the fiber (µg dendrimer/mg fiber).  The total amount of dendrimer 
dopant incorporated into the fibers (t[dendrimer]) was determined by the following equation, 
where t[NO]dendrimer is the total NO payload released per milligram of dendrimer scaffold and 
t[NO]HCl is the total NO payload released per milligram of fiber in 50 mM HCl: 
                      t[dendrimer] = t[NO]HCl / t[NO]dendrimer x 1000                   Eq. 6.1 
6.2.5 Characterization of electrospun polyurethane fibers 
Fiber diameter and morphology were assessed using a FEI Helios 600 Nanolab Dual Beam 
System (Hillsboro, OR) without additional metal coating.  Fiber diameters were determined using 
NIH ImageJ software (Bethesda, MD) and averaged for at least 300 measurements over three 
separate fiber samples. 
Water absorption capabilities of the electrospun fibrous mats were assessed by comparing 
weights of the dry and hydrated samples.  Dry electrospun fibers were weighed before soaking in 
Milli-Q water overnight at room temperature.  The hydrated samples were removed from water, 
and the excess surface water was removed by dabbing with a Kimwipe before weighing the 
samples again.  Water absorption was calculated by the following equation, where WH is the 
weight of the hydrated sample and WD is the initial weight of the dry fiber mat: 
                     Water Absorption (%) = [(WH – WD)/WD] x 100%              Eq. 6.2 
The porosity of the electrospun fibrous mats was determined using the liquid intrusion 
method.45, 46  Fiber mats were weighed prior to immersion in 100% ethanol at room temperature 
overnight to allow diffusion of ethanol into the void volume.  After this incubation, fibers were 
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removed from ethanol, dabbed with a Kimwipe, and weighed again.  Porosity was calculated by 
dividing the volume of intruded ethanol (determined by the change in mass and the density of 
ethanol, 0.789 g/mL) by the total volume after intrusion (volume of ethanol and fibers, determined 
by initial fiber mass and polyurethane density, 1.1 g/mL). 
Leaching assays for determining dendrimer delivery were performed by doping RITC-
tagged G4 PAMAM dendrimers into the fibers.  Fluorescently-labeled G4 PAMAM dendrimers 
were synthesized as described previously.36, 37, 47  Briefly, 100 mg G4 PAMAM was added to a 
vial containing one molar equivalent of RITC per mole dendrimer (3.8 mg) in 2 mL methanol.  
One equivalent of triethylamine (with respect to the molar amount of primary amines) was then 
added to the vial.  The solution was stirred for 24 h in the dark, followed by solvent removal in 
vacuo.  Dendrimers were dissolved in water, dialyzed against water (3 d), and then lyophilized.  
The above procedures for dendrimer modification and fiber mat fabrication were performed in the 
dark to yield RITC-tagged electrospun fibrous mats.  Individual fiber mats were incubated in 500 
µL PBS (pH 7.4, 37 °C) for 30 min, 2 h, 6 h, and 24 h.  After incubation, 100 µL of each solution 
was transferred to a black 96-well plate in triplicate.  The fluorescence intensity was measured 
using a BMG PolarStar Omega fluorescence plate reader (Ortenberg, Germany).  Calibration 
standards were prepared at concentrations ranging from 0 – 200 µg/mL in triplicate.   
6.2.6 Zone of inhibition assays 
Lyophilized P. aeruginosa, E. coli, S. aureus, and MRSA were reconstituted in tryptic soy 
broth (TSB) or Luria-Bertani (LB) broth (E. coli) and cultured overnight at 37 °C.  A 0.5 mL 
aliquot of culture was grown in 50 mL TSB or LB broth to a concentration of 108 colony forming 
units per mL (cfu/mL), collected by centrifugation (2355×g), resuspended in 15% glycerol (v/v in 
PBS), and stored at -80 °C in 1 mL aliquots.  For daily experiments, colonies of bacteria culture 
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were inoculated in 2 mL TSB or LB broth overnight at 37 °C and recultured in fresh TSB or LB 
broth (50 mL) the next day. 
The antibacterial action of the electrospun fibers was evaluated using a corrected zone of 
inhibition test.48  Briefly, P. aeruginosa, E. coli, S. aureus, and MRSA were cultured in TSB or 
LB broth (E. coli) to a concentration of 108 cfu/mL, and 50 µL of the bacterial suspension in broth 
was spared over Mueller Hinton agar plates.  Individual fiber mat samples (blank, control, and 
NO-releasing) were placed on the bacteria-containing agar.  The plates were then incubated at 37 
°C overnight.  Zones of growth inhibition (ZOI) surrounding the fibers were measured (in mm) 
from the edge of the sample using calipers.  Of note, no plate dehydration was observed.  All zone 
of inhibition tests were repeated in triplicate. 
6.2.7 Bacterial log reduction assays 
An adapted time-kill kinetic log reduction assay was also employed to further assess the 
antibacterial action of the electrospun fibrous mats.48  Briefly, P. aeruginosa, E. coli, S. aureus, 
and MRSA were cultured in TSB or LB broth (E. coli) to a concentration of 108 cfu/mL.  Individual 
fiber mat samples (blank, control, and NO-releasing) were added to 1 dram glass vials and 
sterilized under UV light for 2 h prior to the bacteria assays.  Fibers were exposed to 200 µL 108 
cfu/mL bacteria in broth for either 2 or 24 h at 37 °C with light agitation.  Untreated controls 
(blanks) were included in each experiment to ensure the bacteria remained viable over the 2 or 24 
h assays.  After 2 h exposure, the bacteria solutions were vortexed and a 10 µL aliquot was removed 
for dilution and plating on tryptic soy agar (TSA) or LB agar (E. coli) plates.  The bacteria and 
fiber solutions were then returned to 37 °C with light agitation for the remainder of the 24 h 
incubation.  After exposure, the bacteria solutions were vortexed and then spiral-plated at 100-, 
1000-, and 10,000-fold dilutions on TSA or LB agar plates using an Eddy Jet spiral plater (IUL; 
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Farmingdale, NY).  Bacterial viability was assessed by counting the number of colonies formed 
on the agar plate using a Flash & Go colony counter (IUL; Farmingdale, NY).  Log reductions in 
bacterial viability were determined by the following equation, where Blank Viability is the 
viability of the unexposed bacterial blank solution and Exposed Viability is the resulting viability 
of bacteria solutions exposed to either blank, control, or NO-releasing electrospun fibers: 
                      Log Reduction = log10
𝐵𝑙𝑎𝑛𝑘 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑐𝑓𝑢/𝑚𝐿)
𝐸𝑥𝑝𝑜𝑠𝑒𝑑 𝑉𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (𝑐𝑓𝑢/𝑚𝐿)
             Eq. 6.3 
6.2.8 Fluorescence microscopy for detection of intracellular NO and cell death 
P. aeruginosa was cultured in TSB to a concentration of 108 cfu/mL, collected by 
centrifugation (2355×g), and resuspended in PBS containing 30 µM PI and 20 µM DAF-2 DA at 
108 cfu/mL.  Nitric oxide-releasing fibers were exposed to 200 µL P. aeruginosa in PBS/PI/DAF-
2 DA for 30 min.  Every 5 min, a 10 µL aliquot of the bacteria solution was deposited on a glass 
slide with a coverslip for wide-field fluorescence imaging.  An Olympus iX80 inverted microscope 
with an Olympus light source (Chroma) and Hamamatsu ORCA detector were used to image 
bacteria on slides.  Fluorescent PI images (red) were obtained using a BP 542 – 582 nm excitation 
and BP 604 – 644 nm emission filters.  Green DAF-2 images were obtained using BP 464 – 500 
nm emission and BP 516 – 556 nm excitation filters.  Images were acquired using Metamorph 
software and a 0.45 NA lens with a 20× objective.   
6.2.9 In vitro cytotoxicity 
L929 mouse fibroblasts were grown in DMEM supplemented with 10 vol% FBS and 1 
wt% PS and incubated in 5 vol% CO2 under humidified conditions at 37 °C.  After reaching 80% 
confluency, cells were trypsinized and seeded onto tissue culture-treated polystyrene.  To assess 
fiber cytotoxicity, L929 cells were seeded onto tissue culture-treated polystyrene 24-well plates at 
a density of 105 cells/mL, and incubated at 37 °C for 72 h.  The supernatant was then aspirated and 
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replaced with 1 mL of fresh growth medium and the electrospun fiber mats.  Dimethyl sulfoxide 
(10%) was used as a positive control.  After incubation for 2 or 24 h at 37 °C, the fiber mats were 
removed from the wells and the supernatant was aspirated.  Next, 500 µL of a mixture of 
DMEM/MTS/PMS (105/20/1, v/v/v) was added to each well.  After 1.5 h incubation at 37 °C, 100 
µL of the colored solution was transferred to a 96-well plate in triplicate.  The absorbance was 
quantified at 490 nm using a Thermoscientific Multiskan EX plate reader (Waltham, MA), with 
the DMEM/MTS/PMS mixture and untreated cells used as blanks and controls, respectively.  
Results were expressed as percentage of relative cell viability as follows: 
                    % Cell Viability = [(Abs490 – Absblank)/(Abscontrol – Absblank)] x 100%             Eq. 6.4 
To determine dendrimer toxicity, L929 cells were seeded onto tissue culture-treated 
polystyrene 96-well plates at a density of 2 x 104 cells/mL, and incubated at 37 °C for 72 h.  The 
supernatant was then aspirated and replaced with 200 µL of fresh growth medium and 50 µL of 
varying concentrations of dendrimer in PBS.  Dimethyl sulfoxide (10%) and 50 µL PBS were used 
as positive and negative controls, respectively.  After 2 or 24 h incubation at 37 °C, the supernatant 
was aspirated and 120 µL of a mixture of DMEM/MTS/PMS (105/20/1, v/v/v) was added to each 
well.  After 1.5 h incubation at 37 °C, the absorbance of the colored solutions was quantified at 
490 nm with percent cell viability determined using Eq. 4.  A killing curve was constructed for 
each dendrimer modification by plotting % cell viability versus dendrimer concentration.  IC50 
values, defined as the dendrimer concentration that corresponded to a 50% reduction in cell 
viability, were determined from each plot. 
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6.3 Results and Discussion 
6.3.1 Synthesis and characterization of NO-releasing G4 dendrimers 
Generation 4 (G4) poly(amidoamine) (PAMAM) dendrimers were modified with octyl 
alkyl chains or octylQA moieties through a ring-opening reaction at the peripheral primary amines 
as described previously (Scheme 1).36, 37  Covalent chemical modifications were confirmed using 
1H NMR spectroscopy.  On average, 40 – 50 functional groups were added to the G4 scaffold, 
resulting in ~70% functionalization of the terminal primary amines (Appendix).   
The resulting secondary amines were converted to N-diazeniumdiolate NO donors under high 
pressures of NO.  Nitric oxide storage was tuned by adjusting the ratio of THF:methanol, resulting 
in similar NO payloads of ~1 µmol/mg for each scaffold (Appendix).  The NO-releasing octyl-
modified dendrimers exhibited a half-life (t1/2) of ~25 min and duration of 9 h.  In contrast, G4 
octylQA/NO dendrimers were characterized by slower NO-release kinetics, with an initial max 
flux about half that of the G4 octyl/NO dendrimers and extended NO-release (t1/2 of 115 min and 
duration exceeding 16 h).  This longer NO release suggests that the permanent positive charge of 
the QA moiety stabilizes the N-diazeniumdiolate group.  The effects of dendrimer NO-release 
kinetics on the NO-release characteristics of electrospun polyurethane fibers could thus be 
evaluated due to the variation of dendrimer half-lives. 
6.3.2 Fabrication and characterization of electrospun polyurethane fibers 
To fabricate antibacterial wound dressings, electrospun fibers were formed from three 
medical grade thermoplastic polyurethanes.  Tecoplast (TP 470), a rigid, aromatic polyurethane, 
was the most hydrophobic system evaluated.  Tecoflex (SG 80A) and Tecophilic (HP 93A) 
represent hydrophilic aliphatic polyurethanes, with HP 93A, a polyether-based polyurethane, 
demonstrating the greatest water uptake capabilities.  The dendrimer-containing core solution was   
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Scheme 6.1 Reaction of G4 PAMAM scaffold with either (A) octyl alkyl chain or (B) octylQA 
epoxides to yield G4 octyl and G4 octylQA dendrimers, respectively, followed by reaction with 
high pressures of NO to generate NO-releasing dendrimers. 
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composed of either SG 80A or HP 93A aliphatic polyurethanes, while the outer (non-dendrimer-
containing) sheath polymer was either SG 80A or TP 470.  For clarity, the polymer compositions 
are denoted Sheath/Core-Dopant; for example, a G4 octyl-doped HP 93A core combined with a 
TP 470 sheath is referred to as TP 470/HP 93A-G4 octyl.  Fibers were fabricated using a custom 
electrospinning apparatus with a co-axial setup using concentric needles to introduce both core 
and sheath polymer solutions (Appendix).   
Blank (no dendrimer dopant), control (non-NO-releasing), and NO-releasing composite 
electrospun polyurethane fibers were prepared using three polymer compositions (i.e., SG 80A/HP 
93A, TP 470/SG 80A, and TP 470/HP 93A) and two dendrimer modifications (i.e., G4 octyl and 
G4 octylQA).  The resulting semi-porous electrospun fibrous mats exhibited smooth morphology 
with little to no bead formation (Figure 6.1).  Altering the polyurethane composition greatly 
influenced the macroscopic physical characteristics of the electrospun fiber mats (Figure 6.2).  
Fiber mats fabricated using SG 80A as either the core or sheath polyurethane were elastic and 
adhered to each other.  Alternately, the TP 470/HP 93A electrospun fibers maintained good shape 
over time and were easier to handle.  Fiber diameter distributions for polyurethane compositions 
were more dependent on the identity of the sheath polyurethane rather than the core (Figure 6.3).  
The SG 80A/HP 93A fiber diameters skewed larger, averaging around 600 nm compared to 400 – 
450 nm for both TP 470 sheath compositions.  These differences in fiber diameter were attributed 
to greater kinematic viscosity of the Tecoflex polyurethane solutions.43   
The allowance of gaseous and fluid exchanges represents an important characteristic for 
wound dressings.4  A porous nanofiber structure allows for adequate wound respiration and helps 
maintain an appropriately moist environment.  The porosity of dendrimer-doped electrospun 
fibrous mats was evaluated via liquid intrusion by measuring the ability of a non-wetting liquid to  
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Figure 6.1 Scanning electron micrographs of blank, control, and NO-releasing G4 octyl-doped 
electrospun SG 80A/HP 93A, TP 470/SG 80A, and TP 470/HP 93A fibers. 
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Figure 6.2 Image of electrospun fiber substrates (1.267 cm2).  From left to right: SG 80A/HP 93A, 
TP 470/SG 80A, and TP 470/HP 93A. 
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permeate the pores.45, 46  The SG 80A/HP 93A fibers exhibited greater mat porosity compared to 
fibers containing a TP 470 sheath (Table 6.1).  The cause of this substantial decrease in porosity, 
from ~70 to 30 – 50%, when moving from the SG 80A to TP 470 sheath polyurethane is unclear 
but most likely the result of larger fiber diameter distributions of the SG 80A/HP 93A fibers.  
Further, composite fibers containing TP 470 exhibited similar porosities regardless of core 
polyurethane.  While adding dendrimers to the TP 470/SG 80A fibers increased fiber mat porosity 
by ~10%, control and NO-releasing TP 470/HP 93A fibers exhibited porosities ~10% lower than 
blank fibers.  Overall, the electrospun fiber characteristics were more influenced by the 
composition of the sheath polymer than either the core polyurethane or dendrimer dopant. 
The absorption of water by electrospun fibers is an indicator of how efficiently the wound 
dressings can remove fluid from highly exuding wounds, preventing wound stagnation.4, 22  
Although all of the fiber samples demonstrated sufficient water uptake capabilities (>100%), SG 
80A/HP 93A fibers absorbed roughly half the water as fibers prepared using a TP 470 sheath 
(Table 6.1).  This result was initially surprising due to the greater hydrophobicity of the TP 470 
polyurethane compared to SG 80A.  However, the water absorption capabilities of the electrospun 
polyurethane fibers correlated directly with the percent porosity exhibited by the fibrous mat.  
Electrospun SG 80A/HP 93A fiber mats demonstrated both the largest porosity (~70%) and modest 
water absorption (~130%), while fibers prepared using a TP 470 sheath had lower porosities (30 – 
50%) and absorbed more water (>300%).  Control and NO-releasing TP 470/HP 93A fibers 
exhibited ~10% lower porosity than the blank fibers with enhanced water absorption (150 to 
~350%).  The increased water uptake with lower fiber mat porosity is attributed to the greater 
surface area available per volume allowing for more efficient absorption of water into the 
individual fibers.   
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Total NO and dendrimer storage were determined by measuring the NO release under acidic 
conditions (50 mM HCl).  Despite doping the core polyurethane solution with the same dendrimer 
concentration (25 mg/mL), total dendrimer incorporation varied dramatically between 
polyurethane compositions (Table 6.2).  SG 80A/HP 93A-G4 octyl/NO fibers demonstrated the 
largest dendrimer storage (~110 µg/mg), followed by the TP 470/SG 80A-G4 octyl/NO (~80 
µg/mg) and the TP 470/HP 93A-G4 octyl/NO (~60 µg/mg) fibers.  Additionally, dendrimer 
incorporation varied between dendrimer modifications, with the TP 470/HP 93A-G4 octylQA/NO 
fibers exhibiting the second largest storage (~95 µg/mg).  The identity of the core or sheath 
polyurethane had no clear effect on the amount of dendrimer incorporated into the fibers, 
suggesting the dendrimer loading cannot be projected prior to fiber fabrication due to potential 
dendrimer loss during the electrospinning process.  However, the total dendrimer incorporation 
could be tuned by varying the concentration of dendrimer in the initial core polyurethane solution.  
Doping G4 octyl/NO dendrimers into SG 80A/HP 93A fibers at initial concentrations of 5, 15, and 
25 mg/mL led to greater total dendrimer incorporation with increasing dendrimer concentration, 
highlighting the tunability of dendrimer loading within electrospun fibers.  Due to the low 
dendrimer loading within the 5 mg/mL SG 80A/HP 93A-G4 octyl/NO fibers (~5 µg/mg), only the 
15 and 25 mg/mL compositions were further evaluated. 
To evaluate dendrimer delivery from composite polyurethane fibers, control and NO-
releasing dendrimers were modified with a fluorescent RITC tag prior to electrospinning.  The 
resulting RITC-containing electrospun fiber mats (Appendix) were soaked in PBS to quantify the 
amount of dendrimer released over 24 h.  Impact of the fluorescent label on the scaffold was 
minimized by limiting the amount of RITC incorporated to one molecule per dendrimer scaffold 
(~3% of G4 PAMAM mass).  For all of the composite polyurethane fibers, most of the dendrimer  
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Figure 6.3 Histograms depicting fiber diameter distribution (nm) for blank, control, and NO-
releasing G4 octyl-doped electrospun SG 80A/HP 93A, TP 470/SG 80A, and TP 470/HP 93A 
fibers. 
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Table 6.1 Characterization of co-axial electrospun polyurethane fibers.a 
 
Substrate 
Mass 
(mg) 
Fiber 
Diameter 
(nm) 
Porosity 
(%) 
Water 
Absorption 
(%) 
SG 80A/HP 93A 1.41 ± 0.40 645 ± 292 71.4 ± 8.3 128 ± 41 
SG 80A/HP 93A-G4 octyl 1.58 ± 0.34 585 ± 228 78.0 ± 4.0 145 ± 26 
SG 80A/HP 93A-G4 octyl/NO 1.63 ± 0.60 590 ± 217 70.1 ± 7.4 120 ± 42 
TP 470/SG 80A 1.41 ± 0.25 394 ± 156 29.4 ± 5.0 306 ± 40 
TP 470/SG 80A-G4 octyl 1.74 ± 0.52 412 ± 127 40.3 ± 3.8 397 ± 44 
TP 470/SG 80A-G4 octyl/NO 1.36 ± 0.35 393 ± 157 42.6 ± 4.0 210 ± 48 
TP 470/HP 93A 1.77 ± 0.43 443 ± 152 51.3 ± 4.0 156 ± 70 
TP 470/HP 93A-G4 octyl 1.40 ± 0.28 409 ± 176 37.1 ± 5.0 333 ± 107 
TP 470/HP 93A-G4 octyl/NO 1.99 ± 0.78 433 ± 165 37.4 ± 8.3 379 ± 80 
TP 470/HP 93A-G4 octylQA 1.68 ± 0.36 440 ± 182 45.9 ± 5.3 435 ± 68 
TP 470/HP 93A-G4 octylQA/NO 1.82 ± 0.55 418 ± 155 39.0 ± 10.5 335 ± 90 
aFor all measurements, n ≥ 3 pooled experiments.  
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Table 6.2 Total nitric oxide storage and dendrimer encapsulation by fiber mass.a 
 
[Dendrimer]b 
(mg/mL) 
t[NO]c 
(nmol/mg) 
t[NO]HCl
d 
(nmol/mg) 
t[dendrimer]e 
(µg/mg) 
SG 80A/HP 93A-G4 octyl/NO 5 1.8 ± 0.8 3.8 ± 0.4 5 ± 1 
SG 80A/HP 93A-G4 octyl/NO 15 26.0 ± 3.6 35.0 ± 5.2 42 ± 6 
SG 80A/HP 93A-G4 octyl/NO 25 72.3 ± 9.0 93.8 ± 7.4 111 ± 10 
TP 470/SG 80A-G4 octyl/NO 25 42.4 ± 4.4 71.1 ± 8.3 81 ± 6 
TP 470/HP 93A-G4 octyl/NO 25 27.3 ± 4.1 51.0 ± 12.7 63 ± 13 
TP 470/HP 93A-G4 octylQA/NO 25 44.7 ± 11.0 88.8 ± 18.9 94 ± 23 
aFor all measurements, n ≥ 3 pooled experiments. bDendrimer concentration in the original 
polymer solution. cTotal NO payload released per mg of fiber in PBS (pH 7.4). dTotal NO payload 
released per mg of fiber in 50 mM HCl. eTotal amount of dendrimer encapsulated per mg of fiber 
(determined by total NO release in 50 mM HCl).   
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delivery occurred over the first 2 h, with only a slight increase in dendrimer release over the 
remaining 24 h (Figure 6.4).  Of note, an insignificant increase in dendrimer delivery was observed 
after 7 d, indicating the majority of dendrimer release is achieved during the first 24 h (data not 
shown).   
The polyurethane composition dramatically influenced the rate of control dendrimer 
delivery from composite electrospun fibers.  Fibers containing a SG 80A sheath were characterized 
by greater delivery of control dendrimers than either of the corresponding fibers with TP 470 as 
the sheath polyurethane (Figure 6.4 A-B).  Both the 15 and 25 mg/mL SG 80A/HP 93A-G4 octyl 
fibers exhibited similar dendrimer release (~30 µg/mL), although it corresponded to 65 and 30% 
of the total incorporated dendrimer, respectively.  Alternately, control TP 470/HP 93A and TP 
470/SG 80A fibers release dendrimer doses corresponding to ~10 and ~20% of the total 
incorporated dendrimer, respectively, indicating both core and sheath polyurethane identity 
influence the rate of dendrimer delivery.  The decreased dendrimer release exhibited by the TP 
470/SG 80A and TP 470/HP 93A fibers compared to the fibers containing an SG 80A sheath is 
attributed to the more rigid and hydrophobic TP 470 polyurethane acting as a more effective barrier 
layer compared to the aliphatic SG 80A.  Further, the greater release of control G4 octyl dendrimers 
from TP 470/SG 80A fibers compared to TP 470/HP 93A fibers is attributed to greater charge 
stabilization of the dendrimers within the more hydrophilic, polyether-based HP 93A 
polyurethane.   
Release of the NO-releasing dendrimers was dependent on the amount of dendrimer 
incorporated and sheath polyurethane, with the fibers containing an SG 80A polyurethane sheath 
resulting in greater dendrimer release.  Indeed, the 25 mg/mL SG 80A/HP 93A-G4 octyl/NO fibers 
delivered the largest total dendrimer dose (~60 µg/mg), representing ~50% of the total dendrimer 
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storage.  While the remaining G4 octyl/NO-doped fibers exhibited similar dendrimer release (~40 
µg/mg), this amount corresponded to ~55% of the total incorporated dendrimer for the fibers 
composed using a TP 470 sheath and ~100% delivery for the 15 mg/mL SG 80A/HP 93A-G4 
octyl/NO fibers, again demonstrating that the aliphatic SG 80A provides a less effective barrier 
layer than the hydrophobic TP 470 polyurethane. 
Larger doses of NO-releasing dendrimer were delivered than control dendrimers for all of 
the polyurethane compositions.  The N-diazeniumdiolate NO donor is zwitterionic and thus may 
destabilize the dendrimer scaffold within the polyurethane fibers relative to control dendrimers 
due to an overall increase in electrostatic charge.49  In a similar manner, control and NO-releasing 
TP 470/HP 93A-G4 octylQA fibers delivered greater dendrimer doses compared to the G4 octyl 
system (Figure 6.4 C), which lacks a cationic QA moiety.  Dendrimer release rates were clearly 
dependent on the resulting charge of the dendrimer scaffold after modification (e.g., QA moiety 
or N-diazeniumdiolate), with increased charge resulting in decreased dendrimer stability within 
the polyurethane fibers and faster delivery. 
Similar to dendrimer delivery, NO-release kinetics of the composite electrospun fibers was 
found to be dependent on both the polyurethane identity and dendrimer modification.  To evaluate 
NO-release kinetics from composite electrospun fibers under physiological conditions (pH 7.4, 37 
°C), fiber mats were cut into circular coupons with a standard surface area (1.27 cm2), and NO 
release was measured in real-time via chemiluminescence. 
Regardless of polyurethane composition, all of the NO-releasing fibers demonstrated an 
initial maximum burst of NO followed by a steady decline in release (Appendix).  The initial NO 
burst for both of the SG 80A/HP 93A-G4 octyl/NO fiber compositions was higher than that for 
either of the fibers containing a TP 470 sheath (Table 6.3).  This difference in initial NO flux was 
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attributed to the aliphatic SG 80A polyurethane being a less effective barrier layer to both water 
and dendrimers, leading to a faster release of dendrimers in solution and greater water access for 
N-diazeniumdiolate dissociation.  Further, while the 15 mg/mL SG 80A/HP 93A-G4 octyl/NO 
fibers exhibited similar NO totals as the G4 octyl/NO-doped fibers containing a TP 470 sheath 
(~45 nmol/cm2), they demonstrated faster NO-release kinetics.  Indeed, the SG 80A/HP 93A-G4 
octyl/NO fibers had a shorter half-life (22 min) and duration (2.2 h) than either of the fibers 
fabricated using a TP 470 sheath (half-life ~40 min, duration ~3 h), indicating the sheath 
polyurethane has a greater influence on fiber release kinetics than the core polyurethane identity. 
Between the two SG 80A/HP 93A-G4 octyl/NO compositions, both NO-release totals and kinetics 
were dependent on total dendrimer incorporation.  The 25 mg/mL composition exhibited larger 
total NO storage (87 versus 45 nmol/cm2) and longer NO-release half-life (36 versus 22 min) and 
duration (4.2 versus 2.2 h) than the 15 mg/mL fibers, demonstrating the ability to tune NO-release 
characteristics as well as dendrimer delivery for the electrospun fibers.  Similarly, the TP 470/HP 
93A-G4 octylQA/NO fibers exhibited both a greater NO-release half-life (102 min) and duration 
(~7 h) relative to the G4 octyl/NO-containing fibers.  This was attributed to the extended NO-
release properties characteristic of the G4 octylQA/NO scaffold (NO-release half-life ~115 min), 
indicating that fiber NO-release kinetics are highly dependent on the dendrimer modification. 
6.3.3 Zone of inhibition 
P. aeruginosa, E. coli, and S. aureus (including methicillin-resistant strains) are among the 
most commonly isolated species in chronic wounds.2, 50, 51  These pathogens were thus selected to 
evaluate the potential antibacterial action of control and NO-releasing electrospun fibers.  The use 
of two Gram-negative (P. aeruginosa, E. coli) and two Gram-positive (S. aureus, MRSA) bacterial 
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Figure 6.4 (A) Delivery of control (solid line) and NO-releasing (dashed line) G4 octyl dendrimers 
from electrospun SG 80A/HP 93A fibers at 15 (blue) and 25 (purple) mg/mL initial dendrimer 
concentration. (B) Delivery of control (solid line) and NO-releasing (dashed line) G4 octyl 
dendrimers from electrospun SG 80A/HP 93A (blue), TP 470/SG 80A (red), TP 470/HP 93A 
(black) fibers. (C) Delivery of control (solid line) and NO-releasing (dashed line) G4 octyl (square) 
and G4 octylQA (triangle) dendrimers from electrospun TP 470/HP 93A fibers. For all 
measurements, n ≥ 3 pooled experiments with error bars representing standard deviation of the 
mean. 
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Table 6.3 Nitric oxide-release properties for NO-releasing electrospun fibers in PBS (pH 7.4, 37 °C).a 
 
[Dendrimer]b 
(mg/mL) 
[NO]maxc 
(pmol/cm2) 
tmax
d 
(min) 
t[NO]e 
(nmol/cm2) 
t[NO]2h
f 
(nmol/cm2) 
t1/2
g 
(min) 
td
h 
(h) 
SG 80A/HP 93A-G4 octyl/NO 15 21.8 ± 5.7 6.1 ± 2.9 44.6 ± 11.1 43.7 ± 10.2 22.4 ± 3.3 2.2 ± 0.3 
SG 80A/HP 93A-G4 octyl/NO 25 27.6 ± 11.7 6.2 ± 2.2 87.2 ± 19.1 71.2 ± 17.3 35.7 ± 3.9 4.2 ± 0.8 
TP 470/SG 80A-G4 octyl/NO 25 14.0 ± 2.1 3.3 ± 0.6 46.7 ± 9.5 38.3 ± 7.2 47.8 ± 6.9 3.6 ± 0.5 
TP 470/HP 93A-G4 octyl/NO 25 17.2 ± 6.2 4.0 ± 1.6 44.3 ± 10.1 39.9 ± 9.1 39.0 ± 4.5 2.9 ± 0.4 
TP 470/HP 93A-G4 octylQA/NO 25 10.6 ± 1.5 4.3 ± 0.6 66.5 ± 16.5 36.2 ± 5.6 102.4 ± 24.6 6.8 ± 1.5 
 aFor all measurements, n ≥ 3 pooled experiments. bDendrimer concentration in the original polymer solution. cMaximum 
flux of NO release. dTime required to reach maximum flux. eTotal NO payload released per surface area.  fNO payload 
released after 2 h. gNO release half-life. hDuration of NO release.   22
1
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strains allowed for an initial evaluation of the effect of Gram designation on antibacterial action.   
As expected, electrospun composite polyurethane fibers prepared without dendrimers (i.e., 
blanks) were void of antibacterial action.  Nearly every control and NO-releasing polyurethane 
composition exhibited low antibacterial activity (ZOI <1 mm) against each of the Gram-negative 
strains, with only the TP 470/SG 80A-G4 octyl/NO fibers displaying an inhibition zone of 1.7 mm 
(Table 6.4).  Moderate bactericidal action was observed against Gram-positive bacteria.  Both 
control and NO-releasing SG 80A/HP 93A-G4 octyl fibers resulted in inhibition zones of ~1 mm, 
while the TP 470/SG 80A-G4 octyl/NO fibers again exhibited greater inhibition zones of 2.0 and 
1.6 mm against S. aureus and MRSA, respectively.  While NO-releasing TP 470/HP 93A fibers 
(i.e., G4 octyl and G4 octylQA) resulted in low to moderate antibacterial action against both Gram-
positive strains (ZOI 0.4 – 0.7 mm), the control TP 470/HP 93A fibers exhibited little to no 
bactericidal activity against either Gram-negative or Gram-positive bacteria (ZOI ≤0.2 mm).  
Despite small inhibition zones, bacterial growth was not observed beneath any of the control or 
NO-releasing fiber samples (Appendix).  The larger zones of inhibition (ZOI >0.6 mm) agree with 
results published by Vogt et al. who demonstrated the antibacterial efficacy of NO-releasing 
nanofibers against S. aureus (ZOI 0.75 – 1.2 mm).52  However, as NO diffuses in all directions, 
not just along the agar surface,52 we evaluated the reduction of bacterial growth in solution in 
conjunction with the zone of inhibition assay to fully assess the antibacterial action of NO-
releasing electrospun polyurethane fiber mats.   
6.3.4 Bacterial log reduction 
For log reduction tests, a compound is considered bactericidal if it reduces bacterial 
viability by at least three orders of magnitude.48, 53  Using this assay, we evaluated the ability of 
blank, control, and NO-releasing TP 470/HP 93A fibers to reduce the viability of P. aeruginosa, 
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Table 6.4 Average zone of inhibition against planktonic bacteria.a 
 
P. aeruginosa 
ZOI (mm) 
E. coli 
ZOI (mm) 
S. aureus 
ZOI (mm) 
MRSA 
ZOI (mm) 
SG 80A/HP 93A-G4 octyl 0.4 ± 0.3 0.5 ± 0.1 1.0 ± 0.1 1.2 ± 0.3 
SG 80A/HP 93A-G4 octyl/NO 0.5 ± 0.3 0.4 ± 0.1 0.9 ± 0.3 0.6 ± 0.1 
TP 470/SG 80A-G4 octyl 0.4 ± 0.5 0.4 ± 0.3 0.2 ± 0.3 0.0 ± 0.0 
TP 470/SG 80A-G4 octyl/NO 1.7 ± 0.3 1.8 ± 0.3 2.0 ± 0.1 1.6 ± 0.2 
TP 470/HP 93A-G4 octyl 0.1 ± 0.3 0.1 ± 0.2 0.2 ± 0.3 0.2 ± 0.3 
TP 470/HP 93A-G4 octyl/NO 0.4 ± 0.5 0.1 ± 0.2 0.7 ± 0.2 0.6 ± 0.1 
TP 470/HP 93A-G4 octylQA 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 
TP 470/HP 93A-G4 octylQA/NO 0.3 ± 0.5 0.6 ± 0.4 0.6 ± 0.2 0.4 ± 0.2 
aFor all measurements, n ≥ 3 pooled experiments. 
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E. coli, S. aureus, or MRSA planktonic cultures as a function of NO-release kinetics and dendrimer 
modification.  These studies were performed under growth conditions (i.e., in nutrient broth) over 
2 and 24 h to determine both the short- and long-term bactericidal action of control and NO-
releasing polyurethane fibers.  Fiber mats displayed high antibacterial activity if they exhibited at 
least a 3-log reduction in bacterial viability, moderate activity for a 1- to 3-log reduction, and low 
activity for <1-log reduction.48 
As expected, blank TP 470/HP 93A fibers did not eradicate bacteria (Appendix), while the 
antibacterial activity of control (i.e., non-NO-releasing) fibers was dependent on the dendrimer 
dopant.  Similar to the zone of inhibition studies, TP 470/HP 93A-G4 octylQA fibers demonstrated 
little to no antibacterial action against any of the pathogens at either timepoint (Table 6.5).  
Alternatively, TP 470/HP 93A-G4 octyl fibers were moderately antibacterial against the majority 
of bacterial strains tested (≥1-log reduction), only exhibiting low antibacterial action against S. 
aureus (<1-log reduction).  The increased bactericidal action of the G4 octyl-doped fibers over 
their G4 octylQA counterparts was surprising due to the lower corresponding dendrimer dose, but 
corroborates our previous observations that alkyl chains are more potent biocides than the QA 
moieties.36, 37  The G4 octyl-doped fibers were generally more effective at shorter timescales, with 
an average 2-log bacterial reduction after 2 h and only a 1-log reduction after 24 h.  This result 
was expected, however, as the majority of the low dendrimer dose is delivered over the first 2 h.   
Nitric oxide-releasing electrospun fibers proved to have greater antibacterial action than either 
blank or control fibers.  Indeed, moderate to high antibacterial activity was consistently observed 
against the bacterial strains evaluated.  The TP 470/HP 93A-G4 octyl/NO fibers demonstrated 
greater bactericidal action against Gram-negative pathogens while TP 470/HP 93A-G4 
octylQA/NO fibers were more effective against the Gram-positive strains, although the differences 
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in efficacy were modest (~1-log difference between the two dendrimer modifications).  In contrast 
to control fibers, the NO-releasing TP 470/HP 93A fibers were more effective at reducing bacterial 
viability at extended time periods (24 h), suggesting the greater doses provided by the NO-
releasing polyurethane fibers allows for continued bactericidal action of the dendrimer scaffold in 
solution.  Of note, at least one of the NO-releasing fiber formulations displayed high antibacterial 
activity against each bacterial strain, with an average 4-log reduction in bacterial viability observed 
at 24 h.  However, as TP 470/HP 93A-G4 octylQA/NO fibers deliver almost twice as much 
dendrimer per milligram of fiber (~35 and 80 µg/mg for G4 octyl/NO and G4 octylQA/NO fibers, 
respectively), the TP 470/HP 93A-G4 octyl/NO fibers exhibited greater broad-spectrum 
bactericidal activity with less antibacterial dendrimer delivery.  The broad-spectrum antibacterial 
action exhibited by the NO-releasing electrospun fibers is noteworthy, particularly in comparison 
to certain commercially available silver-releasing dressings that do not exhibit adequate 
bactericidal action against Gram-positive bacteria.48 
To elucidate the mechanism of antibacterial action for the NO-releasing electrospun fibers, 
DAF-2 DA and PI fluorescent probes were used to visualize intracellular NO and cell membrane 
damage, respectively.  After 5 min exposure to TP 470/HP 93A-G4 octyl/NO fibers, planktonic P. 
aeruginosa bacteria show evidence of both intracellular NO and substantial membrane damage 
(Figure 6.5).  Almost no overlap between the bacterial cells with compromised membranes and 
the localization of intracellular NO was noted, however, indicating the biocidal actions of G4 
octyl-modified dendrimers and NO are exerted independently from one another.  The diminished 
intracellular NO levels after 15 min and undetectable DAF-2 fluorescence at later timepoints 
suggests that any antibacterial activity derived from NO release is only observed at short 
timescales.  As such, the majority of bactericidal action exhibited by the NO-releasing fibers is the  
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Table 6.5 Average log reduction against planktonic bacteria.a 
 P. aeruginosa E. coli S. aureus MRSA 
 2 h 24 h 2 h 24 h 2 h 24 h 2 h 24 h 
TP 470/HP 93A 0.4 ± 0.8 0.6 ± 0.7 0.0 ± 0.2 0.2 ± 0.2 0.0 ± 0.1 -0.2 ± 0.2 0.0 ± 0.1 0.7 ± 0.8 
G4 octyl 2.0 ± 0.6 1.2 ± 1.4 2.5 ± 0.5 1.1 ± 1.0 0.7 ± 1.0 0.4 ± 0.9 1.5 ± 0.8 2.4 ± 1.5 
G4 octyl/NO 4.0 ± 0.8 3.7 ± 0.4 3.0 ± 0.6 4.2 ± 0.8 2.7 ± 0.8 4.3 ± 1.4 2.6 ± 0.6 4.4 ± 1.0 
G4 octylQA 0.5 ± 0.9 0.1 ± 0.5 0.0 ± 0.3 0.2 ± 0.3 0.2 ± 0.4 -0.2 ± 0.1 0.5 ± 0.5 0.4 ± 0.8 
G4 octylQA/NO 4.1 ± 0.9 3.5 ± 1.3 2.3 ± 0.5 2.6 ± 0.8 3.4 ± 0.7 4.7 ± 1.2 3.2 ± 1.0 4.7 ± 0.9 
aFor all measurements, n ≥ 3 pooled experiments. 
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Figure 6.5 Fluorescence microscopy images of P. aeruginosa exposed to TP 470/HP 93A-G4 
octyl/NO fibers for 5 and 15 minutes. DAF-2 green fluorescence depicts intracellular NO, while 
PI red fluorescence indicates compromised membranes.  Threshold inverted for clarity. 
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result of dendrimer-induced bacterial killing, corroborating our observation that greater dendrimer 
delivery from NO-releasing fibers increases bactericidal action compared to control fibers.  
6.3.5 In vitro cytotoxicity 
Toxicity of the electrospun fibers was assessed against L929 mouse fibroblast cells over 2 
and 24 h.  For comparison, the inhibitory concentrations at 50% cell viability (IC50) against L929 
mouse fibroblasts were evaluated for each of the control and NO-releasing dendrimers at both 
timepoints.  As expected, both control and NO-releasing dendrimers were significantly more toxic 
at longer timescales, with IC50 values ranging from 200 – 360 and 40 – 100 µg/mL after 2 and 24 
h, respectively (Appendix).  Due to this toxicity of octyl- and octylQA-modified dendrimers alone 
at relatively low concentrations, we hypothesized that the NO-releasing polyurethane fibers would 
exhibit substantial toxicity to L929 cells after 24 h exposure.  Yet, all of the fiber formulations 
were relatively non-toxic (≥ 80% cell viability) at both timepoints (Figure 6.6, Appendix).  The 
most significant toxicity was observed for the blank and control SG 80A/HP 93A fibers after 24 h 
(86 and 82% cell viability, respectively), while the SG 80A/HP 93A-G4 octyl/NO fibers exhibited 
no reduction in viability.  The reduction in cell viability observed for the blank fibers is attributed 
to cell adhesion to the fiber mat and subsequent removal from the culture plate.  All of NO-
releasing fibers demonstrated at least ~95% cell viability or greater, suggesting that releasing 
antibacterial dendrimers from electrospun fibers over time reduces their toxicity compared to 
direct exposure. 
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Figure 6.6 Viability (%) of L929 mouse fibroblast cells following (A) 2 h or (B) 24 h exposure to 
blank, control, and NO-releasing electrospun SG 80A/HP 93A (blue), TP 470/SG 80A (red), and 
TP 470/HP 93A (gray) fibers. For all measurements, n ≥ 3 pooled experiments with error bars 
representing standard deviation of the mean.  
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6.4 Conclusions 
The utility of dendrimer- and NO-releasing electrospun polyurethane fibers as potential 
antibacterial wound dressings was evaluated as a function of polyurethane composition and 
dendrimer modification.  The dendrimer-doped electrospun fibers exhibited adequate porosity and 
water absorption capabilities that should enable dynamic gas and fluid exchange in a chronic 
wound setting.  The release of antibacterial dendrimers and NO were tuned by adjusting the sheath 
polyurethane hydrophobicity, dendrimer modification, and amount of dendrimer incorporated into 
the fibers.  Fibers fabricated using a less hydrophobic sheath polyurethane were characterized by 
faster dendrimer and NO release, while the charged dendrimer modifications (e.g., N-
diazeniumdiolate or QA moieties) resulted in greater dendrimer delivery.  Similarly, NO-release 
kinetics were dependent on the dendrimer modification, reflecting the relative kinetics of the NO-
releasing dendrimers in solution.  The NO-releasing TP 470/HP 93A fibers demonstrated moderate 
to high antibacterial activity against several Gram-negative and Gram-positive species at both 
short and long timescales, averaging a 4-log reduction in bacterial viability after 24 h exposure.  
Finally, the release of the control and NO-releasing dendrimers from the electrospun fibers reduced 
the overall toxicity of the dendrimer scaffold to mammalian cells, demonstrating the utility of these 
fibers as broad-spectrum antibacterial dressings with minimal cytotoxic effects.   
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CHAPTER 7: 
Summary and Future Directions 
7.1 Summary 
The synthesis and subsequent microbiological evaluation of dual-action poly(amidoamine) 
(PAMAM) dendrimer biocides, followed by the design and preparation of nitric oxide (NO)-
releasing electrospun polyurethane fibers, represented the focus of my dissertation research.  
Chapter 1 provided an overview of the formation and protective mechanisms of biofilm-based 
infections, current research into anti-biofilm therapies, and the need for novel therapeutic agents 
capable of eradicating biofilms.  This introduction chapter further highlighted the benefits of 
combining multiple biocidal mechanisms to create dual-action antibacterial agents with increased 
bactericidal action while minimizing the emergence of bacterial resistance.   
Chapter 2 focused on modifying PAMAM dendrimers of varying generation (i.e., size and 
functional group density) with either quaternary ammonium (QA) moieties or alkyl chains of 
varying chain lengths.  Nitric oxide-release kinetics were dependent on the type of modification 
(e.g., QA moiety or alkyl chain) and alkyl chain length but independent of dendrimer generation.  
Quaternary ammonium-modified PAMAM dendrimers exhibited longer NO-release half-lives 
than their alkyl chain-modified counterparts, suggesting stabilization of the zwitterionic N-
diazeniumdiolate by the cationic QA moiety.  While half-lives for the QA-modified dendrimers 
were dependent on the alkyl chain length due to bilayer vesicle formation in solution, the NO-
release characteristics of the alkyl chain modifications were successfully controlled to yield dual-
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action dendrimers with similar NO totals and release kinetics.  The antibacterial and anti-biofilm 
actions of the resulting single- and dual-action dendrimers were evaluated in subsequent chapters. 
In Chapter 3, the antibacterial activity of QA- and alkyl chain-modified dendrimers was 
determined against planktonic cultures of pathogenic bacteria.  Both single and dual-action QA-
modified PAMAM dendrimers exhibited biocidal activity against P. aeruginosa and S. aureus, 
with longer QA alkyl chains (i.e., octylQA and dodecylQA) proving more effective than shorter 
chain (i.e., methylQA and butylQA) modifications for both G1 and G4 dendrimer scaffolds.  This 
work established the mechanism of biocidal action for the QA-modified dendrimers as a function 
of alkyl chain length and Gram designation that was lacking in previous research.1-3  The NO-
releasing octylQA- and dodecylQA-modified dendrimers exhibited similar bactericidal efficacy as 
their single-action counterparts due to the membrane damage inflicted on bacterial cell membranes 
by the long alkyl chains, greatly increasing their biocidal action but precluding the buildup of 
intracellular NO.  However, the addition of NO-release capabilities both improved the antibacterial 
action of short alkyl chain QA-modified dendrimers markedly and lessened the overall toxicity of 
the dendrimer scaffolds to mouse fibroblast cells, indicating the benefits of the dual-action system.  
The alkyl chain-modified dendrimers exhibited similar trends in bactericidal action as the QA 
modifications, with the shorter alkyl chains proving more effective against P. aeruginosa than S. 
aureus.  The addition of NO release, however, had mixed effects on both the bactericidal action 
and cytotoxicity of the alkyl chain-modified dendrimers.  Although the short alkyl chain-modified 
G1 dendrimers were more bactericidal with NO release, the antibacterial action for most of the 
remaining dendrimer biocides was not affected by NO release.  However, low levels of NO release 
from the more effective scaffolds were found to mitigate toxicity to mammalian cells, regardless 
of improvements to bactericidal action. 
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These studies were expanded in Chapter 4 to evaluate the ability of dual-action alkyl chain-
modified dendrimers to eradicate pathogenic biofilms as a function of dendrimer generation, alkyl 
chain length, and bacterial Gram class.  Single- and dual-action dendrimers were significantly 
more bactericidal against P. aeruginosa than Gram-positive S. aureus or MRSA biofilms.  Using 
confocal microscopy, this increased efficacy was attributed to the inability of the dendrimer 
biocides to effectively damage cell membranes in S. aureus biofilms compared to P. aeruginosa, 
most likely due to differences in the biofilm architecture.  Dendrimer anti-biofilm efficacy was 
found to be highly dependent on the biocide’s ability to penetrate into the biofilm and compromise 
cell membranes, which was corroborated using confocal microscopy.  Hexyl-modified dendrimers 
were considerably more effective at biofilm eradication than the butyl system, likely due to a 
combination of greater membrane intercalation, cell membrane damage, and biofilm penetration.  
Furthermore, the addition of NO release enhanced the anti-biofilm action of dendrimer biocides 
incapable of efficient membrane disruption and biofilm penetration.  While the majority of 
dendrimer biocides were toxic at concentrations required to eradicate Gram-positive biofilms, 
single- and dual-action G3 hexyl dendrimers were characterized as having a clinically relevant 
therapeutic index against all bacterial strains tested, suggesting the G3 dendrimer scaffold 
represents the ideal balance of dendrimer size and functional group density for optimal biofilm 
eradication with minimal cytotoxicity.  Indeed, NO-releasing alkyl chain-modified G3 dendrimers 
demonstrated moderate to high synergy with vancomycin in the eradication of Gram-positive 
biofilms, reducing the toxicity of the therapy to mouse fibroblasts and indicating the possible 
clinical utility of these scaffolds. 
In Chapter 5, G4 PAMAM dendrimers with various exterior modifications were 
incorporated into single component electrospun polyurethane fibers.  Control and NO-releasing 
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G4 octyl dendrimers were first doped into fibers fabricated from one of three polyurethanes 
exhibiting distinct water uptake capabilities.  While the fiber characteristics (i.e., fiber diameter, 
porosity, water absorption, and electrospinning efficiency) were dependent on polyurethane 
composition, the NO-release characteristics were overall independent of polyurethane 
hydrophobicity.  Electrospun fibers composed of a moderately hydrophilic polyurethane 
(Tecoflex) were doped with dendrimers exhibiting various exterior modifications (e.g., alkyl 
chains and QAs) and a range of NO-release kinetics.  The NO-release properties of the resulting 
electrospun fibers reflected those of the dendrimer dopant, indicating the dendrimer modification 
has greater influence on the NO-release characteristics of single component electrospun fibers than 
the polyurethane composition.  Both control and NO-releasing dendrimer-doped electrospun 
Tecoflex fibers exhibited decreased L929 cell adhesion from blank Tecoflex fibers, with the 
fibroblasts exposed to NO-releasing fibers demonstrating non-adhesive morphologies, suggesting 
NO-releasing electrospun fibers will allow for easy, painless wound dressing removal without 
harming the newly formed skin underneath.  However, the NO-releasing Tecoflex fibers exhibited 
low antibacterial and anti-adhesive action against P. aeruginosa and S. aureus bacteria, limiting 
the clinical utility of these fibers and necessitating the development of fibers capable of greater 
NO storage to allow for enhanced bactericidal action. 
To improve the antibacterial action of NO-releasing electrospun fibers, antibacterial 
dendrimers were incorporated into electrospun composite polyurethane fibers in Chapter 6.  
Composite electrospun fibers were formed from three medical grade thermoplastic polyurethanes 
using a co-axial electrospinning method.  The dendrimer dopant (i.e., G4 octyl or G4 octylQA) 
and polyurethane composition were varied to evaluate the effects of dendrimer modification and 
polyurethane hydrophobicity on fiber mat characteristics, including leaching of the dual-action 
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antibacterial scaffold into solution.  Release of antibacterial dendrimers from the fibrous mats was 
influenced by the polyurethane composition and dendrimer modification.  Increased 
hydrophobicity of the sheath polyurethane slowed dendrimer release from the electrospun fibers, 
while charged dendrimer modifications resulted in greater overall dendrimer release.  While the 
identity of the core polyurethane had little effect on NO-release kinetics, the use of a more 
hydrophilic sheath polyurethane led to faster NO release due to the sheath polyurethane being a 
less effective barrier layer to both water and dendrimer leaching.  Similar to the results in Chapter 
5, NO-release kinetics were dependent on the dendrimer modification and reflected the kinetics of 
the dendrimers alone in solution.  Nitric oxide-releasing fibers demonstrated moderate to high 
broad-spectrum antibacterial activity against four pathogenic species at both short (2 h) and long 
(24 h) timescales.  The long-term bactericidal action was due to the release of greater dual-action 
dendrimer concentrations from the NO-releasing fibers, averaging a 4-log reduction in bacterial 
viability after 24 h exposure.  Finally, release of the control and NO-releasing dendrimers from 
electrospun fibers reduced their overall toxicity to mammalian cells, demonstrating the utility of 
these fibers as broad-spectrum antibacterial dressings with minimal cytotoxic effects. 
7.2  Future Directions 
The investigations described in the prior chapters established the utility of NO-releasing 
dendrimer scaffolds as dual-action antibacterial agents, including the first report of NO-releasing 
dendrimer efficacy against MRSA biofilms.  Incorporation of these dendrimer biocides into 
electrospun polyurethane fibers proved highly antibacterial (≥3-log reduction in bacterial viability) 
against four strains of pathogenic bacteria.  While the results described herein demonstrate the 
utility of NO-releasing dendrimers as dual-action antibacterial agents alone and as dopants in 
electrospun fibers, substantial work is required before these therapeutics can be employed in a 
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clinical setting.  In this section, techniques to improve the efficacy and utility of NO-releasing 
dendrimers and electrospun fibers will be discussed, as well as studies to further demonstrate the 
ability of these materials to eradicate pathogenic biofilms. 
7.2.1 Studies to increase the antibacterial action of dual-action scaffolds 
In Chapters 3 and 4, the antibacterial and anti-biofilm efficacy of dual-action dendrimer 
scaffolds was evaluated, with control and NO-releasing G3 hexyl dendrimers exhibiting the most 
efficient anti-biofilm action and minimal toxicity to mammalian cells.  However, the addition of 
NO release had little impact on the antibacterial action of the dendrimer scaffold for many of the 
highly bactericidal agents discussed herein due to significant membrane disruption precluding 
buildup of intracellular NO.  To improve the antibacterial action of NO in conjunction with these 
contact-based biocides, the effects of NO-release kinetics on bactericidal action must be evaluated.  
In previous work, the antibacterial activity of NO-releasing silica nanoparticles was found to be 
highly dependent on NO flux and bacterial identity.4, 5  Lu et al. demonstrated that silica particles 
exhibiting faster NO-release kinetics eradicated planktonic cultures of both S. aureus and P. 
aeruginosa at significantly lower NO doses.  Designing NO-releasing dendrimers with shorter 
NO-release half-lives and larger initial NO fluxes may improve the anti-biofilm action of the dual-
action scaffold against these pathogenic strains. 
In addition to improving the efficacy of dendrimer scaffolds, future work should evaluate 
the bactericidal action of NO-releasing hyperbranched polymers.  While hyperbranched polymers 
exhibit similar multivalency as dendrimers, they can be synthesized via a one-pot reaction versus 
the time-consuming synthetic protocols required to form dendrimer scaffolds.6-9  Similar to 
dendrimers, the scaffold exterior can be tailored through modification of the terminal end groups, 
although these can be either primary amines or hydroxyl groups.6  Scaffold properties may be 
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altered further through backbone or hybrid modification, allowing for greater synthetic control 
over the hyperbranched structure and the fabrication of biocompatible or biodegradable polymers 
that may be less toxic to mammalian cells.  The use of hyperbranched polymers may allow for the 
same advantages afforded by the multivalent dendrimer scaffold while reducing the overall 
toxicity of the therapeutic. 
7.2.2 Methods to extend nitric oxide release from electrospun fibers 
In Chapters 5 and 6, electrospun polyurethane fibers were fabricated to incorporate 
antibacterial NO-releasing dendrimer scaffolds.  The resulting NO-release characteristics were 
highly dependent on dendrimer modification, reflecting the release kinetics of the dendrimers in 
solution.  The release durations for these fibers were relatively short (<12 h), likely limiting the 
ability of NO to enhance wound healing or antibacterial action.  Ideally, prolonged NO release 
would improve clinical utility by allowing for greater time between dressing changes (i.e., 1 – 3 
days versus <1 day) while maintaining antibacterial action and wound healing.10 
A promising method for extending NO release from electrospun fibers may be direct 
modification of the polyurethane with NO donors prior to electrospinning.  Direct polymer 
functionalization has several advantages over the incorporation of NO donors, including mitigating 
any potential toxicity from leached NO donors and extending NO release.  Direct modification of 
the polymer may alter its overall characteristics, which would require further investigation into 
polymer stability and mechanical properties.  Previous work has demonstrated the modification of 
polyurethanes with N-diazeniumdiolate NO donors through two general methods: 1) incorporating 
amine sites pendant to the polymer backbone and subsequent reaction with gaseous NO; or, 2) 
modifying the polymer backbone with O2-protected diazeniumdiolate functionalities followed by 
deprotection.11-13  Several methods have been developed to tether amine sites to the polymer 
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backbone, including adding secondary amine-containing monomers to the synthetic solution prior 
to polymerization, linking secondary amines to the polyurethane amide, and integrating lysine 
residues into polymer chain extenders.12-15  The resultant NO storage is dependent on the 
efficiencies of polymer modification and NO reaction with the derivatized polymer.  However, the 
use of protected N-diazeniumdiolate functionalities may potentially allow for controlled and 
predictable NO payloads from the polymer.13  Directly modifying polyurethanes with NO donors 
should allow for increased control over the NO-release characteristics, including NO flux, payload, 
and duration.  To evaluate the potential synthetic control, electrospun fibers should be fabricated 
from secondary-amine containing polyurethanes both before and after N-diazeniumdiolate 
formation.   
In all of the aforementioned studies, PAMAM dendrimers were modified with N-
diazeniumdiolate NO donors to allow for controllable NO storage and release.  In aqueous 
solutions at neutral or acidic pH, N-diazeniumdiolate moieties undergo proton-initiated 
dissociation to spontaneously release NO (Figure 1.4B).16, 17  Alternatively, NO release from S-
nitrosothiol (RSNO) donors is achieved through a number of decomposition pathways (Figure 
1.4A), including homolytic cleavage of the S-NO bond by light or heat, copper ion-mediated 
catalytic decomposition, and reaction with reducing agents (e.g., ascorbate).18, 19  As the RSNO-
derived NO release is independent of water uptake, it may be more useful in designing wound 
dressings for dry, low-exuding wounds where the aqueous decomposition of N-diazeniumdiolate 
NO donors would be inhibited.10 
Modifying electrospun fibers with RSNO-derived NO release could be accomplished 
through either direct polyurethane functionalization or incorporation of S-nitrosothiol-modified 
scaffolds (i.e., dendrimers, hyperbranched polyesters).6, 7, 20  In contrast to N-diazeniumdiolate 
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moieties, RSNO donors are uncharged and should be better retained within the fibers to allow for 
extended NO release.  Initial studies in the development of NO-releasing fibers have directly 
modified polymers with thiols groups for RSNO donor formation.  For example, Reynolds and 
coworkers reported the modification of polymers with three distinct thiol functionalities prior to 
electrospinning, followed by nitrosation to yield NO-releasing fibers with variable NO-release 
kinetics and durations.21  Similarly, Vogt et al. formed a highly porous nanofibrous gelatin matrix 
through phase separation fabrication.22  This scaffold was subsequently functionalized with a thiol 
precursor and nitrosated to produce photoinitiated NO-releasing matrices.  Coneski et al. 
incorporated free thiols into both the hard and soft segment polyurethane domains, with soft 
segment-thiol modification demonstrating retention of polyurethane characteristics and high thiol 
to RSNO conversion efficiencies.23  The various methods of RSNO integration into electrospun 
fibers should allow for synthetic control to finely tune the duration and flux of NO release 
independent of water uptake. 
7.2.3 Antibacterial action against polymicrobial biofilms 
As discussed in Chapter 1, pathogenic biofilms are complex and diverse multi-organism 
communities.24-29  As such, polymicrobial biofilm models (i.e., biofilms composed of several 
bacterial strains) should be used to more accurately represent in vivo biofilms as opposed to the 
over-simplified monomicrobial biofilms studied herein.  As P. aeruginosa and S. aureus represent 
the most commonly isolated species in clinical infections,24 a proper polymicrobial model would 
include both of these pathogens and their antibiotic-resistant strains.  A more complex model of 
polymicrobial biofilms would include other commonly isolated bacterial strains, such as S. 
epidermidis, E. coli, Klebsiella pneumoniae, and Enterococcus faecalis.27, 30 
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The biggest challenge in studying polymicrobial biofilms is quantifying the individual 
bacterial species present before and after treatment to accurately assess the bactericidal action of 
dual-action antibacterial agents.  Selective plating methods can provide accurate colony counts for 
distinct bacterial species within polymicrobial biofilms.  For example, mannitol salt agar, specific 
for staphylococci strains, does not allow for the growth of Gram-negative bacteria (e.g., E. coli, P. 
aeruginosa).31-33  The addition of a phenol red indicator further allows for differentiation between 
coagulase positive (e.g., S. aureus) and coagulase negative staphylococci.32  Isolation of P. 
aeruginosa is achieved using agar containing triclosan, an antimicrobial agent that selectively 
inhibits Gram-positive and Gram-negative bacteria, excluding Pseudomonas strains.34-36  While 
selective plating methods allow for general isolation of bacterial strains, additional evaluation is 
often required for further identification or quantification. 
Fluorescence in situ hybridization (FISH) can be used in combination with confocal 
microscopy to visualize individual bacterial strains within a polymicrobial biofilm.  The use of 
bacteria-specific probes in conjunction with FISH allows for the identification of specific 
pathogenic strains, including S. aureus, P. aeruginosa, E. faecalis, and K. pneumoniae.37, 38  
Fluorescence measurements can then be used to quantify specific bacterial strains within a mixed 
bacterial population.  Additionally, the polymerase chain reaction (PCR) can be used to isolate, 
amplify, and selectively detect pathogens from a complex bacterial community.  Species-specific 
primers have been developed for P. aeruginosa, S. aureus, MRSA, and E. faecalis, allowing for 
the determination of population distribution and bacterial load using quantitative, real-time PCR.38-
40 
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7.3 Conclusions 
The work described herein highlights the importance of complete biofilm eradication in 
treating infections.  As NO is a broad-spectrum antibacterial agent unlikely to foster bacterial 
resistance, particular focus was given to establishing the utility of NO-releasing dendrimer 
scaffolds as dual-action antibacterial agents capable of pathogenic biofilm eradication.  Higher 
generation (i.e., G3 or G4) hexyl-modified dendrimers demonstrated efficient and extensive 
biofilm penetration, eradicating biofilms at lower concentrations and mitigating toxicity to 
mammalian cells.  The addition of NO-release capabilities significantly enhanced the anti-biofilm 
activity of dendrimer scaffolds incapable of good biofilm penetration, highlighting the benefits of 
this dual-action system.  Further, the incorporation of dual-action dendrimer biocides into 
electrospun composite polyurethane fibers resulted in high broad-spectrum antibacterial action and 
lessened the toxicity of the dendrimer scaffold against mouse fibroblast cells.  The observations 
made in the prior chapters will aid in the future design of NO-releasing dual-action therapeutics 
with maximal anti-biofilm action while minimizing unwanted cytotoxicity. 
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Table A1. Characterization and NO-release properties of G4 dendrimers in PBS (pH 7.4, 37 °C) 
as measured by a chemiluminescence NO analyzera. 
 
No. 
Modified 
End 
Groupsa 
% 
Modified 
Molec. 
Weight 
(Da) 
[NO]max
c 
(ppb/mg) 
tmax
d 
(min) 
t[NO]e 
(µmol/mg) 
t1/2
f 
(min) 
td
g 
(h) 
G4 octyl/NO 47 ± 3 74 ± 5 25987.7 4760 ± 920 2.7 ± 0.4 0.92 ± 0.06 25 ± 6 9 ± 1 
G4 octylQA/NO 39 ± 5 61 ± 8 23953.6 1570 ± 150 2.0 ± 0.3 1.03 ± 0.06 115 ± 6 16 ± 1 
aFor all measurements, n ≥ 3 pooled experiments. bDetermined by 1H NMR. cMaximum flux of 
NO release. eTime required to reach maximum flux. eTotal NO payload released. fNO release 
half-life. gDuration of NO release.  
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Table A2. Inhibitory concentrations at 50% viability (IC50) against L929 mouse fibroblast cells.
a 
 
2h IC50 
(µg/mL) 
24h IC50 
(µg/mL) 
G4 octyl 200 60 
G4 octyl/NO 360 100 
G4 octylQA 300 60 
G4 octylQA/NO 280 40 
aFor all measurements, n ≥ 3 pooled experiments  
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Figure A1. Custom electrospinning apparatus in co-axial configuration 
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Figure A2. Scanning electron micrographs of (A) TP 470/HP 93A-G4 octylQA and (B) TP 
470/HP 93A-G4 octylQA/NO electrospun fibers with corresponding fiber diameter histograms. 
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Figure A3. Scanning electron micrographs of (A) TP 470/HP 93A-G4 RITC octyl/NO and (B) TP 
470/HP 93A-G4 RITC octylQA/NO electrospun fibers.   
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Figure A4. Representative NO-release profiles for (A) SG 80A/HP 93A-G4 octyl/NO fibers at 5 
(red), 15 (blue), and 25 (black) mg/mL dendrimer concentrations, and (B) G4 octyl/NO-doped 
electrospun SG 80A/HP 93A (blue), TP 470/SG 80A (red), TP 470/HP 93A (black) fibers.   
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Figure A5.  Zone of inhibition images against MRSA showing no bacteria growth under control 
and NO-releasing TP 470/SG80A-G4 octyl fibers 
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Figure A6. Viability of (A) P. aeruginosa, (B) E. coli, (C) S. aureus, and (D) MRSA after 2 h 
exposure to blank, control, and NO-releasing co-axial electrospun TP 470/HP 93A fibers. For all 
measurements, n ≥ 3 pooled experiments with error bars representing standard deviation of the 
mean. Asterisk (*) indicates significant differences from blank (p < 0.05) and double asterisk (**) 
indicates significant differences (p < 0.05) using two-tailed student’s t-test. 
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Figure A7. Viability of (A) P. aeruginosa, (B) E. coli, (C) S. aureus, and (D) MRSA after 24 h 
exposure to blank, control, and NO-releasing co-axial electrospun TP 470/HP 93A fibers. For all 
measurements, n ≥ 3 pooled experiments with error bars representing standard deviation of the 
mean. Asterisk (*) indicates significant differences from blank (p < 0.05) and double asterisk (**) 
indicates significant differences (p < 0.05) using two-tailed student’s t-test. 
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Figure A8. Viability (%) of L929 mouse fibroblast cells following 2 h (solid) or 24 h (diagonal 
lines) exposure to blank, control, and NO-releasing electrospun TP 470/HP 93A-G4 octylQA 
fibers. For all measurements, n ≥ 3 pooled experiments with error bars representing standard 
deviation of the mean.  
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